Unigene eben auf N24 empfohlen ?! - 500 Beiträge pro Seite

[Crush.]

Eben gerade auf N24 (Aktionärs TV)
UNIGENE (WKN: 875852) empfohlen???
Habe ich das richtig verstanden?

Kann das wer bestätigen?

Kurs zieht hier richtig an.

Bereits 10 %

[printmedien]

Ja stimmt !
Der Aktionär hat aufgenommen !

[Crush.]

[posting]17.534.777 von printmedien am 12.08.05 15:09:53[/posting]Eure Meinungen dazu???

[newzealaender]

[posting]17.534.803 von Crush. am 12.08.05 15:11:27[/posting]Kauf ich in USA, muß ich keinen Aufschlag zahlen.

[printmedien]

Kenne ich garnicht aber für nen Hype war die Aktie gerade GUT !

[Dakommtwas]

Deutsche Lemminge treiben wieder einen USA-Wert.

[Crush.]

Es geht up

[Crush.]

[posting]17.534.883 von Dakommtwas am 12.08.05 15:16:12[/posting]Du willst wohl noch etwas drücken, damit du in USA billig reinkommst was???

[Crush.]

[posting]17.534.949 von Crush. am 12.08.05 15:20:30[/posting]RT eben 1, 66

[Crush.]

RT 1,67

[Dakommtwas]

RT 1,62

[Dakommtwas]

RT 1,61

[Dakommtwas]

RT 1,60

[Dakommtwas]

RT 1,58

[trickygirl]

Unigene / WKN 875 852 / Kursziel 3,00 Euro
Das US-Biotechnologieunternehmen Unigene dürfte den treuen Zuschauern des AKTIONÄR TVs bekannt sein: Die Aktien der Gesellschaft waren bereits während der ersten Spielrunde für einige Zeit im Depot vertreten. Das Papier wurde zudem vor einigen Monaten in das Musterdepot vom BIOTECH-REPORT aufgenommen.

Großes Kurspotenzial für Unigene erwartet das Team vom AKTIONÄR von einem positiven Bescheid durch die US-Gesundheitsbehörde FDA für ein Osteoporose-Medikament. Diese dürfte schon bald erfolgen - das Unternehmen befindet sich bereits in so genannten "Labeling discussions".

Aus charttechnischer Sicht ist das Überwinden der 200-Tage-Linie, die derzeit bei knapp 1,92 Dollar verläuft, von großer Bedeutung. Nächster Widerstand wäre dann das Vier-Jahres-Hoch bei 2,63 Dollar. Eine positive Entscheidung der Gesundheitsbehörde könnte den Kurs schnell wieder in diese Region katapultieren.

[thecatcher]

Bei uns ist ja immer noch Lemmingalarm!!

US-Kurs 1,90$ d.h. 1,52/53€

Gehandelt wird aber 1,60/61



Warum verschenkt ihr alle euer Geld???

Gebt es doch lieber mir bevor ihr hier einen Aufschlag bezahlt

[erdbeerblaue Nuss]

Press Release Source: Unigene Laboratories, Inc.


FDA Approves Fortical, Unigene`s Nasal Calcitonin Product for Postmenopausal Osteoporosis
Monday August 15, 7:00 am ET
Unigene to Receive $4 Million Milestone Payment from Upsher-Smith


FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 15, 2005--Unigene Laboratories, Inc. (OTCBB:UGNE - News) has received approval from the U.S. Food and Drug Administration ("FDA") for Fortical® calcitonin-salmon (rDNA origin) Nasal Spray, its patented nasal calcitonin product for the treatment of postmenopausal osteoporosis. FDA approval triggers the final milestone payment of $4 million under Unigene`s exclusive U.S. licensing agreement with Upsher-Smith Laboratories, Inc.
ADVERTISEMENT




Fortical® will be manufactured at Unigene`s production facility in Boonton, New Jersey. The final product will be packaged, marketed and sold in the United States by Upsher-Smith. Unigene will sell the filled product to Upsher-Smith and receive royalties on Upsher-Smith`s sales.

"We are understandably excited to receive FDA approval for our first pharmaceutical product in the U.S.," commented Dr. Warren Levy, President and CEO of Unigene. "This is a pivotal accomplishment for any company in our industry and it will provide the rapidly growing population of postmenopausal osteoporosis sufferers with an additional option for managing the disease. We are confident that Upsher-Smith`s enthusiasm and commitment to the product will give us the best opportunity to realize Fortical®`s potential. We expect that the revenues generated from sales of Fortical® will allow us to strengthen our financial position and expand our activities into new applications of our patented peptide manufacturing and oral delivery technologies."

"We are thrilled that the FDA has approved Unigene`s Fortical® as an important therapy for the osteoporosis market, which in 2004 grew nearly 18% to reach $4 billion," said Mark Evenstad, Upsher-Smith President and Vice Chair. "We look forward to engaging our marketing and distribution expertise to help make this important calcitonin product available to the millions of Americans affected by osteoporosis."

Fortical® Indication

Fortical® is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women.

Conference Call Details

Unigene will host a conference call on August 15, 2005 beginning at 2:00 P.M. EDT to discuss the FDA approval of Fortical®.

Unigene invites all those interested in hearing management`s discussion of the FDA approval of Fortical to join the call by dialing 1-888-802-2266 for participants in the United States and 1-913-312-1270 for international participants and entering access code 4204125 when prompted. A replay will be available for 45 days after the call and can be accessed by dialing 1-888-203-1112 for participants in the United States and 1-719-457-0820 for international participants and entering access code 4204125 when prompted.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Unigene has licensed its oral PTH technology to GlaxoSmithKline. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com.

About Upsher-Smith

Upsher-Smith Laboratories, Inc. is a fully integrated pharmaceutical company that manufactures and markets prescription pharmaceutical, OTC and cosmetic products. Upsher-Smith is also actively involved in licensing innovative compounds that are currently in clinical development. For more information about Upsher-Smith Laboratories, call [phone] or visit www.upsher-smith.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings.. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.



--------------------------------------------------------------------------------
Contact:
The Investor Relations Group
Investors:
Damian McIntosh or Dian Griesel, Ph.D.
Media: Janet Vasquez
212-825-3210
or
Upsher-Smith Laboratories, Inc.
Phill Dritsas, 763-315-2169



--------------------------------------------------------------------------------
Source: Unigene Laboratories, Inc.

[Grafvonlahnstein]

Sind das jetzt die erwarteten News???

[longwave]

NEWS und explosives Orderbuch!!!!

UNIGENE LABORATORIES INC (UGNE:OTC:BB) UGNE: Price Change

vorbörslich in Kanada
BID / ASK
1.94 (10) / 1.94 (5)


UNIGENE LABS INC
Skontroführer: Berliner Freiverkehr Aktien (1170)


Best Bid
Volumen Taxe
- 1,65

Kauf Orders
Stücke Limit
3.000 1,69
2.000 1,65
900 1,6
1.000 1,51
2.000 1,45
Weitere: 1
Best Ask
Taxe Volumen
1,7 -

Verkauf Orders
Limit Stücke
1,7 7.000
- -
- -
- -
- -
Weitere: 0

[schusterjunge]

na,wo bleibt dein beitrag,he ,haste kurse etwa noch nicht mitbekommen????

[BC01]

Unigene / WKN 875 852 / Kursziel 3,00 Euro
Perfektes Timing: Nur wenige Tage nachdem die Aktie von Unigene ins Depot aufgenommen wurde, hat das Biotech-Unternehmen von der US-Gesundheitsbehörde FDA die lang ersehnte Zulassung für das Osteoporose-Mittel Fortical erhalten. Fortical ist das erste Medikament, das Unigene bis zur Marktreife entwickelt hat. Die Vermarktungserlaubnis für das Osteoporose-Medikament, das über die Nasenschleimhäute aufgenommen wird, stellt für die kleine Firma aus Fairfield in New Jersey deshalb in jeder Hinsicht einen Meilenstein dar.

Fundamental steht das Unternehmen nun vor einer Neubewertung. Bereits im kommenden Jahr soll sich die Vermarktung von Fortical, die von Upsher-Smith Laboratories übernommen wird, massiv im Ergebnis niederschlagen. Vorab erhält Unigene von Upsher-Smith bereits eine Meilensteinzahlung in Höhe von vier Millionen Dollar.

Die Aktie reagierte auf die Meldung mit einem Kursprung von fast 20 Prozent. Und es gibt gute Gründe, dass die Rallye sich auch in den kommenden Wochen und Monaten fortsetzen wird. Denn durch die positive Publicity dürften zunehmend Analysten und auch Fonds auf den Wert aufmerksam werden. Als nächstes Kursziel sollte das Papier das Vier-Jahres-Hoch bei 2,63 Dollar ins Visier nehmen. Wird diese Marke überschritten, winken Kurse um drei Dollar

[toothstone]

Aus ihub:


The current price around 2.50 does not nearly reflect the fair value at this stage of the co`s development. While approval of nasal calcitonin legitamizes the technology, it also permits all other events to possibly come to fruition. Cash flow will permit the company to continue R&D as well as starting up China sales. The $3.00 level will start a snowball effect as the company can then be listed on a more liquid exchange and not be subject to the vagaries of market maker manipuation. If you own enogh Mr. nitetrak you will be very wealthy soon.If you don`t, I encourage you to buy more at these levels sinc it won`t be here for long. Anyone of three ot for possible events should cause the price to move t the $4-5 level in a Vioxx heartbeat.


Hört sich doch gut an.
Die Aktionärempfehlung würde ich aber nicht überbewerten,
macht eure eigene DD.

[rk091161]

August 22, 2005 - 7:00 AM EDT
UGNE 2.50 0.07

Today 5d 1m 3m 1y 5y 10y



Unigene and Novartis Complete Technology Transfer For Calcitonin Manufacturing; Sandoz Successfully Concludes First Full-Scale Production Campaign
The transfer of Unigene Laboratories, Inc. (OTCBB: UGNE) proprietary manufacturing technology to Novartis for manufacturing calcitonin has been completed successfully.

Sandoz, a Novartis affiliate, has concluded a manufacturing campaign based on Unigene`s process and produced multiple kilograms of calcitonin at a scale that represents a ten-fold increase above Unigene`s current production capacity. Calcitonin produced by Sandoz is projected to be used by Novartis in future studies including clinical trials.

According to the terms of the agreement between Unigene and Novartis signed in 2004, Novartis was granted an exclusive worldwide license to produce recombinant calcitonin using Unigene`s patented process for manufacturing recombinant peptides. Under that agreement, Unigene has received $8.2 million to date and is eligible to receive up to $10.5 million in milestones in addition to royalties on sales of any current or future Novartis products that will contain calcitonin made using Unigene`s process.

"The rapid implementation of our process in Sandoz`s large-scale facilities was made possible because of the efficient and productive collaboration between Sandoz and Unigene scientists coupled with the extensive recombinant manufacturing experience of Sandoz," commented Dr. Warren P. Levy, President and CEO of Unigene. "We believe that the Sandoz facility should be capable of supporting the future requirements of Novartis and Unigene for calcitonin."

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Unigene has licensed the U.S. rights for its nasal calcitonin product to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched this month. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings.. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.


The Investor Relations Group
Investors: Damian McIntosh/Dian Griesel, Ph.D.
Media: Janet Vasquez
212-825-3210



Source: Business Wire (August 22, 2005 - 7:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

[rk091161]

leider wieder ein grauenhaftes übersetzungsprogramm


Heute 5d 1m 3m 1y 5y 10y Unigene und Novartis kompletter Technologietransfer für Calcitonin Herstellung; Sandoz folgert erfolgreich erste maßstäbliche Produktion Kampagne die Übertragung von Unigene Laboratories, Inc. (OTCBB: UGNE) ist eigene Herstellung Technologie zu Novartis für Herstellung calcitonin erfolgreich durchgeführt worden. Sandoz, ein Novartis Teilnehmer, hat eine Herstellung Kampagne gefolgert, die auf Prozeß Unigenes basiert und mehrfache Kilogramm calcitonin an einer Skala produziert, die eine zehnfache Zunahme über der gegenwärtigen Kapazität Produktion Unigenes darstellt. Calcitonin produzierte durch Sandoz wird projiziert, durch Novartis in den zukünftigen Studien einschließlich klinische Versuche verwendet zu werden. Entsprechend den Bezeichnungen der Vereinbarung zwischen Unigene und Novartis, die 2004 unterzeichnet wurden, wurde Novartis eine exklusive weltweite Lizenz bewilligt, recombinant calcitonin mit Unigenes patentiertem Prozeß für die Produktion der recombinant Peptide zu produzieren. Unter dieser Vereinbarung hat Unigene $8.2 Million bis jetzt empfangen und geeignet ist, bis $10.5 Million in den Meilensteinen zusätzlich zu den Abgaben auf Verkäufen aller gegenwärtigen oder zukünftigen Novartis Produkte zu empfangen, die das calcitonin enthalten, das mit Prozeß Unigenes gebildet wird. "die schnelle Implementierung unseres Prozesses Sandozs im großräumigen Service wurde wegen der leistungsfähigen und produktiven Zusammenarbeit zwischen Sandoz und Unigene den Wissenschaftlern ermöglicht, die mit der umfangreichen recombinant Herstellung Erfahrung von Sandoz verbunden wurden," kommentierte Dr. Warren P. Levy, Präsident und CEO von Unigene. "wir glauben, daß der Sandoz Service zum Stützen der zukünftigen Anforderungen von Novartis und von Unigene für calcitonin fähig sein sollte." Über Unigene Unigene Laboratories, Inc. ist eine biopharmaceutical Firma, die auf die Mund- und nasale Anlieferung der Großmarkt Peptiddrogen konzentriert. Wegen der Größe des weltweiten Osteoporosemarktes, Unigene zielt seine Ausgangsbemühungen auf sich entwickelndem calcitonin und PTH-gegründeten Therapien. Unigene hat die VEREINIGTE STAATEN Rechte für sein nasales calcitonin Produkt zu den Upsher-Smith Labors, die weltweiten Rechte für seine Mund-PTH Technologie zu GlaxoSmithKline und die weltweiten Rechte für seine calcitonin Herstellung Technologie zu Novartis genehmigt. Fortical(R), nasales Produkt calcitonin Unigenes für die Behandlung der postmenopausal Osteoporose, empfangene FDA-Zustimmung und wurde dieser Monat ausgestoßen. Hat patentierte MundTechnologie anlieferung Unigenes erfolgreich, in die preclinical und/oder klinischen Versuche, verschiedene Peptide einschließlich calcitonin, PTH und Insulin geliefert. Unigenes patentierte herstellentechnologie ist entworfen, um Peptide in den Quantitäten kosteneffektiv zu produzieren, die genügend sind, ihre weltweite Kommerzialisierung als Mund- oder nasale Therapeutik zu stützen. Zu mehr Information über Unigene, benennen Sie [phone] oder besuchen Sie www.unigene.com. Sichere Hafenaussagen unter der privaten Sicherheiten Rechtsstreit-Verbesserung-Tat von 1995: Dieses Pressekommuniquã© enthält das Vorwärts-Schauen der Aussagen betreffend sind uns und unser Geschäft, finanzieller Zustand, Resultate der Betriebe und Aussichten. Solche Vorwärts-schauende Aussagen schließen die mit ein, die ausdrückliche Pläne, Erwartung, Absicht, Möglichkeit, Ziele, Ziele oder zukünftige Entwicklung und/oder anders nicht Aussagen über historische Tatsache sind. Wir haben diese Vorwärts-schauenden Aussagen auf unseren gegenwärtigen Erwartungen gegründet und Projektionen über zukünftige Fälle und sie sind abhängig von den bekannten Gefahren und Ungewißheiten und Unbekanntes, die tatsächliche Resultate und Entwicklungen veranlassen konnten, sich von denen materiell zu unterscheiden, die in solchen Aussagen ausgedrückt wurden oder angedeutet waren. Diese Vorwärts-schauenden Aussagen schließen Aussagen über das folgende ein: allgemeine ökonomische und Geschäft Zustände, unser finanzieller Zustand, Konkurrenz, unsere Abhängigkeit auf anderen Firmen, Produkte mit unseren Technologien in den Handel zu bringen, herzustellen und zu verkaufen, die Ungewißheit von Resultaten Tier- und menschlichen, die Gefahr der Zuverläßlichkeit von Produkten und Verbindlichkeit auf menschliche Versuche innen prüfen, unserer Abhängigkeit auf Patenten und andere eigene Rechte, der Abhängigkeit auf Schlüsselmanagementbeamten, der Verwendbarkeit und der Kosten der Kapitalbeschaffung, der Verwendbarkeit des qualifizierten Personals, der Änderungen oder der Störung, mit einzuwilligen, der Regierungsregelungen, die Störung, Genehmigungen durch die zuständige Aufsichtsbehörde für unsere Produkte und andere Gefahr Faktoren zu erreichen besprochen in unseren Sicherheiten und Austausch-Kommission Archivierungen. Wörter wie "nimmt," "erwartet," "beabsichtigt," "Pläne," "voraussagt," "glaubt," "Suchvorgänge," "Schätzungen," "können," "werden," "vorweg, wenn," "," "Potential," "fortfahren," wurde und Veränderungen dieser Wörter (oder Negative dieser Wörter) oder ähnliche Ausdrücke, sollen das Vorwärts-Schauen von von Aussagen kennzeichnen. Zusätzlich Vorwärts-schauen alle mögliche Aussagen, die auf Erwartungen, Projektionen sich beziehen oder andere Kennzeichnungen der zukünftigen Fälle oder der Umstände, einschließlich irgendwelche zugrundeliegenden Annahmen, Aussagen. Diese Vorwärts-schauenden Aussagen sind nicht Garantien der zukünftigen Leistung und sind abhängig von bestimmten Gefahren, Ungewißheiten und Annahmen, die schwierig vorauszusagen sind. Folglich konnten unsere tatsächlichen Resultate von denen materiell und nachteilig sich unterscheiden, die in allen möglichen Vorwärts-schauenden Aussagen resultierend aus verschiedenen Gefahr Faktoren ausgedrückt wurden. Die Beziehungen zwischen den Investoren Gruppieren Investoren: Damian McIntosh/Dian Griesel, Ph.D. Media: Janet Vasquez 212-825-3210 Quelle: Geschäft Leitung (August 22, 2005 - 7:00 Morgens EDT) Nachrichten durch QuoteMedia www.quotemedia.com

[rk091161]

Unigene zum Geschenk an den ThinkEquity Partner-Konferenz Unigene Labors, Inc. (OTCBB: UGNE) Präsident und CEO, Dr. Warren Levy, sprechen bei der 3. jährlichen ThinkEquity Partner-Konferenz am Donnerstag, September 15, 2005 bei 9:00AM PDT. Dr. Levy stellt Informationen über der die Produkte und die collaborations Firma Analytikern, Portefeuille-Verwaltern, Investmentbankern und anderen finanziellen Fachleuten dar. Die Konferenz wird im Ritz Carlton Hotel in San Francisco von einem September 12-15, 2005 gehalten. Über Unigene Unigene Laboratories, Inc. ist eine biopharmaceutical Firma, die auf die Mund- und nasale Anlieferung der Großmarkt Peptiddrogen konzentriert. Wegen der Größe des weltweiten Osteoporosemarktes, Unigene zielt seine Ausgangsbemühungen auf sich entwickelndem calcitonin und PTH-gegründeten Therapien. Fortical(R), nasales Produkt calcitonin Unigenes für die Behandlung der postmenopausal Osteoporose, empfangene FDA-Zustimmung und wurde im August 2005 ausgestoßen. Unigene hat die VEREINIGTE STAATEN Rechte für Fortical(R) zu den Upsher-Smith Labors, die weltweiten Rechte für seine Mund-PTH Technologie zu GlaxoSmithKline und die weltweiten Rechte für seine calcitonin Herstellung Technologie zu Novartis genehmigt. Hat patentierte MundTechnologie anlieferung Unigenes erfolgreich, in die preclinical und/oder klinischen Versuche, verschiedene Peptide einschließlich calcitonin, PTH und Insulin geliefert. Unigenes patentierte herstellentechnologie ist entworfen, um Peptide in den Quantitäten kosteneffektiv zu produzieren, die genügend sind, ihre weltweite Kommerzialisierung als Mund- oder nasale Therapeutik zu stützen. Zu mehr Information über Unigene, benennen Sie [phone] oder besuchen Sie www.unigene.com. Sichere Hafenaussagen unter der privaten Sicherheiten Rechtsstreit-Verbesserung-Tat von 1995: Dieses Pressekommuniquã© enthält das Vorwärts-Schauen von von Aussagen, wie definiert im Abschnitt 27A der Sicherheiten Tat von 1933, wie geändert und Abschnitt 21E des Börsengesetzes von 1934, wie geändert. Solche Vorwärts-schauende Aussagen basieren nach Unigene Labor-, Inc.management gegenwärtige Erwartungen, Schätzungen, Glaube, Annahmen und Projektionen über Geschäft und Industrie Unigenes. Wörter wie "nimmt," "erwartet," "beabsichtigt," "Pläne," "voraussagt," "glaubt," "Suchvorgänge," "Schätzungen," "können," "werden," "vorweg, wenn," "," "Potential," "fortfahren," wurde und Veränderungen dieser Wörter (oder Negative dieser Wörter) oder ähnliche Ausdrücke, sollen das Vorwärts-Schauen von von Aussagen kennzeichnen. Zusätzlich Vorwärts-schauen alle mögliche Aussagen, die auf Erwartungen, Projektionen sich beziehen oder andere Kennzeichnungen der zukünftigen Fälle oder der Umstände, einschließlich irgendwelche zugrundeliegenden Annahmen, Aussagen. Diese Vorwärts-schauenden Aussagen sind nicht Garantien der zukünftigen Leistung und sind abhängig von bestimmten Gefahren, Ungewißheiten und Annahmen, die schwierig vorauszusagen sind. Folglich konnten unsere tatsächlichen Resultate von denen materiell und nachteilig sich unterscheiden, die in allen möglichen Vorwärts-schauenden Aussagen resultierend aus verschiedenen Gefahr Faktoren ausgedrückt wurden. Diese Gefahren und Ungewißheiten schließen die Gefahren ein, die mit dem Effekt des Änderns von von Wirtschaftslage, von von Tendenzen in den Produktmärkten, von von Schwankungen des Bargeldumlaufs Unigenes, von von Marktannahmegefahren, von von technischen Entwicklung Gefahren und anderen von von Gefahr Faktoren genau geschildert werden in den Sicherheiten und Austausch-Kommission Archivierungen Unigenes verbunden sind. Die Beziehungen zwischen den Investoren Gruppieren Damian McIntosh/Dian Griesel, Ph.D., 212-825-3210 Quelle: Geschäft Leitung (September 8, 2005 - 8:31 Morgens EDT) Nachrichten durch QuoteMedia

[rk091161]

14.09.2005

Unigene Receives $4 Million Milestone Payment for Fortical(R) Approval; Product Rollout on Target
Unigene Laboratories, Inc. (OTCBB:UGNE) has received a $4 million milestone payment from Upsher-Smith Laboratories, Inc. for receiving FDA approval for Fortical(R), its nasal calcitonin product for the treatment of postmenopausal osteoporosis. This is the final milestone payment in Unigene`s exclusive U.S. licensing agreement with Upsher-Smith. Fortical, Unigene`s first U.S. product, was approved and launched last month and is currently available by prescription at retail pharmacies nationwide.

"The expected steady stream of revenue, from both product sales to Upsher-Smith as well as royalties, should greatly improve our cash flow," commented Dr. Warren Levy, President and CEO of Unigene. "We are working closely with Upsher-Smith to support their commercialization activities and continue to be impressed with their commitment to Fortical."

"Upsher-Smith is excited with the significant uptake Fortical has enjoyed since launch," says Phill Dritsas, Vice President, Marketing and Sales for Upsher-Smith. "Our customers are excited to be able to offer a low-cost, branded alternative in the osteoporosis market."

"The final milestone payment signifies what we hope to be the beginning of a long and profitable relationship for both Upsher-Smith and Unigene Laboratories," says Mark Evenstad, Vice Chairman and President of Upsher-Smith Laboratories, Inc.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com.

About Upsher-Smith

Upsher-Smith Laboratories, Inc. is a fully integrated pharmaceutical company that manufactures and markets prescription pharmaceutical, OTC and cosmetic products. Upsher-Smith is also actively involved in licensing innovative compounds that are in clinical development. For more information about Upsher-Smith Laboratories, Inc., call 800-654-2299 or visit www.upsher-smith.com

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.`s management`s current expectations, estimates, beliefs, assumptions, and projections about Unigene`s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene`s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene`s Securities and Exchange Commission filings.


The Investor Relations Group
Damian McIntosh / Dian Griesel, Ph.D.
Phone: [phone]



Source: Business Wire (September 14, 2005 - 8:32 AM EDT)

[rk091161]

Unigene and Yale University Invent Technologies to Build New Bone
Unigene Laboratories, Inc. (OTCBB:UGNE) and Yale University have executed agreements to enable Unigene to acquire exclusive rights to their jointly-owned inventions for procedures that may provide physicians with new methodologies for treating and preventing fractures more effectively. Patent applications have been filed for two inventions.

The first invention is designed to facilitate and accelerate bone growth in precisely targeted locations in the body using a simple surgical procedure that can be performed with minimal intervention on an outpatient basis in combination with one or more therapeutic compounds. The second invention covers unique devices that could be used to facilitate bone repair or to create novel prostheses. Both inventions were conceived in collaboration with Dr. Agnes Vignery, Associate Professor of Orthopaedic Surgery at Yale School of Medicine.

Unigene is currently sponsoring developmental research activities at the University and is assembling an internationally distinguished group of orthopedic surgeons with whom it will evaluate the technologies in animal and human studies.

"The Unigene/Yale techniques have the potential to provide a dramatic new treatment for these problems," commented Dr. Donlin M. Long, M.D., Ph.D., Distinguished Service Professor of Neurosurgery at the Johns Hopkins University School of Medicine. "The ability to facilitate bone growth is of great practical importance for the treatment of spinal fractures, especially in the elderly. Compression fractures are common and can be very painful. Growing new bone with this invention offers potential relief for the large number of patients who cannot be helped by any treatment now in use. Improved bone healing can improve outcomes from many spinal surgeries and can reduce the incidence of pain and prolonged disability."

"These technologies further enhance our corporate profile in the field of bone-related therapies," said Dr. Ronald S. Levy, Executive Vice President of Unigene. "Both the physicians and the pharma industry representatives with whom we discussed this have confirmed the extensive potential of these inventions. They could have a major impact on the way in which serious bone fractures are treated."

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call 973-882-0860 or visit www.unigene.com.


The Investor Relations Group
Damian McIntosh or Dian Griesel, Ph.D.
or
Janet Vasquez or Mary Ann Mullady (Media)
Phone: [phone]
or
Yale Public Affairs
Dr. Janet Emanuel, 203-432-2157

[rk091161]

Unigene und Yale Universität erfinden Technologien, um New Bone Unigene Laboratories, Inc. (OTCBB:UGNE) zu errichten und Yale haben Universität Vereinbarungen durchgeführt, Unigene zu ermöglichen, ausschließliche Rechte zu ihren gemeinsam-besessenen Erfindungen für Verfahren zu erwerben, die Ärzte mit neuen Methodenlehren für Brüche effektiv behandeln und verhindern versehen können. Patentanfragen sind für zwei Erfindungen eingeordnet worden. Die erste Erfindung ist entworfen, um zu erleichtern und beschleunigt Knochenwachstum in genau gerichteten Positionen im Körper mit einem einfachen chirurgischen Verfahren, das mit minimaler Intervention auf einer Patientgrundlage im Verbindung mit einem oder mehr therapeutischen Mitteln durchgeführt werden kann. Die zweite Erfindung umfaßt einzigartige Vorrichtungen, die benutzt werden konnten, um Knochenreparatur zu erleichtern oder Romanprothesen herzustellen. Beide Erfindungen wurden gemeinsam mit Dr. Agnes Vignery, Teilnehmer-Professor der orthopädischen Chirurgie an der Yale Schule von Medizin begriffen. Unigene z.Z. fördert Entwicklungsforschung Tätigkeiten an der Universität und baut eine international bemerkenswerte Gruppe orthopädische Chirurgen zusammen, mit denen sie die Technologien in den Tier- und Mensch Studien auswertet. "die Unigene/Yale Techniken haben das Potential, eine drastische neue Behandlung für diese Probleme zur Verfügung zu stellen," kommentierter Dr. Donlin M. Long, M.D., Ph.D., bemerkenswerter Service-Professor der Neurochirurgie an der Johns Hopkins Universitätsschule von Medizin. "die Fähigkeit, Knochenwachstum zu erleichtern ist vom großen praktischen Wert für die Behandlung der spinalen Brüche, besonders in den älteren Personen. Kompression Brüche sind allgemein und können sehr schmerzlich sein. Wachsender neuer Knochen mit dieser Erfindung bietet mögliche Entlastung für the.large.number.of Patienten an, die nicht durch irgendeine Behandlung im Gebrauch jetzt geholfen werden können. Der verbesserte heilend Knochen kann Resultate von vielen spinalen Operationen verbessern und kann die Ausdehnung der Schmerz und der verlängerten Unfähigkeit verringern." "diese weiteren Technologien erhöhen unser Unternehmensprofil in auffangen der Knochen-in Verbindung stehenden Therapien,", sagte Dr. Ronald S. Levy, Executivvizepräsident von Unigene. "haben die Ärzte und die pharma Industrierepräsentanten, mit denen wir dieses besprachen, das umfangreiche Potential dieser Erfindungen bestätigt. Sie konnten eine spürbare Auswirkung auf die Weise haben, in der ernste Knochenbrüche werden behandelt." Über Unigene Unigene Laboratories, Inc. ist eine biopharmaceutical Firma, die auf die Mund- und nasale Anlieferung der Großmarkt Peptiddrogen konzentriert. Wegen der Größe des weltweiten Osteoporosemarktes, Unigene zielt seine Ausgangsbemühungen auf sich entwickelndem calcitonin und PTH-gegründeten Therapien. Fortical(R), nasales Produkt calcitonin Unigenes für die Behandlung der postmenopausal Osteoporose, empfangene FDA-Zustimmung und wurde im August 2005 ausgestoßen. Unigene hat die VEREINIGTE STAATEN Rechte für Fortical zu den Upsher-Smith Labors, die weltweiten Rechte für seine Mund-PTH Technologie zu GlaxoSmithKline und die weltweiten Rechte für seine calcitonin Herstellung Technologie zu Novartis genehmigt. Hat patentierte MundTechnologie anlieferung Unigenes erfolgreich, in die preclinical und/oder klinischen Versuche, verschiedene Peptide einschließlich calcitonin, PTH und Insulin geliefert. Unigenes patentierte herstellentechnologie ist entworfen, um Peptide in den Quantitäten kosteneffektiv zu produzieren, die genügend sind, ihre weltweite Kommerzialisierung als Mund- oder nasale Therapeutik zu stützen. Zu mehr Information über Unigene, benennen Sie 973-882-0860 oder besuchen Sie www.unigene.com. Die Beziehungen zwischen den Investoren gruppieren Damian McIntosh oder Dian Griesel, Ph.D. oder Janet Vasquez oder Mary Ann Mullady (Mittel) Telefon: [phone] oder Yale öffentliche Angelegenheitendr. Janet Emanuel, 203-432-2157

[toothstone]

Wieder einmal eine super positive Überraschung.
Unigene ist sicher eine der bestaufgestellten Biotechfirmen
überhaupt.
Als nächstes sollte ein Glaxo-Smith-Update kommen.
Und ganz wichtig noch die Chinazulasung von Fortical in diesem Jahr. Der Kurs würde höher stehen, wenn nicht ein paar große Blöcke ins ask reingestellt worden wären. Vielleicht aber auch nur Mm-Spielchen, die wissen was kommt. Oder aber einige, die schon 1000% haben und Geld brauchen. Ich denke´, daß die Umschichtung in feste Hände abgeschloßen ist.
Am Donnerstag Ubs-Konferenz und im Oktober steht auch noch einiges an.
Von Calcitonin und anderen Überaschungen möchte ich gar nicht sprechen.

[toothstone]

Gibt auch einen sehr schönen Ragingbull-Thread, ohne irgendwelches Gepushe, sehr angenehm.

[rk091161]

Unigene to Present at the UBS Warburg Global Life Sciences Conference
Unigene Laboratories, Inc.`s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the 7th Annual UBS Warburg Global Life Sciences Conference on Thursday, September 29, 2005 at 4:00 P.M. Dr. Levy will present information on Unigene`s products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Grand Hyatt in New York City from September 26-29, 2005.

A live audio webcast of the presentation will also be available on the UBS website at www.ibb.ubs.com. An audio replay of the presentation will begin three hours after the presentation time and will be available until October 29, 2005.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.`s management`s current expectations, estimates, beliefs, assumptions, and projections about Unigene`s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene`s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene`s Securities and Exchange Commission filings.


Investors:
The Investor Relations Group
Damian McIntosh or Dian Griesel, 212-825-3210



Source: Business Wire (September 26, 2005 - 8:45 AM EDT)

News by QuoteMedia

[toothstone]

Aus RB:
DD on UGNE.ob

1. ONLY biotech company to both manufacture and deliver peptides.
2. Has approval for competitor to Miacalcin (norvartis drug) for osteoporosis ($236 mm/year) .
a. Makes calcitonin so pure and cheap that NVS licenced
manufacturing technology to implement in own drugs.
1. UGNE to reap benefits in royalty from any
product made with their calcitonin manufacturing
2. Able to buy all calcitonin it needs from NVS at
pre-negotiated price.
3. Fortical is being heavily promoted by UGNE partner Upsher-Smith laboratories ( a billion dollar drug company), while miacalcin apparently has not been promoted by NVS.
4. NEW indications for calcitonin nasal sprays might be approved in the near future...possibly for osteoarthritis, a condition 20mm people have in the USA.
5. Fortical is not only much cheaper to make than miacalcin,
but also doesn`t have the known nasal irritant
benzalkonium chloride, which is irritating to the nasal
mucous membranes.
6. NVS has implemented UGNE process, and is in the process
of launching sometime in the near future, a phase III
for oral calcitonin, a drug which has blockbuster
potential, giving UGNE royalties indefinitely.
7. According to CEO, UGNE has own oral calcitonin program,
which they have already completed 7 human studies
with...and they are apparently in discussions with
Anxious partners currently.
8. UGNE also has a worldwide deal (worth > $150mm) with GSK
for an oral PTH drug. GSK is reportedly agressively
planning phase II study. Only $5/150mm been received
so far.
a. PTH has potential to grow bone.
b. Calcitonin stops bone from degenerating.
1. Drugs could someday be complementary combo.
9. Recently announced they have made inventions which could
someday grow bone in an outpatient setting.
a. Improve healing process in fractures.

10. UGNE has potential to manufacture/deliver ORALLY...

a. DDAVP
b. INSULIN
c. Lupron

****Tried to gather info from company reports/filings...feel
free to add more objective info and distribute******

Vergessen hat dieser user noch den dicken Chinadeal.

[rk091161]

demnächst zulassung fortical in china und update mit glaxo...mfg

[rk091161]

heute kommt die meldung über zulassung fortical in china oder das update mit glaxo..

[rk091161]

Unigene Laboratories To Present at the C.E. Unterberg, Towbin 2005 Life Sciences Conference
Unigene Laboratories, Inc.`s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference on Tuesday, October 25th at 4:40 PM EDT. Dr. Levy will present information on Unigene`s products and collaborations. The conference will be held at The Palace Hotel in New York City on October 25th and 26th.

The C.E. Unterberg Towbin Emerging Life Sciences Conference features more than 60 emerging leaders in the life science, diagnostics, med tech, specialty pharmacy and medical device industries.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

The presentation time is subject to change. Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.`s management`s current expectations, estimates, beliefs, assumptions, and projections about Unigene`s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene`s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene`s Securities and Exchange Commission filings.


Investor:
The Investor Relations Group
Damian McIntosh / Dian Griesel, Ph.D.
Media: Janet Vasquez
212-825-3210

[toothstone]

@ rk dauert wohl noch ein bißchen, aber sie wird kommen.

[rk091161]

...dachte ich schreib hier alleine....mfg

[rk091161]

von heute:

Unigene Laboratories to Present at the PIPEs Conference 2005
Unigene Laboratories, Inc.`s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the PIPEs Conference 2005 on Wednesday, October 26th at 11:30 AM, 12:00 PM, and 2:30 PM EDT. Dr. Levy will present information on Unigene`s products and collaborations. The conference will be held at the Waldorf-Astoria in New York City on October 26th and 27th.

The PIPEs Conference 2005 features investors, investment bankers, attorneys, company executives, and industry analysts active in the small cap equity market. The conference includes CLE-accredited workshops, roundtables, and presentations from leading industry professionals. Information about the event can be found at www.thepipesconference.com

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

The presentation time is subject to change. Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.`s management`s current expectations, estimates, beliefs, assumptions, and projections about Unigene`s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene`s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene`s Securities and Exchange Commission filings.


The Investor Relations Group
Investors:
Damian McIntosh/Dian Griesel, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210



Source: Business Wire (October 20, 2005 - 8:45 AM EDT

[toothstone]

Schaut ja hervorragend aus. Und es gingen richtig große Blöcke über den Tisch, wenn da mal einer nicht mehr weiß.

[cripplecreek]

[posting]18.365.446 von toothstone am 21.10.05 09:52:41[/posting]Die shares der MM´s wurden sehr schnell aufgesogen. Es gibt anscheinend eine enorme Nachfrage nach Aktien. Bin mir ziemlich sicher, dass wir schnell auf die 4 laufen werden, evtl. höher. Zum Jahresende stehen einige Meldungen an.

[toothstone]

Sie läuft und läuft und es ist hier total ruhig, aber eigentlich ist das schön.
Dieses professionelle einkaufen geht weiter, ganz interessant auch an manchen Tagen gegen handelsende dieser Versuch mit ein paar Stücken den Kurs zu drücken, um etwas negativen Beigeschmack einzumischen.
Long and Strong

[rk091161]

...weiss jemand wann es die quartalszahlen gibt?mfg

[toothstone]

Sollten so Mitte November kommen.
Lies das rb-board wird schon heiß spekuliert, welche milestones und was sonst noch mit drin sein könnte.

[rk091161]

von gestern eine meldung:

November 2, 2005 - 10:20 AM EST
UGNE 3.14 N/A

Today 5d 1m 3m 1y 5y 10y



Unigene Laboratories to Present at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference
Unigene Laboratories, Inc.`s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference on Monday, November 7th at 12:20 PM EST. Dr. Levy will present information on Unigene`s products and collaborations. The conference will be held at The Palace Hotel in New York City on November 7-9.

An audio webcast of the presentation will be available on the date of the presentation and will be archived for 90 days. The link for the presentation is http://www.wsw.com/webcast/rrshq7/ugne/.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

The presentation time is subject to change. Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.`s management`s current expectations, estimates, beliefs, assumptions, and projections about Unigene`s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene`s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene`s Securities and Exchange Commission filings.


The Investor Relations Group
Investor:
Damian McIntosh/Dian Griesel, Ph.D.
Media: Janet Vasquez
212-825-3210



Source: Business Wire (November 2, 2005 - 10:20 AM EST)

[rk091161]

http://www.stockta.com/cgi-bin/analysis.pl?symb=UGNE&num1=1&…

[rk091161]

http://www.unigene.com/products/partnerships.html

[rk091161]

..was ist los???...

[rk091161]

verdammte shorties...

[dehoim]

Hier hast Du deine Shorties

Eintrag aus RB
gogi73
15 Nov 2005, 07:39 AM EST
Msg. 7203 of 7203
Jump to msg. #
10-Q: UGNE filed a notification of late filing for the 10-Q "due to to the prolonged illness and absence of the CFO during the reporting period..."

[rk091161]

wer weiss denn wann die zahlen kommen?

[toothstone]

auf rb vermuten sie in 5 Tagen, weil der ceo einen bypass
gekriegt hat, also ruhig blut, wahrscheinlich gute nachkaufchance.

[jonathanheart]

[posting]18.827.490 von toothstone am 15.11.05 18:02:10[/posting]ich stocke weiter kräftig auf
bin mal gespannt was der earnings cc so alles ans licht bringen wird.
was hat man bereits an US verkauft ? wie schlägt sich Fortical im markt .......

[dehoim]

[posting]18.844.008 von jonathanheart am 16.11.05 19:41:10[/posting]Du musst ja Kohle haben

[toothstone]

earnings 22.11. before the bell,
dann um 9 uhr eastern conferencecall

[rk091161]

wie sind eure meinungen zum quartal?im letzten quartal sind zweimal meilenstein zahlungen eingegangen,4 und einmal glaub ich 8,5 mill.normalerweise müsste es ein gutes ergebniss werden,vielleicht sogar ein kleiner gewinn pro aktie?mfg

[toothstone]

denke, daß die zahlen gar nicht so wichtig sein werden,
china, calcitonin und marktpotential von fortical in usa.
außerdem fehlt noch ein update in europa.

[rk091161]

..hat einer eine vermutung wieso der kurs hier bei uns nicht so mitläuft wie in amiland,normalerweise müssten wir jetzt bei 2,90 stehen....

[rk091161]

was ist jetzt wieder los..warum fällt der kurs in amiland..quartalszahlen schlecht???mfg

[toothstone]

nix, waren wohl bloß enttäuschte daytrader,
bei 9 cent gewinn per share, und in den nächsten quartalen sicher mögliche 40 cent wurde diese wohl auf dem falschen fuß erwischt.

[dehoim]

Habt Ihr diese Zahlen gesehen

So geil 9 cent net income pro Share alleine in diesem Quartal.

Die haben nach nur 3 Wochen Verkauf schon über 2 Mio royalties

Hammer echt, royalties gibt es nur nach tatsächlichen Verkauf

Wenn man das vom Quartal auf Jahr bringt sind das 36 cent netto Gewinn.
Bei einem KGV von 30 muss die Aktie dann bei 10.80 $ stehen.

Und das ohne China welches auch nimmer so weit weg sein muss laut 10K aus dem Jahre 2003

Macht euer DD und freut euch

[jonathanheart]

[posting]18.934.234 von dehoim am 22.11.05 09:57:15[/posting] lecker

[toothstone]

Das ganze ohne Monat September, wenn man bedenkt, daß fortical gerade anläuft, sicher kein schlechter sein wird.

[toothstone]

Hier nochmal das ganze Potential aus rb, für wohl eine der best aufgestelltesten biotech überhaupt.

DD on UGNE.ob

1. ONLY biotech company to both manufacture and deliver peptides.
2. Has approval for competitor to Miacalcin (norvartis drug) for osteoporosis ($236 mm/year)...branded FORTICAL.
a. Makes calcitonin so pure and cheap that NVS licenced
manufacturing technology to implement in own drugs.
1. UGNE to reap benefits in royalty from any
product made with their calcitonin manufacturing
2. Able to buy all calcitonin it needs from NVS at
pre-negotiated price.
3. Fortical is being heavily promoted by UGNE partner Upsher-Smith laboratories ( a billion dollar drug company), while miacalcin apparently has not been promoted by NVS.
4. NEW indications for calcitonin nasal sprays might be approved in the near future...possibly for osteoarthritis, a condition 20mm people have in the USA.
5. Fortical is not only much cheaper to make than miacalcin,
but also doesn`t have the known nasal irritant
benzalkonium chloride, which is irritating to the nasal
mucous membranes.
**UGNE has filed an ANDA in China for Fortical on
09/04/03, and has a partner ready to launch once
approval is granted. China is by far the biggest
osteoporosis market on earth.
6. NVS has implemented UGNE process (at a tenfold scale
and is in the process of launching sometime in the near
future, a phase III for oral calcitonin, a drug which has blockbuster potential, giving UGNE royalties indefinitely.
7. According to CEO, UGNE has own oral calcitonin program,
which they have already completed 7 human studies
with...and they are apparently in discussions with
Anxious partners currently.
8. UGNE also has a worldwide deal (worth > $150mm) with GSK
for an oral PTH drug. GSK is reportedly agressively
planning phase II study. Only $5/150mm been received
so far.
a. PTH has potential to grow bone.
b. Calcitonin stops bone from degenerating.
1. Drugs could someday be complementary combo.
9. Recently announced they have made inventions which could
someday grow bone in an outpatient setting.
a. Improve healing process in fractures.

10. UGNE has potential to manufacture/deliver ORALLY...

a. DDAVP
b. INSULIN
c. Lupron

**ALWAYS DO YOUR OWN DD BEFORE BUYING OR SELLING ANY STOCK**

[dehoim]

[posting]18.935.774 von toothstone am 22.11.05 11:41:32[/posting]Schönes posting Tooth

ugne hat etwas über 80 mio aktien draußen.
So in etwa wie biph.

Das Umsatz und Gewinnpotenzial ist bei ugne sicher gleich hoch wie bei biph, nur eben sind die schon jetzt wie man sieht im Gewinn. Und das nur 2-3 Wochen nach Markteintritt.
Wie hoch biph in ein paar Jahren gehen kann wissen viele
Ugne ist schon dort angekommen aber keiner hat es (bisher)bemerkt!!

Ein mittlere Position kann sicher nicht schaden
Zocker sind nicht willkommen

[jonathanheart]

NEWS, es sind 10 Cents geworden....

Unigene Reports Record Revenue and Operating Profit for Third Quarter; Net Income of $.10 Per Share for Three Months Ended September 30, 2005

Tuesday , November 22, 2005 07:00 ET

FAIRFIELD, N.J., Nov 22, 2005 (BUSINESS WIRE) -- Unigene Laboratories, Inc. (OTCBB: UGNE) announced its financial results for the period ended September 30, 2005.

Revenue for the nine months ended September 30, 2005 was $12,676,000 compared to $6,409,000 for the nine months ended September 30, 2004. Revenue for the three months ended September 30, 2005 was $11,873,000 compared to $5,216,000 for the three months ended September 30, 2004. Revenue for both the three-month and nine-month periods ended September 30, 2005 included Fortical(R) product sales to Upsher-Smith Laboratories ("USL") representing launch quantities into distribution channels as well as royalties earned from USL sales following the August 16th product launch. Unigene`s net income for the nine months ended September 30, 2005 was $2,157,000 or $.03 per share (basic) compared to a net loss of $4,195,000 or ($.05) per share (basic) for the nine months ended September 30, 2004. Net income for the three months ended September 30, 2005 was $7,897,000 or $.10 per share (basic) compared to net income of $932,000 or $.01 per share (basic) for the three months ended September 30, 2004.

"We are very pleased about the acceptance of Fortical in the marketplace to date," commented Dr. Warren Levy, President and CEO of Unigene. "Product sales are in line with Unigene`s expectations and the product is now available at most pharmacies throughout the U.S. We believe that Fortical will remain a key revenue driver for Unigene for the near future."

[rk091161]

nimmt mann das letzte quartal dazu kommt mann auf ein eventuelles jahresergebnis von ca 20 cent,kgv von 40 bis 50 in dieser branche,gibt einen kurs von 8 bis 10 $...schauen wir mal,aber ist auch egal einfach lange halten.nächtstes jahr wird der gewinn bei ca. 0,70 bis 1$ liegen.was dies dann für den kurs bringt weiss jeder selbst..mfg

[rk091161]

der haken ist das instis nicht kaufen können,weil es ein otc wert ist.wäre unigene an der amex gelistet,ging es heute ab...vielleicht kommt der wechsel bald..mfg

[toothstone]

Zu Börsenende, typische MM-Manipulation, schade trotzdem, daß wir am ath abgeprallt sind.
Kommt bestimmt im 2. Anlauf.

[toothstone]

Hat jemand times and sales von gestern zu börsenende genau beobachtet, war doch wieder richtige manipulation, wäre cool´, wenn es jemand reinstellen könnte.
Mal schauen, was die ammis mit dem truthahnbauch am freitag machenwerden.

[kobv]

Hallo, bin neu hier, habe nach den zahlen eine Pos UGNE gekauft.
Im rb -board wird etwas von verbindlichkeiten bei Levys die getilgt werden müssen bevor ein Amexwechsel stattfinden kann, weiss jemand genaueres?
Danke und Güße
kobv

[toothstone]

Levy ist ceo, wenn dann hat er noch verbindlichkeiten, die den wechsel blockiern könnten, hatte es auch gelesen, denke aber das es keinerlei bedeutung hat.

[rk091161]

kommt der wechsel dürfen auch fonds kaufen...weiter ist aber interessant,die künfigen quartalsergebnisse,denke zwischen 20 und 40 cent...mfg

[kobv]

Wann darf ein Wechsel erwartet werden?
Jedenfalls hat das Fortical Zukunftsperspektiven:
Alternde Bevölkerung!!! und bringt schon Umsätze.
Andere Unternehmen haben Phase II und III Produkte und sind höher bewertet. UGNE ist M.E. risikoarm.
Grüße
kobv

[toothstone]

Habt ihr den schönen 75k Block wieder 5 Minuten vor Schluß gesehen,zu 3,5, nachdem davor schon einige 10k durchgegangen sind.
Wenn das keine fonds sind, fress ich besen, also der wechsel scheint nicht so weit weg zu sein.

[kobv]

Hallo, welches Kurziel schätzt ihr bis Ende 2006 konservativ ein ?
Grüße
kobv

[dehoim]

Hallo kobv

als so 8 $ könnte hier drin sein.
Bei entsprechenden Meldungen auch 10-12.

Denk hier nicht zu kurzfristig.
Diese Aktie kann sich schön lange nach oben ziehen bis 40-50$ in 2-3 Jahren.

Sind wohl die Creme de la creme in der Aktie drin.

[dehoim]

[posting]19.007.879 von dehoim am 27.11.05 14:47:14[/posting]Ja shit, liegt daran wenn man im Keller arbeitet und schnell an den PC rennt um nachzuschauen.

Das war für HBX/Hana gedacht , sorry

Ugne ist schwer zu sagen denke ich.

Hier bei ugne ist alles möglich von 4-6$

[kobv]

Danke, habe eh beide Aktien
Du meintest sicherlich Ende 2005. Und bei UGNE bis 2006?
Ich hoffe ich werde Geduld haben diese Aktien lange zu halten da ich auch an das große Potential glaube.

Grüße
kobv

[dehoim]

[posting]19.009.627 von kobv am 27.11.05 16:52:21[/posting]Ja sorry 2005

Man sollte Sonntags nicht arbeiten

[kobv]

Meinst du UGNE kann über 1 Jahr halten?
Gibt es ein Zeithorizont für das China -Approval?

Grüße
kobv

[toothstone]

Morgen,
Chinadeal "sollte " heuer noch abgeschloßen werden,
dann fehlt noch ein zweites update in Europa, Griechenland gibt es auch noch connections.
Novartis liefert 20.1. Zahlen, da müßten wir auch schon die fortical-umsätze erkennen können.
ugne wohl wieder erst mitte februar.
Wie hoch ugne klettert, kann keiner beantworten, aber bei 10 cents gewinn, sind wir total nach unten abgesichert.
hana kann wohl höher klettern, aber ist sicher riskanter.

[dehoim]

Ja, das ist ja das schöne es kommt recht viel in der nächsten Zeit.
Plus ein Produkt das Gewinn bringt.

Ob China schon dieses Jahr kommt muss man mal abwarten.
Das Jahr ist schnell vorbei!

[toothstone]

hab ja auch geschrieben sollte, in ankündigung stand doch 2003-2005. aber das kennen wir ja nur zur genüge, diese timeframes.

[toothstone]

Bin ja heute auf das ende in usa gespannt, heute scheinen die mms nicht soviele stücke einsammeln zu können, um sie den großen zuschieben zu können.
waren ja wohl 600k in den letzten 2 handelstagen, in schön feste hände. wär cool wenn es so weiter geht, der kurs folgt irgendwann automatisch.

[kobv]

[posting]19.052.979 von toothstone am 28.11.05 16:59:00[/posting]Hallo, können Fonds UGNE handeln oder horten MMs diese Aktien und verkaufen sie an Instis nach Börsenwechsel weiter?

[toothstone]

Ich glaube sicher, daß fonds handeln können, vielleicht manche nicht offiziell, aber auf ihren eigenen acount sicher.
Die Mms horten nur kurzfristig, wollen ja jeden tag das selbe spiel betreiben.
Gestern hätt ich anders erwartet, aber die Geduld zahlt sich ganz sicher aus, aller spätestens bei den nächsten Quartalszahlen.

[kobv]

[posting]19.082.165 von toothstone am 29.11.05 08:36:35[/posting]Überlege noch eine Position dazuzukaufen, hälst du den Zeitpunkt für günstig oder wie weit kann der kurs zurückkommen?

Grüße
kobv

[dehoim]

[posting]19.083.636 von kobv am 29.11.05 09:49:39[/posting]Wenn die Zahlen sieht und die Zukunft dazu ist ein Nachkauf sicher nicht schlecht.
Kurzzocker gehen immer ein Risiko, aber das scheinst Du nicht zu sein!

[toothstone]

Ep hat auf rb geschrieben, 3,25 ist möglich.schon vor tagen. aber laß nur irgendeine meldung kommen, über 3,67 hinaus, sind wir ganz schnell bei 5.
also mir sind hier 3% billiger kaufen ,ziemlich egal.

[kobv]

Danke, werde nachkaufen, da ich auch mind. 1 Jahr halten möchte. Es auch auf ein paar Prozent nicht an.
2006 Kaufe ich mir dann ein schönes Weihnachtsgeschenk vom Gewinn .

[rk091161]

.zum handelsschluss wieder grosse blöcke...50,12,10,5 k blöcke..gut...

[kobv]

Sehr wenige Umsätze heute und Kurs eingefroren?

[toothstone]

Morgen, hat sich wohl gestern noch geändert!
Und am Schluß, immer noch mit kleinen Stücken runterdrücken, um ja einen negativen Eindruck zu hinterlassen, ja, ja unsere lieben MMs.
Das hatten wir schon in der 2,9-Gegend.
Long and strong.

[kobv]

Sind dieses Jahr noch Nachrichten zu erwarten?

[toothstone]

Gute Frage, aber jede kleine nachricht, bedeutet sicher breakout.

[kobv]

Breakout ist da, 3.70 wann kommt die Nachricht?

[cripplecreek]

[posting]19.156.766 von toothstone am 05.12.05 11:32:05[/posting]...oder auch ohne...

[rk091161]

Last night, after the closing bell, BI Research, a stock newsletter that has been consistently rated in the top five by Hulbert, made Unigene its new stock pick. BI`s stamp of approval is a nice step for Unigene. It`s the first BB stock that I can remember BI picking. I think this is the driving force behind today`s action.

[dehoim]

Klarer Ausbruch und Kaufsignal

[toothstone]

Egal ob dieser research es bewirkt hat oder nicht, wir sind am richtigen weg.

[kobv]

[posting]19.176.601 von toothstone am 06.12.05 18:25:04[/posting]Jetzt noch ein Börsenwechsel...

[toothstone]

Aus Rb, es ist noch viel möglich, wow.
Gestern war doch erst der Anfang.

so whats next?

Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of the small proteins, known as peptides. The company develops recombinant peptide hormone production and analytical technologies for the treatment of osteoporosis and other indications. It offer Salmon Calcitonin, which is a amidated peptide hormone for the treatment of postmenopausal osteoporosis, symptomatic paget`s disease of bone, and hypercalcemia; Parathyroid Hormone, an 84 amino acid peptide hormone, which is involved in the regulation of calcium and phosphate metabolism in the bones and kidney; and Glucagon Like Peptide-1, a 30 amino acid amidated peptide hormone that stimulates insulin secretion and simultaneously decreases the secretion of glucagons, and used for the treatment of type 2 diabetes. The company also provides Leuprolide, a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone, which reduces the amount of the hormones testosterone and estrogen in the body; Desmopressin, a synthetic, nonapeptide hormone analog of the natural pituitary hormone 8-arginine vasopressin, used for bedwetting, central diabetes insipidus, testing kidney function, and blood disorders; and PYY(3-36)NH2, a naturally occurring amidated hormone, helps in promoting weight loss in obese individuals due to the modulation of feeding behavior.

[dehoim]

Ich liebe es!

Einfach streßfrei Geldverdienen

[kobv]

[posting]19.189.106 von dehoim am 07.12.05 16:31:58[/posting]Ich hoffe jetzt bildet sich ein stabiler langer Aufwärtstrend.
Du hattest in einem anderen Board vioquest erwähnt, könntest du mal etwas dazu schreiben bitte( sorry gehört nicht in dieses Board)
Grüße
kobv

[dehoim]

[posting]19.190.384 von kobv am 07.12.05 18:05:21[/posting]VQPH
soll 100 % Umsatz steigern die nächsten 3-4 Jahre.
Siehe BIO Report.

Bin mal gespannt wenn es dort los geht

UGNE HBX schauen schon mal super aus
HBX hat die 6 $ nicht geschafft also ein wenig down.
Schaut aber super aus.

[jonathanheart]

klasse tage, gestern und heute
aber in meinen augen erst der anfang...
die firma wird nun anscheinend profitabel und leitet den turnaround ein, lt. research von gestern ganz konserv. geschätzte 20 cents pro aktie die man für 2006 erwartet.
sollte fortical jedoch, wonach es momentan aussieht ( preferred drugs von blue cross), miacalcin den rang ablaufen sind bereits in 2006 m.m. nach auch 30-40 cents oder mehr drin. man bedenke alleine 3 wochen verkauf brachten ugne bereits über 2 mio an royalties ( nur tatsächliche verkäufe an "endverbraucher" ) und dies bereits kurz nach einführung.

diese rechnungen sind jedoch hinfällig wenn man die china zulassung erhält.dann ist alles nach oben hin offen...

zudem noch updates zu NVS und GSK ( 150 mio milestones )...

frohe weihnachten

[Brettvormkopp]

Brutaler Steigflug. Bin mal gespannt, wohin das noch
geht. Ich tippe auf Börsenwechel. Evtl China Deals ?
Ne Menge Phantasie in der Bude...

[dehoim]

Das wäre ein Traum

Produkte dafür haben Sie schon am Markt in USA

[amorphis]

na...wer von euch gehört denn hier zu den ugne spezialisten...?bin auf diese firma aufmerksam geworden...wer kann mir denn mal ein paar stichhaltige infos zur pipeline und deren marktpotential geben?

greez und danke

[dehoim]

Ist immer schwer auf die schnelle.

Der Wettbewerber macht weltweit 3,4 MRD Umsatz.

ugne ist anscheinend 40 % billiger und effektiver.
Zulassung war im August in den USA
Nach 3 Wochen Verkauf schon über 2 Mio Einnahmen für ugne als Lizenzzahlung.
Also tatsächliche Verkaufsprovision.

Erwarten kann man nur durch USA Verkäufe 30-40 cent net income.
Also Kurse über 10 $

Ferner wartet man auf Zulassung in China.

Reicht das mal zu beginn?

[kobv]

[posting]19.207.146 von dehoim am 08.12.05 20:42:39[/posting]Wer ist der Wettbewerber?

[dehoim]

Weitere Infos

[toothstone]

Morgen
der Wettbewerber ist das Miacalcin von Novartis,
auf rb haben sie schon vermutet, daß Novartis komplett darauf verzichtet, um Fortical voll einzubauen.

Netter Sk von gestern, das läßt für heute einiges wieder vermuten.
Endlich sind die letzte Viertelstundedrücker raus, also sind viele shares in feste Hände gekommen und andere große werden auf unser baby aufmerksam.

[kobv]

Starke Umsätze und stabiler Trend "trotz" OTC ,vielkleicht verhält sich der Kurs ja tatsächlich wie VPHM!

[kobv]

Pronosen für nächste Wochen? Weiter aufstocken oder größerer Rücksetzer? habe Positionen bei 3.5 und bei 4 USD.

[rk091161]

http://www.stockta.com/cgi-bin/analysis.pl?symb=UGNE&num1=3&…

[kobv]

Hat Micalcin Marktanteile in China?

[rk091161]

http://ragingbull.lycos.com/mboard/boards.cgi?board=UGNE&rea…


lesenswert!!!!!!!!!!!!

[cripplecreek]

Gute Daten von Novartis heute, die ja bekanntlich mit Unigene ein Lizenzabkommen haben: Im Januar startet Phase III und für uns gibts wieder Cash...

Emisphere Technologies, Inc. Announces the Presentation of Positive Results from a Clinical Study Conducted by Independent Investigators Using Oral Salmon Calcitonin in Osteoarthritis Patients
Monday December 12, 1:29 pm ET
Results from Preclinical and Clinical Studies Presented at the OARSI


TARRYTOWN, N.Y., Dec. 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS - News) today announced that positive clinical data generated by Drs. Daniel Manicourt and Jean-Pierre Devogelaer from the Department of Rheumatology at the University Hospital St-Luc, Universite Catholique de Louvain, Brussels, Belgium evaluating oral salmon calcitonin (CT) supplied by Novartis Pharma AG (NYSE: NVS - News) using Emisphere`s eligen® technology in treating osteoarthritis (OA) were presented at the 10th World Congress of the Osteoarthritis Research Society International (OARSI) in Boston. Results of this study strongly suggest that Oral CT (enabled by Emisphere`s proprietary eligen® technology licensed to Novartis for the use with calcitonin) exhibits not only clinical efficacy but also reduces markedly the levels of several biochemical markers of joint metabolism, which all have been shown to have a pejorative prognostic value of the OA disease process in longitudinal studies including large cohorts of patients.
ADVERTISEMENT


The randomized, double-blind, placebo-controlled, parallel study was conducted for 3 months in OA patients to assess the efficacy of this novel form of CT in patients suffering from knee OA. Patients received daily either a placebo (n=16), 0.5 mg of oral CT (n=17) or 1 mg of oral CT (n=18).

Clinical Efficacy

Clinical efficacy on pain, function and stiffness were evaluated by Lequesne`s algofunctional indices (LI).

In the placebo group, there was no significant change in the mean +/- SD value of LI. In the 2 CT groups, the mean value of LI was similar at day 0 (15.4 +/- 2.6), and was significantly decreased at day 84 (10.6 +/- 3.8 in the 0.5 mg group, and 9.6 +/- 3.2 in the 1 mg group).

Biochemical Parameters of Joint Metabolism

Biochemical parameters of joint metabolism, as assessed by enzyme immunoassays, included urinary levels of type I and type II collagen C telopeptide (CTX-I and CTX-II, respectively) as well as serum levels of type II collagen neoepitope C2C, matrix metalloproteinase (MMP)-3, collagenase-3 (MMP-13), tissue inhibitors 1 and 2 MMPs (TIMP-1 and TIMP-2) and hyaluronan (HA). Statistical analysis included analysis of variance followed by Tukey test whenever needed.

When compared to values at study entry, levels of biochemical parameters had changed significantly in all groups at day 84 (p<0.05 to 0.01). In the placebo group, there was a significant increase in the mean urinary levels of both CTX-1 (15%), CTX-II (9%) and in the mean serum levels of C2C (29%), MMP-13 (153%), MMP-3 (49%) and HA (25%). In contrast in the 1 mg CT group, there was a significant decrease in the mean urinary levels of both CTX-1 (10%), CTX-II (21%) as well as in the mean serum levels of C2C (25%), MMP-13 (40%), MMP-3 (18%) and HA (28%). Results obtained in the 0.5 mg CT group were intermediate between the other groups and are not reported. No change in the mean serum levels of TIMP-1 and TIMP-2 was observed in the 3 groups.

Study Withdrawals

The number of withdrawals was 2 in the placebo group (lack of efficacy), 4 in the 0.5 mg CT group (1 for lack of efficacy and 3 for nausea and headache), and 4 in the 1 mg CT group (2 for protocol violation and 2 for nausea and headache).

"This pilot study, conducted by the University Hospital St-Luc, Universite Catholique de Louvain, Brussels Belgium demonstrated the ability of the 1 mg dose of our unique oral salmon calcitonin product to not only show clinical efficacy in the study, but also demonstrated a decrease in biochemical markers that have been correlated with continued joint degradation. Over the course of the 84-day study, the placebo patients had no statistically significant change in clinical scores while they had statistically significant increases in biochemical markers that have been correlated with continued joint degradation. We are encouraged by these results and look forward to Novartis commencing pivotal Phase III studies of Oral CT in early 2006," said Michael M. Goldberg, M.D., Chairman and Chief Executive Officer of Emisphere Technologies. "The success of Oral CT in this Phase II study provides hope for the tens of millions of patients worldwide suffering with OA. There are currently no proven pharmaceutical products that can impact on the progression of this chronic disease. Nordic Bioscience presented two additional papers at the OARSI conference that further elucidate the mechanism by which oral calcitonin positively impacts on OA progression."

About Osteoarthritis

Osteoarthritis is a joint disease that mostly affects cartilage. Cartilage is the slippery tissue that covers the ends of bones in a joint. Healthy cartilage allows bones to glide over each other. It also helps absorb shock of movement. In OA, the top layer of cartilage breaks down and wears away. This allows bones under the cartilage to rub together. The rubbing causes pain, swelling, and loss of motion of the joint. Over time, the joint may lose its normal shape. Also, bone spurs may grow on the edges of the joint. Bits of bone or cartilage can break off and float inside the joint space, which causes more pain and damage.

People with OA often have joint pain and reduced motion. Unlike some other forms of arthritis, OA affects only joints and not internal organs. Rheumatoid arthritis -- the second most common form of arthritis -- affects other parts of the body besides the joints. OA is the most common type of arthritis.

About the eligen® Technology

Emisphere`s broad-based oral drug delivery technology platform, known as the eligen® technology, is based on the use of proprietary, synthetic chemical compounds, known as Emisphere delivery agents, or "carriers." These molecules facilitate or enable the transport of the therapeutic macromolecules across biological membranes such as those of the gastrointestinal tract, and exert their desired pharmacological effect. The Emisphere® delivery agents have no known pharmacological activity themselves. Emisphere`s eligen® technology makes it possible to orally deliver a therapeutic molecule without altering its chemical form or biological integrity. Emisphere is pursuing shortened registration timelines for currently marketed drug products whose absorption following oral administration is improved using the eligen® technology through supplemental New Drug Applications or 505(b)(2) filings with the US FDA. Successful achievement of these regulatory strategies may not require large-scale studies to support product registration.

[toothstone]

Schade heute, scheint wohl mit dem lebed-push zu tun haben. Aber die studie von novartis scheint wohl den richtigen weg zu zeigen. Freu mich schon auf mitte januar.

[kobv]

[posting]19.265.764 von toothstone am 12.12.05 22:16:48[/posting]Sehen wir die 3.67 Jetzt als Unterstützung?

[toothstone]

Nehm ich auch an, hoffe aber, daß es nicht kommt.
Ab 3,5 würd ich meine biphs raushauen und 100% Depotanteil in ugne gehen.

[Dornentaenzer]

[posting]19.269.673 von toothstone am 13.12.05 10:29:23[/posting]Sei doch nicht gleich so radikal (auch wenn es sich kurz- und mittelfristig lohnen könnte)

Aber ihr scheint von dem Laden ja richtig begeistert zu sein

[kobv]

Wie siehst Du Kursziel auf 1 Jahr und 2 Jahre?
Grüße
kobv

[toothstone]

Logo bin ich begeistert von dem laden.
Es gapt heute schon wieder auf, komische spielchen.
In einem Jahr sicher zweistellig, 2 jahre ist zu weit zu schätzen.

[toothstone]

Schaut doch gut aus, eine kleine konsolidierung war wohl notwendig.
Am Freitag stehen wir wieder bei 4,20-4,30.

[Dornentaenzer]

Ja zweistellig sollte erstmal das nächste Ziel für die kommenden Monate sein. Die Chancen stehen ganz gut (um nicht gleich zu euphorisch zu werden ), ansonsten werden wohl die nächsten Quartalszahlen recht deutlich machen, wohin die Reise geht.

Dorni

[toothstone]

Aur Rb existieren 2 Meinungen, der nächste große Anstieg bei den Quartalszahlen oder evtl. bei denen von novartis,
oder charttechnisch schon diese Woche, gestern deutete meiner meinung nach auch darauf hin.

[spezialagent]

Hi, wann werden die Zahlen denn erwartet ?

Gruß S.

[toothstone]

War ja richtig interessant gestern wieder, schöner anstieg und am schluß wieder mit wenigen stücken runter,
das hatten wir schon bei 2,9, 3,5 $.
Denke, dasß es ein sehr gutes zeichen ist.
Heute gleich wieder gapup, könnte mir vorstellen, daß dies noch ein paar tage so weitergeht und dann wieder boosh.
Novartiszahlen sind so um den 20.1.
Ugne-quartalszahlen erst mitte februar.

[toothstone]

Und schon wieder gapup, heute werden wir die 4,42 testen.
Ich glaub zwar, daß wir abprallen, aber der nächste versuch später könnte klappen.

[jonathanheart]

UGNE erneut wieder sehr stark heute
jahreshoch geknackt und weiter gehts
diese stärke und diese käufe müssen einen grund haben.
vielleicht haben einige einblick in die verkaufszahlen von fortical....
ich denke wir sind auf einem sehr guten weg.

[toothstone]

9 mms haben sich auf 4,5 gestellt, sowas ist meineserachtens immer eine konzertierte aktion, als psychologische mauer.
dann halt morgen oder auch gute chance in der letzten stunde.

[rk091161]

ím aktionaer ist der wert ja schon drin...thieme hat ihn auch gekauft...normalerweise müsste der wert in naher zeit auch von anderen finanzverlagen entdeckt werden...

[Tscheos]

Bin seit heute mit 3,82 auch dabei. Hoffentlich habt Ihr recht mit nächstes Jahr 2-stellig

[toothstone]

3,82 war ja nicht gerade billlig, solltest in usa kaufen.
Aber egal, heute packen wir die 4,5, jetzt schon über100k und gestern abend wieder mit ein paar stücken runtergedrückt.

[cripplecreek]

[posting]19.351.290 von toothstone am 20.12.05 15:46:51[/posting]der schluss heute richt förmlich nach einem anstieg morgen...tooth...wenn nicht heute, dann dürften wir morgen aber die stärke haben. ist maximal eine frage von tagen und ab über die 5...

grüße, euer cripple

[toothstone]

Das waren ja nochmals richtig dicke blöcke zu börsenschluß. Hab es erst jetzt gesehen.
Obwohl ich es echt gemocht habe, wenn die mms mit ein paar 500er den kurs um ein paar cent drücken, daß die performance einfach schlechter ausschaut und einpaar daytrader abspringen, schaut es für heute wiedereinmal hervorragend aus.
Wir brauchen einen 1 million umsatz-tag und wir heben ab.
Immer das gleiche muster am anfang höherer umsatz, hab ich schon bei vielen aktien gesehen, und gegen ende auch verstärkt, mittags am schwächsten, schaut echt proffessinell aus. wow

[rk091161]

From Stockwire today - I do not beleive UGNE is one of their client companies.

Stockwire.com: The Movers and Shakers Blog, Part 3:


By M2
Last Update: 12/21/2005 10:42:03 AM Data provided by

MIAMI, Dec 21, 2005 (M2 PRESSWIRE via COMTEX) -- We like stocks trading big dollar value volume! A very interesting indicator to look for is where the money is flowing into. We have a filter that we watch every morning that shows us "Dollar Volume". We also like stocks that are trading at bargain prices. As of 10:30AM, a couple of these stocks are: (UGNE), (ARTD), (DYMTF), (GZFX)

To feature your publicly traded company in our alerts, email us at [e-mail]

For the nine months ended 30 September 2005, Unigene Laboratories revenues rose 98% to $12.7M. Net income totaled $2.2M, vs. a loss of $4.2M. Revenues reflect receipt of milestone payment from USL. Net income also reflects lower resaerch and development costs, decrease in cost of goods sold and improved operating margins. UGNE is a biotechnology company engaged in research and production of laboratory- grade calcitonin and bulk pharmaceutical-grade calcitonin.

As a trader, a very intelligent place to put your money, is where the money is flowing into. When you get into stocks that are trading millions of dollars within the first 30-60 minutes of the market being open, chances are you will be able to get out of your position without hurting the stock. These are the kind of trades that you want to get into.

[toothstone]

schaut schon wieder nach einem upgap aus, der 3. versuch auf die 4,5 wird wohl klappen, hab gerade teure weihnachtsgeschenke gekauft.

[toothstone]

Also war wohl der 4.Anlauf, paßt auch zur vollen Zufriedenheit.
Schöne Weihnachten an alle Investierten!

[Bahram70]

Sehen wir heute 4,50€
Ich habe 5k nachgekauft.

[kobv]

4,01 Euro in Frankfurt Umsatz über 35.000, gibt es Nachrichten oder Empfehlungen?
Grüße
kobv

[rk091161]

http://www.otcbb.com/asp/Info_Center.asp

[rk091161]

http://www.stockta.com/cgi-bin/analysis.pl?symb=UGNE&num1=3&…

[cripplecreek]

Kleine Verschnaufpause, die sich das Baby da gönnt. Nichts lieber als das..wer hoch hinaus will, kann tief fallen. Da ist mir jede mögliche Unterstützungslinie recht.

[jonathanheart]

wünsche allen investierten einen guten rutsch in ein erfolgreiches jahr 2006 mit UGNE
ich denke UGNE wird der top-pick in 2006 werden.

januar -- zahlen von novartis ( miacalcin )
evt. milestones-payments an ugne von novartis
februar -- verkaufszahlen fortical :-)

im laufe des jahres ( hoffentlich auch recht zügig ) infos über china-zulassung

milestones mit GSK

NASDAQ Listing

+ vielleicht noch viele viele neue deals mit pharma-riesen....

[Shareholder33]

[posting]19.455.636 von jonathanheart am 30.12.05 12:26:10[/posting]Wünsch Euch auch allen nen guten Rutsch. Was glaubst Du wie weit Unigene in 2006 nach oben gehen kann und bis wann?
Grüße Shareholder

[jonathanheart]

[posting]19.458.626 von Shareholder33 am 30.12.05 15:04:28[/posting]ich denke das werden wir erst besser einschätzen können wenn wir im febr. die fortical zahlen für ein volles quartal erfahren werden.
2 mio an royalties aus produktverkäufen in den ersten 3 wochen aus dem letzten 10Q stimmen mich äusserst positiv.
sollten wir evt. 30-50 cents eps alleine aus den verkäufen von fotical nächstes jahr erzielen, so wird es auf jeden fall 2-stellig.

[dehoim]

Allen hier einen guten Rutsch und alles Gute im neuem Jahr

[Shareholder33]

[posting]19.460.658 von jonathanheart am 30.12.05 17:11:10[/posting]Danke, hoffe 2 Stellig heißt so um 20-30$?
Grüße

[kobv]

Guten Rutsch und Kursgewinne für 2006 an alle Investierten.

[cripplecreek]

[posting]19.461.768 von dehoim am 30.12.05 18:11:40[/posting]Und damit schließe ich mich den Wünschen zum Jahreswechsel an - Guten Rutsch!

[toothstone]

Wünsche natürlich auch allen einen guten Rutsch.

[NurGeduld]

Hallo zusammen,

bin neu eingestiegen und erhoffe mir auch einiges von Unigene.

Ich habe eine Frage zu den Revenues:

Unigene verkauft Fortical an USL und erhält dafür doppelt Geld? Im Q3 Bericht steht, dass Geld durch den Verkauf an USL generiert wurde und das Unigene Royalties erhalten hat.

Ich hätte gedacht, dass Unigene USL das Produkt zu Selbskosten überlässt und danach Royalties einfährt...

Euch auch einen guten Rutsch...

[rk091161]

heute kaufemphelung in der euro am sonntag...ziel 5 euro........

[jonathanheart]

@rk

was stand denn noch im artikel der EamS über UGNE ?

[rk091161]

dasselbe was hier im thread auch steht...

[jonathanheart]

[posting]19.513.681 von rk091161 am 03.01.06 13:26:31[/posting]na dann.....

[jonathanheart]

momentan findet eine gesunde konsolidierung statt....
danach gehts weiter UP...
hoffe wir hören bald was zu novartis

[jonathanheart]

BI Research has chosen Unigene as its "Stock of the Year" recommendation for the Dick Davis Digest. Here is the info they sent to the Digest. If this stock could get coverage from a few more analysts, it would really fly.

The following was sent from BI to the Dick Davis Digest.



“Unigene is a biopharmaceutical company focused on the oral and nasal delivery of peptide drugs with large-markets. Due to the size of the worldwide Osteoporosis market (about $6 - $7 billion), Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. As our population ages, Osteoporosis becomes a bigger and bigger problem afflicting about 10 million Americans, with another 34 million at high risk of developing the disease, leading to about 1.5 million fractures per year as the loss of bone density makes aging, postmenopausal women, in particular, more prone to fractures. In August Unigene received final approval from the FDA for its nasal calcitonin Osteoporosis product, Fortical. This product is easier to administer with less restrictions, and the primary active ingredient- salmon calcitonin- has an excellent safety profile. Fortical, at 25% lower cost than the other nasal product on the market (which is nasally irritating but still does $250 million), is already winning formulary preference battles. Right off the bat Unigene became profitable, reporting about $.10 a share in the launch quarter, of which I estimate about half was due to Fortical and the rest was due to royalty payments… which brings me to everything else… sources of royalty and milestone payments. To me one of the most attractive aspects of Unigene is its technical partnerships. Unigene has licensed the U.S. rights for Fortical, its nasal calcitonin product, to Upsher-Smith which is aggressively marketing the product. Worldwide rights for its oral PTH technology have been snapped up by Glaxo SmithKline (with potential, remaining contractual milestones payments of $142 million if all goes as planned). Glaxo is enthusiastically progressing towards Phase II trials. And worldwide rights for its calcitonin manufacturing technology has been licensed to Novartis who is using Unigene’s salmon calcitonin/manufacturing process in its own oral product. Initial trials indicate that product may well be effective for Osteoarthritis as well as Osteoporosis. And there are lot’s of other goodies in the hopper. I think Unigene could make $.20 a share in 2006, maybe more, with royalty and milestone payments coming in from multiple sources... and lots of blue sky. The stock also scores very high (11.6) in our BI Ranking system.”



And while I`m at it, here are the things one subscriber, likes about the company. I thought it was such a good list, I asked if I could share it-



<<I like UGNE for the following reasons:



- 6 PH.Ds make up the executive team

- company has turned profitable

- in bed with some of the world`s largest pharmaceutical companies

- targeting huge worldwide multi-billion markets

- Fortical cheaper and safer than Miacalcin which has annual revenues of about $230 million in US with no advertising.

- Upsher-Smith is aggressively promoting Fortical

- UGNE receives two revenue streams from Fortical: selling it to Upsher-Smith and royalties from the sales by Upsher-Smith

- modest annual expenses ($14 million)

- relatively unknown company on OTCBB with no analyst coverage

- AMEX or NASDAQ listing by mid-2006

- their debt is owed to the officers within UGNE

- conservative very high BI rank of 12.7!!!



In Peter Lynch`s words: this one could be a 10 to 20 bagger. I vote you pick UGNE as your 2006 stock.>>

[toothstone]

Sehe ich auch so, auch wenn meine Meinung stock of the year wohl nicht so viel zählt.
Spaß beseite, wichtig nicht unter 4 $ zu rutschen, alles andere ist gesund.
Die ammis, die ihre Gewinne nicht in 2005 realisieren wollten, sind jetzt raus.
Wir sind nach oben frei.

[kobv]

- UGNE receives two revenue streams from Fortical: selling it to Upsher-Smith and royalties from the sales by Upsher-Smith


Kkönnte das jemand erklären? Wieveil % sind das vom Verkauf?

Grüße
kobv

[NurGeduld]

Genau das war auch meine Frage (s. unten). Aber anscheinend weiß das hier auch niemand.

Eine spannende Frage ist auch, wann sich die Chinesen entscheiden, ob Fortical dort zugelassen wird.

Der Antrag stammt aus dem 3. Quartal 2003. Allzu lange dürfte es nicht mehr dauern.

Weiss jemand, in welcher Phase sich der Antrag befindet??

[toothstone]

Ich weiß nur, daß es 2 Jahre dauern sollte und daß in china die mühlen sehr langsam mahlen.
Interessant sind die Probleme von fossamax (Merck), könnte einen riesenumsatz für ugne bringen.

[NurGeduld]

Könntest Du das ein wenig näher erklären...?

[toothstone]

Wenn fossamax vom markt muß, mit über 3 Milliarden Umsatz, fällt sicher ein stück vom kuchen auf ugne ab.
Auf china würd ich mich nicht versteifen, als nächstes könnte eine milestones-zahlung kommen, dann vielleicht oder hoffentlich nasdaqwechsel.
Es wird auch viel über das nasale medikament auf rb diskutiert und hast die liste der möglichen hormone gesehen, hierbei können einige studie 1 oder besser 2 folgen.
Alles superzukunftsausichten, aber am wichtigsten die 10c pro share gewinn, die im 4. quartal wohl nicht ohne milestonezahlung gehalten werden können.
3 cent dürfte das minimum sein, alles andere läßt die kurse platzen.

[toothstone]

aus rb, könnte eure fragen aufklären!

In April 2002, we signed a licensing agreement with GSK for a value before royalties, PTH sales and reimbursement for development expenses, of up to $150,000,000 to develop an oral formulation of an analog of PTH currently in clinical development for the treatment of osteoporosis, of which an aggregate of $8,000,000 in up-front and milestone payments has been received through September 30, 2005. GSK could make additional milestone payments in the aggregate amount of up to $142,000,000 subject to the progress of the compound through clinical development and through to the market. We have also received an additional $5,000,000 from GSK for PTH sales and for support of our PTH development activities from inception through September 30, 2005 (see Note C).

In November 2002, we signed an exclusive U.S. licensing agreement with USL for a value before royalties of $10,000,000 to market our patented nasal formulation of calcitonin for the treatment of osteoporosis. Under the terms of the agreement, we received an up-front payment of $3,000,000 from USL in 2002, a milestone payment of $3,000,000 in 2003 and a final milestone payment of $4,000,000 in the third quarter of 2005 (see Note D).

In April 2004, we signed a worldwide licensing agreement with Novartis for a value before royalties of up to $18,700,000 to allow Novartis to manufacture calcitonin using our patented peptide production process. We received $5,600,000 in April 2004 from Novartis in an up-front payment and a partial prepayment for calcitonin purchases. In August 2004, we received $2,000,000 from Novartis for a technology transfer milestone. In January 2005, we received $600,000 from Novartis for the final payment on their calcitonin purchases (see Note E).

[toothstone]

Laut EP ist head and shoulder almost complete.
Also die dem nächsten anstieg steht nix im wege.

[toothstone]

Und mal eine schöne Analystenmeinung aus rb.

OT: TO ALL FAITHFUL HOLDERS OF UGNE. HERE IS AN UNBIASED ANALYSIS BY VECTOE VEST BUONA FORTUNA TO ALL LUIGI VectorVest Stock Analysis of Unigene Labs as of 1/11/2006


This report has five major sections.
Capital Appreciation Analysis
Dividend Analysis
Price-Volume Data
Sales / Market Capitalization Information
Summary



Business: UNIGENE LABORATORIES INC, (UGNE) develops Calcitonin products for the treatment of osteoporosis and other indications.
Business Sector: UGNE has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Industry Group: UGNE has been assigned to the Drug (BiomedicalGenetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

Capital Appreciation Analysis Back to top

Value: Value is a measure of a stock`s current worth. UGNE has a current Value of $7.59 per share. Therefore, it is undervalued compared to its Price of $4.24 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock`s Price and Value always will converge.

RV (Relative Value): RV is an indicator of long-term price appreciation potential. UGNE has an RV of 1.46, which is excellent on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.

RS (Relative Safety): RS is an indicator of risk. UGNE has an RS rating of 0.76, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company`s financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.

RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock`s price trend. UGNE has a Relative Timing rating of 1.34, which is very good on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock`s price movements over one day, one week, one quarter and one year time periods. Once a stock`s price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.

VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. UGNE has a VST rating of 1.22, which is good on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.

Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. UGNE has a Buy recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.

[cripplecreek]

Mir gefällt die Korrektur, die wir derzeit sehen. Zwischen 3,85 und 4 dürfte die Aktie ihren Boden gefunden haben und wieder drehen. Nach dem Mitte November fortgesetzten Aufwärtstrend von 3 bis 4,70 war eine Korrektur gesund, die in der Spitze wohl maximal ca. 15-18 Prozent betragen dürfte.
Das gleiche Chartbild hatten wir bereits von September bis Mitte November. Von 2,5 bis 3,7 (ca. 50 Prozent) und dann Konsolidierung um ca. 18 Prozent auf 3, um dann wie erwähnt die 4,7 in der Spitze zu erreichen.
Auch damals haben wir auf der 50 Tage-Linie aufgesetzt.
Also alles im Lot, solange wir über 3,85 bleiben. Meines Erachtens hat die letzte Phase des kurzfristigen Abwärtstrends begonnen.

Good luck @all


http://stockcharts.com/def/servlet/SC.web?c=ugne,uu[h,a]dacl…

[dehoim]

Novatiszahlen sind draussen

Page 36 Sie verlieren 51 Mio oder 7 %

http://hugin.info/134323/R/1030489/165309.pdf

[dehoim]

[posting]19.780.041 von dehoim am 19.01.06 09:52:08[/posting]Korrektur

Sie machten im letzen Quartal 51 Mio Umsatz das sind 7 % weniger.

[NurGeduld]

Gibt es irgendwelche schlechten News?

Diese Woche war ja katastrophal...

[toothstone]

Nix besonderes, mialcalcin hätte vielleicht mehr einbußen haben müssen. gestern war wohl auch gesamtmarkt schuld.
es sind hauptsächlich gewinnmitnahmen von ammis, die in 2005 nicht mehr realisieren wollten.
leider kann ich nicht mehr nachlegen. 3,7 ist ein super kaufkurs.

[toothstone]

we are back, gewinnmitnahmen sind zwar heftiger aus gefallen als erwartet, aber es hat sich nix an den super perspektiven geändert.

[neatneatneat]

gibts was neues

was sagen die charties ?

doppelboden und ein schönes W ?

wann sollen die Q zahlen kommen ?

thanx

[toothstone]

Chart ist wohl wirklich zum ausbruch bereit, mit volumen über die 50er.
Zahlen können ab dem 15. kommen, kann auch erst anfang märz sein.

[neatneatneat]

[Erwin2208]

News and Events
Press Releases
Date : 15-Feb-2006
Unigene Elects Peter Slusser and Bruce Morra, Senior Financial and Pharmaceutical Executives, to Board of Directors

FAIRFIELD, N.J.--(BUSINESS WIRE)--Feb. 15, 2006--Unigene Laboratories, Inc. (OTCBB: UGNE) has elected Peter Slusser and Bruce Morra to its Board of Directors. With these additions, which are effective immediately, the Board of Directors will consist of a majority of independent directors as required by AMEX and NASDAQ.

Mr. Slusser has extensive experience in the corporate finance and investment banking fields. He is currently the President of Slusser Associates, a private investment banking company. He previously served as a managing director in the Merger and Acquisition Group at PaineWebber, as Senior Vice President and Manager of Corporate Finance at Shields Model Roland and as Manager of Special Situations at Dean Witter. He is currently a director of Ampex Corporation, Sparton Corporation and the Magellan Group. He has also served as a Member of the Financial Advisory Board of Columbia University Graduate School of Business Administration, a Member of the California Senate Special Committee on Local Government Investments and as a Member of the California Senate Commission on Corporate Governance, Securities Transactions and Shareholders` Rights. He received degrees from Stanford and the Harvard Graduate School of Business Administration, and will serve on Unigene`s Audit Committee.

Dr. Morra has many years of experience in the pharmaceutical, medical device, biotechnology and polymers industries. He is currently a consultant and Board member for various companies, including InforMedix Holdings and Medisys Technologies. He previously served as the President of West Pharmaceutical Services Drug Delivery and Contract Clinical Research businesses, as Chief Business Officer of Progenitor Cell Therapy, as President, COO and CFO of Biopore Corporation and Polygenetics, as President, COO and Founder of Flamel Technologies, Inc., and as President of ISP Filters, a subsidiary of GAF Corporation. Dr. Morra was a member of Unigene`s Board of Directors from 2001-2003, after which he resigned to take the position with West Pharmaceutical. He received a chemical engineering degree from Princeton and a Ph.D. in Polymer Science and Engineering and an M.B.A. from the University of Massachusetts at Amherst, and will serve on Unigene`s Compensation Committee.

"We are very pleased to add two such accomplished individuals to Unigene`s Board," commented Dr. Warren Levy, President and CEO of Unigene. "Their financial, scientific and management skills will be very valuable as we develop new business initiatives to expand the Company`s product portfolio and explore ways to enhance shareholder value. These additions should also facilitate a listing for our common stock on a major exchange."

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.`s management`s current expectations, estimates, beliefs, assumptions, and projections about Unigene`s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene`s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene`s Securities and Exchange Commission filings.

Was bedeutet dies?
Scheinbar positive Meldungen der Kurs zieht an

[MrSeriousInvestor]

Hi an alle,

ohhh, was läuft bei UNIGENE? Starker Kursanstieg bei geringen Umsätzen, keine News soweit ich weiss. Hat einer eine Ahnung? Also mir solls recht sein, nur möchte ich verstehen
Schönen Tag an alle

MSI

[toothstone]

Hi,
we are back.
Geduld war angesagt.
Einmal hängt der anstieg sicherlich mit den problemen von nastech zusammen, da kann man viel darübrt spekulieren.
Und 2. haben wir wieder das gleich muster, zu handelsende große käufer, auf rb schreiben sie, daß gestern einer 150k insgesamt eingetütet hat. vorgestern ähnlich.
Einige wissen immer mehr und ganz klar ersichtlich ist es, daß es auf diesem niveau keine verkäufer mehr gibt.
hana hat eine schöne vorlage gegeben, amexwechsel, kurze verschnaufpause und dann...

[neatneatneat]

das warten hat ein ende am freitag gibts sekt oder selters

Unigene to Release Year-End Results and Host Conference Call
Tuesday March 14, 9:27 am ET


FAIRFIELD, N.J.--(BUSINESS WIRE)--March 14, 2006--Unigene Laboratories, Inc. (OTCBB: UGNE - News) will release financial results for the year ended December 31, 2005, at approximately 7:00 AM EST on Friday, March 17, 2006. The Company will also host a conference call on Friday, March 17, 2006 at 9:00 AM EST to discuss the Company`s financial results.

[Erwin2208]

Ich hoffe auf Champagner
Ist es eigentlich üblich die Zahlen vorher anzukündigen.
Vielleicht wird auch der Wechsel an die Nasdag bekanntgegeben

[toothstone]

Vor allem der CC macht mich sehr optimistisch, auch wenn nur 3-5 cent rauskommen konnten, zählt doch der Ausblick.
Fortical hat im Januar schon einen Marktanteil von über 20%, leider kann dies ja noch nicht in das 4.Quartal.
Infos über Börsenwechsel und vor allem über GSK-Milestones kann ich mir schon vorstellen, nachdem jetzt schon neben nastech noch ein Konkurrent gestrauchelt ist, stehen dem PTH-deal goldene Zeiten entgegen.
Was von China zu erfahren erwarte ich nicht.
Bleibt nur eines zu erhoffen, daß Levy sich gut verkauft und den sicher tollen Ausblick auch so rüberbringt.
Was mich noch erstaunt hat, daß die earnings-Ankündigung 3 Tage vorher kommt, also bleibt auch noch Luft was anderes zu newsen, reine Spekulation von mir.

[hellblau]

zur info:

http://www.quote.com/qc/news/story.aspx?story=56768262&symbo…

[neatneatneat]

was für ein tageschart

was sagen die zahlen

[hellblau]

[posting]20.771.724 von neatneatneat am 17.03.06 18:14:02[/posting]die Zahlen kannst du dir hier anschauen

http://www.quote.com/qc/news/story.aspx?story=56768692&symbo…

Grüße von Marg.

[Bahram70]

Unigene Announces Results for 2005


FAIRFIELD, N.J.--(BUSINESS WIRE)--March 17, 2006--

Unigene Laboratories, Inc. (OTCBB: UGNE) announced its financial results for the year ended December 31, 2005.

Revenue for the year ended December 31, 2005 was $14,276,000 compared to $8,400,000 for the year ended December 31, 2004. Unigene`s net loss for the year ended December 31, 2005 was $496,000 or ($.01) per share compared to a net loss of $5,941,000 or ($.08) per share for the year ended December 31, 2004.

"We had record revenues in 2005 of over $14 million," commented Warren P. Levy, Ph.D., President and CEO. "During 2005 we received FDA approval for our first U.S. product, Fortical(R), and prescriptions have increased each month. According to Verispan, in January Fortical achieved an approximate 26% market share of new calcitonin prescriptions and approximately 22% of total prescriptions, representing more than 30,000 prescriptions per month. The increase in total prescriptions from December to January was approximately 27%, suggesting that Fortical sales are growing at a significant rate. We are encouraged by this performance and believe that Fortical will continue to be a revenue driver for the Company."

[toothstone]

Heißer Ritt am Freitag,
aber mit sehr positivem ausklang, das stimmt mich sehr zuversichtlich.
Ich denke, daß es jetzt fast zu einem kompletten austausch der pot. Verkäufer gekommen ist.
Auf Rb stehen sehr aufschlußreiche Kommentare zum CC.
Auch dieses private placement wird durchaus sehr positiv aufgenommen.
Ich bleibe superlong, da vor allem das Risiko nach unten ganz stark begrenzt ist.
Ein neues listing würde sicher allein 1$ bringen.
Das wichtigste für die Zukunft ist PTH, GSK zahlt dann 142 Mio $, die summe muß man sich vor augen halten, laß mal phase 3 beginnen, werden wohl zweistellige mio-beträge fließen.
Forticalsales alleine dürften für 06 kurse von über 10$ bringen. Addiert mit den milestones, ergibt

[toothstone]

Hier ein paar schöne postings aus rb:

ich glaub wir schaffen heut die 4.

Great recent posts by level59, prefab1 + rexeny...
about how well this company is being managed by WL.

Once the general public wakes up and realizes that what we have here is:

- a small biotech company that already has an approved product (Fortical) with rapidly increasing market share. Fortical is cheaper and much safer than the competition.
- a company with a whole bunch of other biotech irons in the fire. Many, such as oral insulin, with blockbuster potential
- a very committed management team that has put up (in the form of loans) significant amounts of their own money into the company
- a very conservative company as far as Presss Releases which leaves plenty of room for future upside surprises
- an AMEX or NASDAQ listing in the next 6 months

this stock is gonna fly. 2006 is going to be a very exciting year.

Holding long and strong and will be adding to my position on any dips.

[toothstone]

The CC I thought was very positive. From December to Jan. they increased scripts about 27%.
In January alone they had 30,000 prescriptions. WL feels that a good portion of that is not out of Miacalcin`s hide but from new growth of the industry.
China-they have been frustrated with the transparency between the two processes (China vs USA) however maintain constant communication and are making progress, albeit slow.
They were very excited about the GSK partnership and hope to have some updates soon as to Phase II. They reiterated that GSK has the PTH-UGNE partnership in the highest priority.
As for the dilution, they want to use the $$ to take the loans out of default and grow the business. Main objective is to get listed.
There were a ton of questions, most wanting guidance but WL was tight lipped.

Yale- patent has been filed and hope to have some news on that soon.

These were the main points. I know more could be added to this post but just wanted to give the quick and dirty.

[toothstone]

Other than all the positive things the Levy`s had to say what impressed me was the fact they had to stop the q&a because they were running out of time. For analyst showing this much interest on a $4:00 stock is short of amazing. One of the better comments was that Glaxco wasn`t in this to be second to market also Upshew Smith has sent letters to 50,000 different pharmacies pushing Fortical.Anybody not willing to hold this stock for the next 18 months might be missing a tremendous opportunity.

[toothstone]

So ruhig hier, seid ihr alle noch enttäuscht oder am freitag zu früh raus.
auf bloomberg kam gestern ein empfehlung gegen us-handelsende mit kursziel 10$ auf ein jahr von einem fondmanager.

[MrSeriousInvestor]

Hi Toothstone,

also das Kursziel vin USD 10,- betreffend UNIGENE LABS bekam ich schon vor 10!!! Jahren von Merril Lynch New York genannt, zwischenzeitleich sackte die Aktie aud 0,22 USD ab.
Aber ich bin ja ein 'Very long4 Investor....
Kanns du mir bitte die Bloomberg-Seite nennen wo diese Empfehlung zu finden ist?

Danke schön und schönen Abend.

MSI

[toothstone]

Ja hast ja recht, levy ist halt kein pr-profi.
Es war im fernsehen auf bloomberg und ich hab es nur auf rb erfahren. aber wenigstens ist 3,5 eine dicke unterstützung.
Gsk, phase 2 oder china läßt ugne wohl erst wieder richtig steigen, aber dann dafür gewaltig. ich glaube sicher verbunden mit einem börsenwechsel.

[neatneatneat]

von der unterstützung hab ich nix gemerkt

[toothstone]

Das Warten hat sich gelohnt, fossamax hat riesenprobleme, die anderen bisphosphonate werden wohl auch die selben probleme kriegen, gerade in usa, wo schadenersatzklagen immens ins geld gehen, wird dies wohl nicht mehr lange dauern.
novartis liefert am 24.4 zahlen, wenn dann auch noch miacalcin um 20% oder mehr prozent eingebrochen ist, gehört fortical bald der ganze kuchen.
allein dadurch wird sich der börsenwechsel ergeben, wir brauchen china, orales calcitonin und pth noch gar nicht.
aber es wird auch kommen und zweistellge kurse lassen grüßen.

[teksene]

Antwort auf Beitrag Nr.: 21.186.480 von toothstone am 13.04.06 09:19:56

Hallo,
in anderem Zusammenhang bin ich auf diesen Thread gestoßen. Anbei eine Denkanregung, wer bei Euch mit im Boot sitzt (wurde in diesem Thread nur 1x kurz erwähnt)

und
http://finance.yahoo.com/q/hl?s=AHERX
Viel Glück
t.

[Caja31]

@ posting 199 von teksene

Kannst Du mir bitte mal den Zusammenhang des American Heritage Fund mit Medigene erläutern? Komme trotz starken Nachdenkens nicht auf ein schlüssiges Ergebnis..

[toothstone]

Erstens sind wir im unigene-thread.
Dieser fond ist doch heiko thieme, das ist wahrlich nix besonderes, spielt aber auch überhaupt keine bedeutende rolle, auch ein blindes huhn findet ein korn.

[teksene]

Antwort auf Beitrag Nr.: 21.225.200 von toothstone am 18.04.06 15:58:20

Viele Körner hat Thieme jedenfalls die letzten Jahre nicht gefunden. Ob da Unigene die Ausnahme ist? Viel Glück jedenfalls.
t.

[toothstone]

Es hat auch nicht thieme ugne gefunden, er ist da nur mitläufer, vielleicht kriegst raus, wer mit ihm das büro an der wallstreet teilt oder wohl inzwischen andersrum.
Auf jeden Fall schaut es doch richtig gut aus, über 4 geschlossen, wird für einige fonds interessant.
auf rb wurde vermutet, daß dieser nue private investor wohl einiges auf diesem niveau schon abgegeben hätte, einerscheits schade weil so kurz orientiert, andererseits gut, weil wenn seine stücke weg sind der weg nach oben so richtig frei wird.
gestern kamen auch schöne große blöcke.
wenn das mit fossamax(merck) noch ernster wird und miacalcinzahlen am montag von novartis auch einen einbruch erlebt haben, sind wir schneller an einer anderen börse, wie wir alle wohl glauben.
ohne irgendwie von china, orales calcitonin, pth, milestones profitiert zu haben. das sind nur die zuckerl.
fortical macht ugne allein profitabel und deshalb ist das risiko nach unten sehr, sehr begrenzt.
ich kann gut schlafen mit meinem depotanteil von fast 70%.

[Bahram70]

Hallo toothstone ,

wie war die miacalcinzahlen bei Novartis ?

[toothstone]

Hatte ich gestern schon geschrieben, hat w:o wohl abgesägt.
-10% in Usa im Vergleich zum Vorquartal.
52 Mio $, vor fortical waren auch schon mal 62 Mio $.
Gestern kamen filings von insiderkäufen. Das hört sich doch nicht schlecht an. 10Q muß bis zum 16.5 gemeldet werden, könnte mir ein paar nette news vorher vorstellen.
Meines erachtens laufen wir nur nicht weiter, weil dieser private investor zu 3,25, einiges schmeißt oder schon geschmissen hat, verkäufe kommen fast immer über den selben mm.
also long and strong

[pepe05]

Date : 09-May-2006
Unigene to Release First Quarter 2006 Results and Host Conference Call

FAIRFIELD, N.J.--(BUSINESS WIRE)--May 9, 2006--Unigene Laboratories, Inc. (OTCBB:UGNE) will release financial results for the quarter ended March 31, 2006, at approximately 7:00 AM EDT on Thursday, May 11th. The Company will also host a conference call on Thursday, May 11th, at 9:00 AM EDT to discuss its 2006 first quarter financial results.

Unigene invites all those interested in hearing management's discussion of first quarter results to join the call by dialing 1-877-407-0782 for participants in the United States and 1-201-689-8567 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 1-877-660-6853 for participants in the United States and 1-201-612-7415 for international participants and entering conference ID # 202596 and access code 286 when prompted.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

CONTACT: The Investor Relations Group for Unigene Laboratories
Damian McIntosh or Dian Griesel, Ph.D., 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210

SOURCE: Unigene Laboratories, Inc.

[toothstone]

Bin auch mal gespannt, auf rb vermuten 0 cent.
Aber wie immer der ausblick ist wichtiger, ein neuer deal oder was vergleichbares.
Fossamax kriegt immer größere probleme, also das umfeld wär nur zu gut.

[Bahram70]

Antwort auf Beitrag Nr.: 21.500.934 von toothstone am 10.05.06 09:59:58

macht Unigene keine Gewinne? was meinst du?

[Dornentaenzer]

Press Release Source: Unigene Laboratories, Inc.

Unigene Enters into Exclusive Distribution Agreement for Fortical(R) Nasal Spray in Israel
Wednesday May 10, 8:30 am ET

FAIRFIELD, N.J.--(BUSINESS WIRE)--May 10, 2006--Unigene Laboratories, Inc. (OTCBB: UGNE - News) has entered into an exclusive distribution agreement with Tzamal Bio Pharma Ltd. to distribute its Fortical® nasal spray in Israel for the treatment of osteoporosis. Tzamal will pay Unigene a fixed price per each unit of product it receives and has guaranteed minimum sales levels for the first three years following the product launch. Tzamal is also responsible for registering the product with the Israeli Ministry of Health, a process that normally requires 6-12 months, and they will reference Unigene's 2005 U.S. approval to facilitate the regulatory review process.


"We are very happy to be the exclusive distributor of Fortical in Israel," commented Eddy Steinberg, General Manager of Tzamal Bio Pharma. "We believe that the product will be well received as a safe alternative to the currently marketed osteoporosis therapies."

"This is a part of our broader strategy to introduce Fortical into additional territories and we feel that Tzamal is well positioned to maximize the product's market penetration in Israel," said Dr. Ronald S. Levy, Unigene's Executive Vice President. "Once the product is approved, we will be supplying them with the identical units that we currently market in the U.S."

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

About Tzamal Pharma

Tzamal Pharma is a privately owned sales and marketing organization for Middle Eastern territories. Tzamal is committed to providing hospitals and healthcare funds with high quality pharmaceuticals for defined therapeutic fields such as cancer, infertility and metabolic diseases. For more information, visit www.tzamal-medical.co.il.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.


Contact:

The Investor Relations Group
Damian McIntosh / Dian Griesel, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210

Source: Unigene Laboratories, Inc.

[schmacki]

4 cent Verlust,bin erstmal raus!

[toothstone]

Ist nicht gerade rosig, der cc läuft gerade.
Die israel-geschichte verpufft somit.
Auf Rb stehen die verordnungen für fortical, sind von februar auf märz um 20% gestiegen. Das ist positiv, aber es braucht zeit und einen anderen deal.

[NurGeduld]

Antwort auf Beitrag Nr.: 21.522.688 von toothstone am 11.05.06 15:18:44

Was ist rb? Ein amerikanischer Chat?? Wo finde ich den? Danke!

[hellblau]

Antwort auf Beitrag Nr.: 21.590.919 von NurGeduld am 15.05.06 17:15:58

ist ein amerikanisches Board, chart, analysten usw.

http://ragingbull.lycos.com/mboard/boards.cgi?board=BB%3AUGN…

früher ging der link direkt, was mach ich falsch??

[toothstone]

DAs ugne ragingbull-board ist sehr gut, keine pusher und basher.
Der Boden scheint gefunden.
Mitte Juni ist Hv, mit diesem KUrs wird LEvy sicher nicht auftauchen wollen.

[chris21101]

Guten Morgen,

hat irgend jemand eine Idee, warum es seit Tagen nur abwerts geht ?

Gruß

Chris

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
10:37:19 Q 2.83 +0.06 3,700
10:37:16 Q 2.82 +0.05 2,500
10:37:10 Q 2.83 +0.06 2,500
10:36:30 Q 2.82 +0.05 2,500
10:36:27 Q 2.83 +0.06 500
10:36:24 Q 2.83 +0.06 2,500
10:28:24 Q 2.83 +0.06 280
10:27:24 Q 2.83 +0.06 500
10:27:04 Q 2.83 +0.06 1,000
10:27:04 Q 2.82 +0.05 1,000

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
11:41:45 Q 2.85 +0.08 1,500
11:40:44 Q 2.85 +0.08 500
11:39:48 Q 2.85 +0.08 500
11:37:36 Q 2.84 +0.07 2,000
11:36:51 Q 2.84 +0.07 500
11:36:22 Q 2.84 +0.07 500
11:20:13 Q 2.81 +0.04 2,500
11:20:04 Q 2.81 +0.04 500
10:51:37 Q 2.84 +0.07 500
10:41:26 Q 2.84 +0.07 500

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
12:42:57 Q 2.86 +0.09 2,000
12:38:16 Q 2.85 +0.08 1,000
12:38:09 Q 2.85 +0.08 500
12:38:09 Q 2.85 +0.08 500
12:37:48 Q 2.85 +0.08 500
12:29:34 Q 2.85 +0.08 200
12:29:29 Q 2.85 +0.08 500
12:29:22 Q 2.85 +0.08 500
12:26:40 Q 2.86 +0.09 1,500
12:26:28 Q 2.86 +0.09 1,500

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
13:06:57 Q 2.90 +0.13 200
13:06:55 Q 2.87 +0.10 500
13:06:05 Q 2.90 +0.13 3,500
13:05:20 Q 2.90 +0.13 265
13:05:13 Q 2.90 +0.13 2,735
12:59:48 Q 2.90 +0.13 500
12:59:12 Q 2.89 +0.12 500
12:58:50 Q 2.89 +0.12 4,000
12:58:43 Q 2.87 +0.10 500
12:51:28 Q 2.87 +0.10 500

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
16:00:12 Q 2.91 +0.06 1,000
16:00:03 Q 2.90 +0.05 10,000
15:58:56 Q 2.90 +0.05 2,500
15:56:34 Q 2.91 +0.06 500
15:56:23 Q 2.91 +0.06 500
15:40:01 Q 2.90 +0.05 2,000
15:38:53 Q 2.90 +0.05 2,500
15:37:46 Q 2.90 +0.05 2,500
15:37:38 Q 2.90 +0.05 500
15:37:34 Q 2.90 +0.05 1,000

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
11:16:52 Q 3.05 +0.15 1,000
11:15:17 Q 3.07 +0.17 2,000
11:12:17 Q 3.05 +0.15 300
10:58:53 Q 3.05 +0.15 500
10:58:29 Q 3.05 +0.15 1,500
10:58:25 Q 3.05 +0.15 500
10:55:31 Q 3.05 +0.15 500
10:49:29 Q 3.05 +0.15 100
10:46:51 Q 3.05 +0.15 1,000
10:46:16 Q 3.05 +0.15 500

[pepe05]

Recent Trades - Last 10
Time Ex Price Change Volume
16:06:34 Q 3.08 +0.18 12,500
15:59:32 Q 3.07 +0.17 1,000
15:59:24 Q 3.07 +0.17 500
15:59:24 Q 3.08 +0.18 500
15:56:56 Q 3.09 +0.19 500
15:43:14 Q 3.09 +0.19 185
15:43:00 Q 3.10 +0.20 1,000
15:34:23 Q 3.09 +0.19 6,000
15:33:02 Q 3.09 +0.19 500
15:32:57 Q 3.08 +0.18 2,500

[pepe05]

Unigene and Upsher-Smith File Patent Infringement Lawsuit against Canadian Drug Manufacturer

2006-07-25 08:30 ET - News Release

FAIRFIELD, N.J. -- (Business Wire) -- July 25, 2006

Unigene Laboratories, Inc. (OTCBB: UGNE) and
Upsher-Smith Laboratories, Inc. have jointly filed in the U.S.
District Court for the Southern District of New York a patent
infringement lawsuit against Apotex Inc., a Canadian generic
pharmaceutical manufacturer, and Apotex Corp., its U.S. subsidiary.
The suit was brought in response to Apotex's filing of an Abbreviated
New Drug Application (ANDA) seeking approval of a nasal spray product
that claims to be a generic equivalent of Fortical(R)
calcitonin-salmon (rDNA origin) Nasal Spray, the nasal calcitonin
product for the treatment of postmenopausal osteoporosis that is
manufactured by Unigene and marketed by Upsher-Smith. The filing of
the lawsuit automatically stays FDA approval of Apotex's ANDA for at
least 30 months, unless an adverse court decision occurs earlier.
Apotex is currently the defendant in a patent infringement lawsuit
involving a nasal calcitonin formulation developed and patented by
Novartis.
"It is our firm intention to defend our patent rights," commented
Dr. Ronald S. Levy, Executive Vice President of Unigene. "We continue
to be very enthusiastic about the commercial opportunity that Fortical
represents. According to NDC data, at the end of May Fortical had
captured 24% of the nasal calcitonin market. We believe that it is
being accepted as a safe, effective and well-tolerated alternative to
established osteoporosis therapies."
Unigene and Upsher-Smith are represented in the action by Morgan &
Finnegan, LLP, in New York, an intellectual property law firm.
Upsher-Smith is Unigene's exclusive U.S. marketing partner for
Fortical. Both parties will contribute to the litigation costs.

About Fortical

Fortical is indicated for the treatment of postmenopausal
osteoporosis in women greater than five years postmenopause with low
bone mass relative to healthy premenopausal women. Recommended in
conjunction with adequate calcium and vitamin D intake. The most
common adverse events were rhinitis, other nasal symptoms, back pain,
arthralgia, epistaxis and headache. Periodic nasal examinations are
recommended; if nasal ulceration occurs, discontinue treatment until
healed. Because calcitonin-salmon is a protein, the possibility of
systemic allergic reaction exists. For more information and complete
product information and most common adverse events for Fortical(R)
Nasal Spray, visit www.upsher-smith.com or call 1-800-654-2299.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call [phone] or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.

About Upsher-Smith

Upsher-Smith Laboratories, Inc. is a fully integrated
pharmaceutical company that manufactures and markets prescription
pharmaceutical, OTC and cosmetic products. Upsher-Smith is also
actively involved in licensing innovative compounds that are in
clinical development. For more information about Upsher-Smith
Laboratories, Inc., call 800-654-2299 or visit www.upsher-smith.com

Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements regarding us and our business, financial condition, results
of operations and prospects. Such forward-looking statements include
those which express plans, anticipation, intent, contingency, goals,
targets or future development and/or otherwise are not statements of
historical fact. We have based these forward-looking statements on our
current expectations and projections about future events and they are
subject to risks and uncertainties known and unknown which could cause
actual results and developments to differ materially from those
expressed or implied in such statements. These forward-looking
statements include statements about the following: general economic
and business conditions, our financial condition, competition, our
dependence on other companies to commercialize, manufacture and sell
products using our technologies, the ability of our products to gain
market acceptance and increase market share, the uncertainty of
results of animal and human testing, the risk of product liability and
liability for human trials, our dependence on patents and other
proprietary rights, dependence on key management officials, the
availability and cost of capital, the availability of qualified
personnel, changes in, or the failure to comply with, governmental
regulations, the failure to obtain regulatory approvals for our
products and other risk factors discussed in our Securities and
Exchange Commission filings. Words such as "anticipates," "expects,"
"intends," "plans," "predicts," "believes," "seeks," "estimates,"
"may," "will," "should," "would," "potential," "continue," and
variations of these words (or negatives of these words) or similar
expressions, are intended to identify forward-looking statements. In
addition, any statements that refer to expectations, projections, or
other characterizations of future events or circumstances, including
any underlying assumptions, are forward-looking statements. These
forward-looking statements are not guarantees of future performance
and are subject to certain risks, uncertainties, and assumptions that
are difficult to predict. Therefore, our actual results could differ
materially and adversely from those expressed in any forward-looking
statements as a result of various risk factors.

Contacts:

Investors:
The Investor Relations Group
Damian McIntosh/Dian Griesel, Ph.D., 212-825-3210

[pepe05]

Unigene to Release Second Quarter 2006 Results and Host Conference Call

2006-08-08 09:00 ET - News Release

FAIRFIELD, N.J. -- (Business Wire) -- Aug. 8, 2006

Unigene Laboratories, Inc. (OTCBB: UGNE) will release
financial results for the quarter ended June 30, 2006, at
approximately 7:30 AM EDT on Thursday, August 10th. The Company will
also host a conference call on Thursday, August 10th, at 9:00 AM EDT
to discuss its 2006 second quarter financial results.
Unigene invites all those interested in hearing management's
discussion of second quarter results to join the call by dialing
1-877-407-0782 for participants in the United States and
1-201-689-8567 for international participants. A replay will be
available for 45 days after the call and can be accessed by dialing
1-877-660-6853 for participants in the United States and
1-201-612-7415 for international participants and entering account #
286 and conference ID # 211188 when prompted.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call [phone] or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.

Contacts:

Unigene
Investors:
The Investor Relations Group
Damian R. McIntosh / Dian Griesel, Ph.D.
or
Media:
Janet Vasquez, 212-825-3210

[toothstone]

Heute nachbörslich,

also ich rechne mit so was wie 0 cent.
die reorder-zahlen sind wohl wichtig,
milestones bezüglich pth scheinen ja immer noch auf sich warten zu lassen und china sowieso.

[pepe05]

Unigene Named Ninth Fastest Growing Technology Company in New Jersey in Deloitte's Technology Fast 50 Program

2006-08-11 07:00 ET - News Release

FAIRFIELD, N.J. -- (Business Wire) -- Aug. 11, 2006

Unigene Laboratories, Inc. (OTCBB: UGNE) has been named
to Deloitte's prestigious Technology Fast 50 Program for New Jersey.
It was ranked ninth out of the 50 fastest growing technology, media,
telecommunications and life sciences companies in the area by Deloitte
& Touche USA LLP, one of the nation's leading professional services
organizations. Rankings are based on the percentage revenue growth
over five years, from 2001 to 2005. Unigene's revenues increased from
$865,000 in 2001 to $14,276,000 in 2005, representing a five-year
growth of 1,550%.
"We are pleased to be recognized as one of the fastest growing
technology companies in New Jersey," commented Dr. Warren Levy,
President and CEO of Unigene. "We thank our employees for their
dedicated efforts which have allowed us to achieve this level of
growth."
"Deloitte's New Jersey Technology Fast 50 companies have shown the
strength, vision and tenacity to succeed in today's very competitive
technology environment," said Paul Mlynarski, a Partner at Deloitte
Tax LLP and Chairperson of Deloitte's New Jersey Technology Fast 50
Program. "We applaud the successes of Unigene and acknowledge it as
one of the very few to accomplish such a fast growth rate over the
past five years."
To qualify for the Technology Fast 50, companies must have had
operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005,
be headquartered in North America, and be a company that owns
proprietary technology or proprietary intellectual property that
contributes to a significant portion of the company's operating
revenues; or devotes a significant proportion of revenues to the
research and development of technology. For more information on
Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit
www.fast500.com.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call [phone] or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a
Swiss Verein, its member firms and their respective subsidiaries and
affiliates. As a Swiss Verein (association), neither Deloitte Touche
Tohmatsu nor any of its member firms has any liability for each
other's acts or omissions. Each of the member firms is a separate and
independent legal entity operating under the names of "Deloitte,"
"Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related
names. Services are provided by the member firms or their subsidiaries
or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the US member firm of Deloitte Touche
Tohmatsu. In the US, services are provided by the subsidiaries of
Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting
LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and
their subsidiaries), and not by Deloitte & Touche USA LLP.


Contacts:

The Investor Relations Group
Investors:
Damian R. McIntosh / Dian Griesel, 212-825-3210
or
Media:
Susan Morgenbesser, 212-825-3210

[hellblau]

heut gab's mal wieder ein bisschen Hoffnung


US 08:45 Unigene to Present at the ThinkEquity Partners Conference; Fortical(R) Sales to Upsher-Smith Resume

FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 30, 2006
Unigene Laboratories, Inc.'s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the 4th Annual ThinkEquity Partners Conference on Tuesday, September 12, 2006 at 9:00AM PDT. Dr.
Levy will present information on the Company's products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Ritz-Carlton Hotel in San Francisco from September 11-14, 2006.
Separately, Unigene reports that as expected and previously disclosed, sales of its nasal calcitonin product Fortical(R) to its U.S. marketing partner, Upsher-Smith Laboratories, have resumed.
"Going forward, we expect to experience a more regular ordering pattern for Fortical from our partner," commented Warren P. Levy, President and CEO of Unigene.

[toothstone]

Das war glaub ich nicht der grund, sondern die monatlich steigenden orders nach fortical, steht auf rb.
es scheint so, daß dieser massive verkaufsdruck weg ist, nach den 2 180000 blöcken vom dienstag nachbörslich.
es lag nicht an ugne, sondern an einem investor, der geplatzt zu sein scheint.

[pepe05]

11:19:05 Q 2.63 +0.13 1,500
11:17:18 Q 2.63 +0.13 500
11:14:17 Q 2.63 +0.13 300
11:09:16 Q 2.63 +0.13 400
11:07:01 Q 2.63 +0.13 350
11:07:01 Q 2.62 +0.12 500
11:06:53 Q 2.60 +0.10 2,500
11:05:56 Q 2.60 +0.10 500
11:04:42 Q 2.65 +0.15 1,100
11:04:17 Q 2.62 +0.12 2,500

[MrSeriousInvestor]

Oha, mein Uralt-Lieblingswert käampft sich wieder nach oben!?!
Verdient hat es die Firma.... und ich auch, nach der laaaangen Wartezeit!



Greetz

MSI

[toothstone]

Das schaut richtig gut aus.
Einerseits gab es eine bloombergempfehlung, andererseits ist miacalcin um 23 % im 3. Quartal eingebrochen.
emis lief schon wahnsinig gut, hier spekulieren sie, ob das mit deren diabetes oder mit unserem novartisprojekt zu tun hat.
also bis zu 15.11. wird ugne so oder so laufen und wahrscheinlich auch für die nächste zeit.

[tiktiki]

Antwort auf Beitrag Nr.: 24.793.987 von toothstone am 23.10.06 08:36:22

hi, was steht denn am 15.11 an? danke für die info!

[pepe05]

Antwort auf Beitrag Nr.: 24.793.987 von toothstone am 23.10.06 08:36:22

Es geht wieder rund.

So kann es mal ein paar Tage gehen.

[toothstone]

schaut richtig gut aus, wurde gestern wohl ein bißchen geschüttelt.
15.11. kommen die quartalszahlen 3. hier könnten wir endgültig im plus liegen, vor allem bei miacalcineinbruch von 23%.

[pepe05]

[hellblau]

Antwort auf Beitrag Nr.: 24.824.783 von pepe05 am 24.10.06 17:21:17

RT 2,99

[tiktiki]

wie sind denn die erwartungen in punkto quartalszahlen?
also charttechnisch gefällt mir das im Moment sehr gut. wenn wir jetzt noch die 200tage linie schaffen...is ja nicht mehr weit!

[toothstone]

Also ich würde sagen ein leichtes plus, so daß es insgesmant ein neutrales jahr ergibt, soweit ich mich recht erinnere, war das erste -4 cent und das zweite -1 cent.
Was natürlich immer zu den forticalumsätzen hinzukommen kann, sind die GSK-milestones, vertraglich vereinbart 140 mio$, bei PTH.
Außerdem kann jederzeit ein oraler calcitonin-deal hinzukommen, china ist wohl zweitrangig.

[tiktiki]

na, des gefällt mir aber gar net...der anstieg ist schon wieder bei der katz...! maue umsätze...irgendwelche news?

[pepe05]

Unigene to Present at the 8th Annual Rodman and Renshaw Healthcare Conference on November 8th 2006

2006-11-03 08:30 ET - News Release


FAIRFIELD, N.J. -- (Business Wire)

Unigene Laboratories, Inc.’s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the 8th Annual Rodman and Renshaw Healthcare Conference on Wednesday, November 8 at 11:00 AM EST. Dr. Levy will present information on Unigene’s products and collaborations. The conference will be held at The New York Palace Hotel in New York City on November 6-8.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

[pepe05]

Unigene to Release Third Quarter 2006 Results and Host Conference Call on November 10th

2006-11-08 08:45 ET - News Release


FAIRFIELD, N.J. -- (Business Wire)

Unigene Laboratories, Inc. (OTCBB: UGNE) will release financial results for the third quarter ended September 30, 2006, before the market opens on Friday, November 10th. The Company will also host a conference call that morning, at 9:00 AM EST to discuss its 2006 third quarter financial results.

Unigene invites all those interested in hearing management’s discussion of the third quarter results to join the call by dialing 877-407-0782 for participants in the United States and 201-689-8567 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 877-660-6853 for participants in the United States and 201-612-7415 for international participants. When prompted, enter account # 286 and conference ID #220249.

[toothstone]

Das wird doch heute nicht mal eine positive Überraschung geben.
DEr intraday ist ja bis jetzt ganz nett.

[pepe05]

[toothstone]

Na ja -3 cent, aber die wortwahl der levys war noch nie so aggressiv.
china soll heuer noch abgeschloßen werden,
und vor allem pth-gsk macht fortschriite.
ich denke trotz der -3 wird es aufwärts gehen wegen den zukunftsaussichten.

[pepe05]

Unigene Engages University Clinicians to Advise on Bone Growth Program

2006-11-30 08:30 ET - News Release

Company Also Acquires License to Bone Growth Patent Applications


FAIRFIELD, N.J. -- (Business Wire)

Unigene Laboratories, Inc. (OTCBB: UGNE) has engaged two leading clinicians as consultants to assist in the development and testing relating to the Site-Directed Bone Growth program currently being conducted by the company in collaboration with investigators from Yale University Medical School.

Unigene scientists, in collaboration with Dr. Agnes Vignery at Yale, co-invented the Site-Directed Bone Growth technology, which involves the use of a simple, minimally invasive outpatient procedure in conjunction with the administration of an anabolic drug that has been shown in animals to facilitate and accelerate natural bone growth at precisely targeted locations. Possible applications of this technology include strengthening of weakened or damaged bones due to osteoporosis or fractures, the treatment of chronic back pain, the prevention of hip fractures and the improvement of bone healing.

The new consultants are leading medical professionals from the Johns Hopkins University School of Medicine:

Dr. Donlin Long, a Distinguished Senior Professor of Neurosurgery at the Johns Hopkins University School of Medicine was also the Neurosurgeon-in-Chief of the Johns Hopkins Hospital and Director of the Department of Neurosurgery at that institution from 1973 to 2000. He has authored more than 200 papers and authored or contributed to over 100 books in bone and related areas. He is actively involved in neurosurgery practice and has a major interest in the origins of spinal pain and the outcomes of treatment of spinal diseases. He is also one of the founders of the International Association for The Study of Pain.

Dr. Kieran Murphy is a Director of Interventional Neuroradiology and Associate Professor of Radiology, Neurology and Neurological Surgery at the Johns Hopkins University School of Medicine. Dr. Murphy is a pioneer in the field of image guided/minimally invasive spine intervention, and the inventor of devices for vertebral stabilization (the Murphy needles) that have become the industry standard worldwide. He has authored more than 100 peer-reviewed publications. His research focus is in the area of image-guided spine intervention with a particular interest in prophylactic spine, hip, and wrist augmentation to reduce inevitable osteoporotic fractures in high-risk patients.

“We are understandably excited to add these outstanding medical experts to our development team for the Site-Directed Bone Growth program,” stated Dr. Warren Levy, President and CEO of Unigene. “In collaboration with our colleagues at Yale University Medical School, we plan to explore the many potential applications of this novel technology, including intervention to prevent bone failure and relief of spinal pain by rebuilding bone naturally rather than replacing it with other foreign material.”

In conjunction with this program, Unigene has licensed three of Dr. Murphy’s patent applications to strengthen its intellectual property portfolio. The patent applications involve the use of specialized equipment and procedures to deliver substances that promote bone growth or strengthen existing bone.

“These novel delivery approaches and combinations should expand our patent protection and complement the Site-Directed Bone Growth technology in ways that may enable and facilitate additional commercialization options,” Dr. Levy added.

[pepe05]

[toothstone]

Schön zu sehen, war schon die letzten handelstage zu beobachten, daß gegen böresnschluß ein paar käufe kamen und jetzt mit einer miniorder den kursanstieg zu bremsen.
das hatten wir vor einem jahr vor dem anstieg 2 oder 3 mal.

[pepe05]

13:10:55 Q 2.73 +0.17 5,000
13:10:45 Q 2.72 +0.16 500
13:08:45 Q 2.72 +0.16 200
13:08:44 Q 2.72 +0.16 500
13:05:20 Q 2.70 +0.14 10,000
13:04:09 Q 2.70 +0.14 1,500
13:04:09 Q 2.70 +0.14 3,200
13:04:09 Q 2.72 +0.16 5,000
13:03:10 Q 2.72 +0.16 500
13:02:25 Q 2.72 +0.16 600

[toothstone]

und auf top geschloßen!
auf rb wird wegen dem 8k, irgendwelche bonusvergütungen schon ziemlich spekuliert, ob da nicht noch was kommt.
manchmal hilft geduld doch noch.

[MrSeriousInvestor]

Hallo @all

weiss einer mehr darüber, wieso der Kurs sich so toll erholt hat?

Vielen Dank für jede Info.

Greetz

MSI

[tiktiki]

news von heute 13.00 Uhr, quelle : businesswire.com:

Unigene Enters Supply Agreement to Manufacture Osteoporosis Peptide

FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) will receive a $2.5 million payment to supply Novartis with specified quantities of a bulk peptide necessary to support Novartis’ development program for a novel osteoporosis treatment. Over the next several months, Unigene will use its patented manufacturing technology to develop an FDA-compliant process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary. Some of this material may be used in clinical studies.

In 2004, Novartis exclusively licensed Unigene’s technology to manufacture another peptide, calcitonin, and it now runs the scaled-up process at its manufacturing facility in Kundl, Austria.

“We are very pleased to expand our relationship with Novartis,” commented Dr. Ronald S. Levy, Executive Vice President of Unigene. “They have a strong commitment to peptide therapeutics as well as to osteoporosis products. Our calcitonin collaboration has been extremely successful, and we hope to have additional opportunities to work with them.”

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.

[pepe05]

09:46:43 Q 2.49 +0.12 500

09:46:36 Q 2.49 +0.12 1,500

09:46:23 Q 2.48 +0.11 500

09:46:20 Q 2.48 +0.11 1,300

09:46:10 Q 2.48 +0.11 1,000

09:45:08 Q 2.45 +0.08 3,000

09:42:45 Q 2.45 +0.08 500

09:42:29 Q 2.45 +0.08 500

09:41:15 Q 2.43 +0.06 500

09:40:22 Q 2.45 +0.08 1,000

[toothstone]

Also freuen kann ich mich darüber noch nicht.
eine gute news, die eigentlich verpufft.
neues hormon, guter kontakt zu novartis,
jedes monat steigende forticalzahlen.
ich versteh es einfach nicht.
und ziemlich sicher ein positives quartal, mit den 2,5 mio das nächste quartal sowieso auch.

[tiktiki]

tja, da gehts mir ähnlich. Der Wert kommt einfach nicht in die Pötte...da müssen wir noch viel geduld aufbringen...!

[tiktiki]

Antwort auf Beitrag Nr.: 27.288.520 von tiktiki am 30.01.07 08:42:00

vielleicht gehts doch schneller.
gestern schöner upmove. wenn wir heute die 200er TL schaffen...wer weiss. volumen ist jedenfalls ok jetzt.
schaut charttechnisch sehr interessant aus...
n.m.M.

[toothstone]

Schaut wirklich schon viel freundlicher aus.
Am 15.2 müßten doch wieder zahlen kommen.
Es bräuchte nur milestones, china, Pth phase2 oder orales calci.
So viele Möglichkeiten.

[pepe05]

Unigene Receives Phase II SBIR Grant for Novel Peptide Discovery Program


2007-02-15 08:37 ET - News Release


FAIRFIELD, N.J. -- (Business Wire)

Unigene Laboratories, Inc. (OTCBB: UGNE) has been awarded a Phase II Small Business Innovative Research (SBIR) Grant from the National Institute for Diabetes and Digestive Kidney Diseases (NIDDK), a division of the National Institutes of Health. The Phase II award, which will provide approximately $900,000 over two years, will fund the continuation of Unigene’s proprietary discovery program to identify novel therapeutic peptide hormones.

In 2003, Unigene received a Phase I grant which allowed the Company to utilize a proprietary technology developed in collaboration with the University of South Florida to establish a procedure for identifying such peptides in various plant or animal tissues. Unigene subsequently confirmed the utility of the technology and achieved all of the objectives of the Phase I program. The Company then filed a Phase II application, which was reviewed and accepted by the funding agency without any modifications.

“We are very pleased that the NIDDK has chosen to continue its support of this innovative program because the competition for such funds is intense,” said Dr. Ronald S. Levy, Executive Vice President of Unigene. “An increasing number of peptides are being shown to play essential roles in fundamental human metabolic processes, yet only a small number of these have already been commercialized. This program can create additional opportunities for the utilization of Unigene’s patented peptide manufacturing and delivery technologies, while enabling us to obtain additional patent protection on the novel peptides themselves.”

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.’s management’s current expectations, estimates, beliefs, assumptions, and projections about Unigene’s business and industry. Words such as “anticipates,”“expects,”“intends,”“plans,”“predicts,”“believes,”“seeks,”“estimates,”“may,”“will,”“should,”“would,”“potential,”“continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Contacts:

Unigene Investor
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media
Janet Vasquez, 212-825-3210

Source: Unigene Laboratories, Inc.

[pepe05]

http://www.americanbulls.com/StockPage.asp?CompanyTicker=UGN…

[pepe05]

Unigene Achieves $5.5 Million Milestone in Calcitonin Collaboration for Phase III Initiation

The initiation of a Phase III clinical study for osteoporosis by Nordic Bioscience, the development partner of Novartis Pharma AG, with oral calcitonin has triggered a $5.5 million milestone to be paid by Novartis to Unigene Laboratories, Inc. (OTCBB: UGNE).

Salmon calcitonin, the active pharmaceutical ingredient in Novartis’ oral product, was produced using Unigene’s patented manufacturing process, which was licensed to Novartis in 2004. In 2005, the technology was transferred successfully to Sandoz, an affiliate of Novartis, who produced multiple kilograms of calcitonin at a scale that represents a ten-fold increase above Unigene’s current production capacity. Under the terms of that agreement, Unigene is eligible to receive up to $18.7 million in payments before royalties. Upon receipt of this milestone payment, Unigene will have received $13.7 million of that total.

“We are pleased that a pivotal study has started with an oral product made with our calcitonin manufacturing technology,” commented Dr. Ronald S. Levy, Executive Vice President of Unigene. “This action confirms Novartis’ intention to utilize Unigene’s technology to commercialize the product. We believe that this study, combined with Novartis’ planned study for oral calcitonin in osteoarthritis, will serve to highlight the significant potential market opportunities for calcitonin-based products in the future.”

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.’s management’s current expectations, estimates, beliefs, assumptions, and projections about Unigene’s business and industry. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Investor Contact:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210

Source: Business Wire (February 27, 2007 - 8:25 AM EST)

News by QuoteMedia
www.quotemedia.com

[tiktiki]

Antwort auf Beitrag Nr.: 28.006.682 von pepe05 am 27.02.07 16:49:43

super news in miesestem umfeld ..was für ein timing...!

[pepe05]

Unigene to Release Fourth Quarter and Year-End 2006 Results and Host Conference Call on March 19th

Unigene Laboratories, Inc. (OTCBB: UGNE) will release financial results for the year ended December 31, 2006, before the market opens on Monday, March 19th. The Company will also host a conference call that morning, at 9:00 AM EDT to discuss its 2006 year end financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing 877-407-0782 for participants in the United States and 201-689-8567 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 877-660-6853 for participants in the United States and 201-612-7415 for international participants. When prompted, enter account # 286 and conference ID #234780.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.

Unigene Investor Contact:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D.
Media Contact: Janet Vasquez
Phone: [phone]

Source: Business Wire (March 13, 2007 - 1:52 PM EDT)

News by QuoteMedia
www.quotemedia.com

[Dorfmeister]

Hallo erstmal ..

Nun mal ernsthaft: Bin ich total bescheuert oder ist diese Aktie nicht total unterbewertet? Marktkapitalisierung von unter 200mio USD! Zusammenfassend kann man ja sagen, dass

- 2007 profitabel sein wird (Marktanteil wurde im ersten Quartal verdoppelt, im 2006 haben Sie 14 mio eingenommen ((fielen aber hauptsächlich im 2005 an!!))
- Die Pipeline mit einem Phase III Blockbuster (Marktpotential von 7bn USD in 2015) und einem baldigem Phase II Blockbuster (PTH mit GSK) gefüllt ist.
- Zulassung in China in 2007 mehr als wahrscheinlich ist (90 Mln Osteoporose Kranke). Wenn jetzt auch nur 1 Mln dieses Medi nehmen und sie pro Patient 20$ pro Jahr verdienen sind dies gleich nochmals 24mln mehr Erträge.
- Sie noch weitere hochinteressante Projekte im Köcher haben (Fähigkeit lokal Knochenaufzubauen, GLP-1 welches dasselbe wie Byetta ist und dieses hat bereits mehrere 100 mio Sales pro Jahr)
- man könnte hier noch endlos weitermachen

... ich würde mal genauer hinsehen. Beantworte jede kritische Frage bei Bedarf !!

[kerzi]

Antwort auf Beitrag Nr.: 28.759.327 von Dorfmeister am 11.04.07 15:54:45

Seh ich auch so ...

Grüsse
Günter

[tiktiki]

Antwort auf Beitrag Nr.: 28.764.280 von kerzi am 11.04.07 20:03:47

tja so habe ich das auch gesehen, als ich vor einiger zeit eingestiegen bin...nur leider der kursverlauf entäuscht schon ziemlich..hier ist wohl noch geduld angesagt...

[Dorfmeister]

Bin optimistisch, dass wir im Q1 einen Gewinn sehen werden. Sollten ca. 1 Mio vom Novartis deal gezeigt werden können plus ca. 4.5 -5 Mio von fortical. Ausgaben sollten nicht wesentlich über 4 mio sein was dann so ein zwei cents geben wird. Gibt dann auch so um die 12mio die sie als cash zeigen können und so sieht dann alles wieder tip top aus und dies wird dann neue investoren anziehen .. dann kann es schnell wieder über 3 dollar gehen. Bist Du in Frankfurt oder an der Nasdq investiert? Nachkaufen?

[tiktiki]

Antwort auf Beitrag Nr.: 28.775.339 von Dorfmeister am 12.04.07 13:34:48

..na ja die zahlen sind eine sache...obs dem kurs hilft..? bin damal in d eingestiegen, Nachkauf ist im moment keine option...sonst liegt evtl noch mehr geld sinnlos in der gegend rum...aber wer kann das schon sagen, nein, meine posi ist gross genug ...im verhältnis zum depot...!

[Dorfmeister]

Ich denke schon das ein Gewinn enorm helfen würde .. viele leute benutzen ja so screener (eps growth quarter over quarter etc )

Auch das EK verhältnis sieht gleich viel besser aus mit den 8 mio zusätzlichen liquiden mitteln etc

werde mir per anfangs mai vor den zahlen noch ein paar reinziehen .. aber an der nasdaq

[pepe05]

so könnte es mal ein paar tage weitergehen

[pepe05]

Unigene's Site-Directed Bone Growth Technology May Have Multiple Large Market Applications According to New Market Analysis

The site-directed bone growth (SDBG) technology currently being developed by Unigene Laboratories, Inc. (OTCBB: UGNE) in conjunction with Yale University may have the potential to provide clinicians with new techniques to target bone growth at the site of a fracture or at sites that are highly susceptible to fracture. This promising early-stage technology is currently being studied in animals. Unigene has identified several possible applications of this technology, each with substantial commercial potential.

The technology, which involves a minimally invasive surgical procedure in conjunction with the administration of one or more biologic agents, including a systemic anabolic agent produced by Unigene, was the subject of a detailed market analysis performed by a leading consulting group which specializes in the pharmaceutical sector. The study evaluates several clinical areas where this technology could have significant utility:

Spine

* Treatment and Prevention of Vertebral Compression Fractures (2004 worldwide device market for spine - $3.5 billion)

-- Treatment - (2006 U.S. incidence - 800,000). SDBG could
be performed as an alternative to the use of current
cements in certain spinal stabilization procedures,
such as vertebroplasty/kyphoplasty, which do not foster
bone integration or growth.

-- SDBG could be used in conjunction with standard
vertebroplasty to protect adjacent vertebrae from
subsequent compression fractures.

-- Prevention - in patients who are severely osteoporotic
(2006 U.S. incidence - 430,000), the physician could
target vertebrae deemed susceptible to future
fractures.

* Treatment of Chronic Back Pain (2006 U.S. market for chronic back pain surgery - $5 billion, with 5 million surgical candidates)

-- SDBG could be used to replace more invasive surgical
procedures, including spinal fusion and diskectomy.

-- Vertebral instability has been identified by leading
clinicians as a possible contributing factor in chronic
back pain. Targeting specific vertebrae and stimulating
new bone synthesis may result in a more stable
vertebrae with a subsequent reduction in bone pain.

Hip

* Treatment of hip fractures (2003 U.S. surgical admissions for hip fractures – 310,000). SDBG may be useful in improving the healing process and clinical outcome.
* Prevention of hip fractures - in patients who are severely osteoporotic (2006 U.S. incidence – 430,000), SDBG may be useful in preventing future hip fractures by specifically increasing bone mineral density at a hip deemed susceptible to future fracture.

Long Bone

* SDBG may be useful in improving the clinical outcome for non-union long bone fractures due to trauma and reducing patient recovery times (2006 U.S. incidence - 390,000). The technology may also reduce the occurrence of subsequent fractures.

“The results of the market analysis support Unigene’s commitment to this program and its potential application to reducing the costs associated with the treatment of debilitating bone disorders,” stated Dr. James Gilligan, Vice President of Product Development. “In addition, the feedback from interviews with clinical leaders in the field suggests that this technology is truly unique and may have the potential to revolutionize treatments for osteoporotic bone disease and fractures.”

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.

Investor:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Janet Vazquez/Lynn Granito
212-825-3210

Source: Business Wire (March 20, 2007 - 8:40 AM EDT)

News by QuoteMedia
www.quotemedia.com

[Dorfmeister]

Neu Käufer werden wohl bald aufspringen. Dies ist das erste mal dass sie an dieser Konferenz sind!!!!!!!!!

Unigene to Present at the UBS Global Generic and Specialty Pharmaceuticals Conference on May 8, 2007
Thursday May 3, 8:00 am ET


FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc.'s (OTCBB: UGNE - News) President and CEO, Dr. Warren Levy, will speak at the UBS Global Generic and Specialty Pharmaceuticals Conference on Tuesday, May 8, 2007 at 4:00 PM. Dr. Levy will present information on Unigene's products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Grand Hyatt in New York City from May 8-9, 2007.
ADVERTISEMENT



A live audio webcast of the presentation will also be available on the UBS website at www.ibb.ubs.com under the conference tab. An audio replay of the presentation will begin three hours after the presentation time and will be available until June 8, 2007.

[Dorfmeister]

Am 11ten May wissen wir also wieder mehr .. oder heute schon um 21.30 ?!?

Press Release Source: Unigene Laboratories, Inc.


Unigene to Release First Quarter 2007 Results and Host Conference Call on May 11th
Tuesday May 8, 8:17 am ET


FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE - News) will release financial results for the first quarter ended March 31 2007, before the market opens on Friday, May 11th. The Company will also host a conference call that morning, at 9:00 AM EDT to discuss its first quarter financial results and to provide a Company update.
ADVERTISEMENT


Unigene invites all those interested in hearing management's discussion to join the call by dialing 866-334-3876 for participants in the United States and 416-849-4292 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 866-245-6755 for participants in the United States and 416-915-1035 for international participants. When prompted, enter passcode #525168. Participants may also access a live webcast of the conference call through the investor relations section of Unigene's website at www.unigene.com. The webcast will be archived on the company's website for 45 days.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

[pepe05]

[Dorfmeister]

habt ihr den call von der ubs konferenz gehört? Was ist eure Meinung?

Pth Phase II scheint ja nicht mehr lichtjahre weit weg zu sein. Final Formulation. Wahrscheinlich müssen sie dann das was sie bei den Tiermodellen festgestellt haben nochmals kurz verifizieren in einer 12 wochen Studie und dann gehts weiter mit phase II.

Unterdessen haben Sie sogar schon eine Vision! Wir wollen die dominante Rolle bei den Peptid basierten Wirkstoffen werden .. es gibt ja nur ca. 100 solche Wirkstoffe ?!? .. Also wenn diese Vision in 10 Jahren Wirklichkeit werden sollte, dann kannst du mal 100 rechnen !

[pepe05]

[Dorfmeister]

Umsatz 6.3 Mln !! (steigerung von 1500% yoy!!!!)
Operativer Cash Flow 1.5 Mln !!
Gewinn pro Aktie 0 cents.

Sieht alles super aus und es wird weiter aufwärts gehen. Bin gespannt auf den Conf Call!

[MrSeriousInvestor]

Hallo an alle Unigenisten,

als Mega-Long Investor dieser kleinen Firma freue ich mich, dass endlich mal wieder etwas Bewegung in den Kurs kommt, hoffentlich hält es an (die Bewegung nach oben).

Schönen Abend.

MSI

[mieckymaus]

Antwort auf Beitrag Nr.: 29.275.400 von MrSeriousInvestor am 11.05.07 20:02:10

Ja allmählich siehts ganz gut aus. Ich habe den Wert seit 2/06 im Depot und bin noch kräftig im Minus; aber wie gesagt als Langfrist-Investment muss man halt Geduld haben.
Pech hatte ich schon mal mit Neopharm.
schöne Grüße mieckymaus

[MrSeriousInvestor]

Antwort auf Beitrag Nr.: 29.279.692 von mieckymaus am 12.05.07 12:23:43

Hello mieckymaus, (toller nick; klingt sweet)

tja, also UNIGENE halte ich (bei sehr variablem Bestand schon seit ... hm.... glaube 1995,) bin damals bei 2 USD rein, habe den H¨henflug bis maximal 6,25 mitgemacht (war aber damals ein falsch übertragener Kurs)sollte USD 5,25 sein, dann habe ich den Absturz bis auf 0,22 USD auch überlebt, um die Wiederbelebung bis auf 4,75 USD zu erleben und den darauf folgenden langsamen Niedergang noch dazu.

In 1995 stellte UNIGENE sich im Auditorium meines Arbeitsgebers vor, viele sprangen auf und verdienten gutes Geld mit dem Papier, jetzt könnte es mal wieder nach oben gehen, es wäre an der Zeit, ich brauche ein neues Auto

So, nach diesem Exkurs in die dunkle Vergangenheit wünsche ich dir und allen Investierten ein tolles Wochenende.

Freundliche Grüsse, Mieckymaus,

und man liest sich

MSI

[Dorfmeister]

Hab mal über das Weekend noch den CC angehört. Tönt ja alles super optimistisch.

- Sie können nun mehr oder weniger alle peptides oral verabreichen.
- Das Interesse von grossen Pharmafirmen hat enorm zugenommen. (Stellt euch nur mal vor Sie können 1 peptide pro Jahr auslizensieren zu 150mln a 15mln upfront. Zum Beispiel PYY an Merck, GLP-1 an Pfizer, Oral Sct an GSK etc. Wobei diese drei sicherlich die Intersantesten sind. Alles Blockbuster Medikamente und wenn wir dann 20% Royalties nehmen dann geht die Rechnerei erst los ! Uiii uiiii uii
- Im März hat der Nasale Calcitonin Markt ein zwei Jahres hoch erreicht
- Mehrere Aertze seien nun wieder bereit dem Nasal calcitonin eine zweite Chance zu geben. Dies Aufgrund der Probleme der Konkurenzprodukte bezgl. den starken Nebeneffekten.
- In den nächsten 18 Monaten sei ein listing an der Nasdaq oder Amex sicherlich kein Problem. Ebenfalls in dieser Zeit sicherlich weitere Meilenstein Zahlungen.
- etc etc !

Viel Glück allen und ich hoffe Ihr habt die Eier dies als ein Longterm Investment zu sehen ..

[pepe05]

Unigene Announces Strong Increase in Revenue and Improved Quarterly Income for First Quarter 2007

Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the quarter ended March 31, 2007.

Revenue for the three months ended March 31, 2007 increased to $6,328,000 compared to $387,000 for the three months ended March 31, 2006. Revenue from Fortical sales and royalties were $4,461,000 for the three months ended March 31, 2007.

Fortical royalties for the three months ended March 31, 2007 increased to $1,845,000 from $198,000 for the three months ended March 31, 2006. First quarter 2007 Fortical royalties include Upsher-Smith sales for the four month period of December 2006 through March 2007. Fortical sales were $2,616,000 for the three months ended March 31, 2007. Sales to Novartis under our supply agreement were $1,408,000 for the three months ended March 31, 2007. There were no product sales for the three months ended March 31, 2006.

Operating income for the three months ended March 31, 2007 increased to $124,000 from an operating loss of $2,856,000 for the three months ended March 31, 2006.

Unigene’s net loss for the three months ended March 31, 2007 was $244,000, or $.00 per share, compared to a net loss of $3,243,000, or $.04 per share for the three months ended March 31, 2006.

The three months ended March 31, 2007 and 2006 includes $393,000 and $165,000, respectively, in expenses for non-cash stock option compensation. As of March 31, 2007, Unigene had approximately $697,000 in expenses for non-cash stock option compensation that remains to be recognized, primarily over the next 12 months.

Total operating expenses were $6,204,000 for the three months ended March 31, 2007, an increase from $3,243,000 for the three months ended March 31, 2006. The increase was primarily due to cost of goods sold on product sales to Upsher-Smith and Novartis.

Our cash balance at March 31, 2007 was $4,646,000, an increase of approximately $1,288,000 from December 31, 2006. Accounts receivable at March 31, 2007 were $7,345,000, an increase of $6,105,000 from December 31, 2006. This was primarily a result of the $5,500,000 milestone payment from Novartis which was received in April 2007.

Deferred licensing fees increased $6,169,000 from December 31, 2006, primarily due to the $8,000,000 in payments from Novartis which were only partially recognized as revenue in the first three months of 2007.

Following are recent highlights and developments:

* According to IMS, prescriptions for Fortical®, the Company’s first U.S. product that was launched in August 2005, grew to 91,000 in March 2007, reflecting a 32% increase from February 2007. The same source reported that prescriptions for the first quarter of 2007 increased 46% as compared to the fourth quarter of 2006. The nasal calcitonin market share for Fortical during that same period grew from 29% to 45%.
* Subsequent to March 31, 2007, the Company repaid $1 million of outstanding debt and has restructured its loan obligations, recasting $15.7 million in debt as eight-year term loans. The new notes have a fixed simple interest rate of 9%, and no payments are required for the first three years of the notes. This restructuring will reduce the Company’s aggregate annual interest payments, replaces all notes that have been in default and will strengthen the Company’s financial position.
* The Company has progressed in its efforts to improve its oral delivery technology and is in the process of filing new patent applications to protect these inventions. These improvements should enhance the Company’s oral delivery technology in general and the calcitonin and PTH programs in particular.

“We are very pleased to report the continued growth of Fortical prescriptions,” commented Dr. Warren Levy, President and CEO of Unigene. “The significant increase in first quarter revenue will help fuel the Company’s activities in new programs. In combination with the partial loan repayment and the restructuring of the Company’s debt to eliminate all defaults and lower interest expense, we will significantly improve the Company’s balance sheet.”
UNIGENE LABORATORIES, INC.
CONDENSED BALANCE SHEETS



March 31, 2007


December 31, 2006
ASSETS (Unaudited)
Current assets:

Cash and cash equivalents $ 4,645,627 $ 3,357,351
Accounts receivable 7,345,442 1,240,114
Inventory 4,554,028 5,283,000
Prepaid expenses and
other current assets 281,303 303,444

Total current assets 16,826,400 10,183,909

Property, plant and equipment, net 2,403,297 2,364,141
Investment in joint venture 30,656 30,545
Patents and other intangibles, net 1,483,009 1,438,848
Other assets 111,389 33,879

Total assets $ 20,854,751 $ 14,051,322


LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:
Accounts payable $ 928,954 $ 884,958
Accrued expenses - other 1,877,721 1,806,707
Current portion - deferred licensing fees 2,162,756 762,752
Notes payable - stockholders 8,095,000 8,105,000
Accrued interest - stockholders 8,467,004 8,081,180
Current portion - capital lease obligations 65,108 70,780

Total current liabilities 21,596,543 19,711,377

Deferred licensing fees, excluding current portion 12,925,402 8,156,262
Capital lease obligations, excluding current portion 28,202 40,880
Deferred compensation 340,016 330,643

Total liabilities 34,890,163 28,239,162

Commitments and contingencies

Stockholders' deficit:

Common Stock - par value $.01 per share,
authorized 135,000,000 shares,
issued and outstanding:
87,734,515 shares in 2007 and
87,731,015 shares in 2006 877,345 877,310
Additional paid-in capital 105,136,739 104,740,178
Accumulated deficit (120,049,496) (119,805,328)

Total stockholders' deficit (14,035,412) (14,187,840)
$ 20,854,751 $ 14,051,322

UNIGENE LABORATORIES, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)





Three months ended March 31,


2007


2006

Revenue:
Product sales $ 4,023,732 $ --
Royalties 1,845,442 197,702
Licensing revenue 230,856 189,189
Development fees and other 228,242 --

6,328,272 386,891
Operating expenses:
Research, development and facility expenses 2,124,135 1,581,106
Cost of goods sold 2,019,651 --
General and administrative 2,060,235 1,661,877

6,204,021 3,242,983

Operating income (loss) 124,251 (2,856,092)

Other income (expense):
Interest income 31,723 27,024
Interest expense-principally to stockholders (400,142) (413,604)

Loss before income taxes (244,168) (3,242,672)

Income tax expense -- --

Net loss
$ (244,168)

$


(3,242,672)

Loss per share – basic and diluted:
Net loss per share $ (0.00) $ (0.04)

Weighted average number of shares outstanding -
basic and diluted 87,731,376 84,084,903


Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D.
212-825-3210

Source: Business Wire (May 11, 2007 - 8:02 AM EDT)

News by QuoteMedia
www.quotemedia.com

[pepe05]

Unigene Restructures Debt

$1 Million Repaid, Interest Rate Lowered, Default Eliminated

Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it has repaid $1 million in stockholder debt and restructured the remaining $15.7 million debt balance as eight-year term notes with a fixed simple interest rate of 9% per annum. The new notes replace short term debt, a portion of which was in default. Payments under the new notes are not required for the first three years.

“This transaction will immediately replace all notes that have been in default, reduce the Company’s aggregate annual interest payments to a rate that is just .75% above the prime lending rate and extend the term required for repayment,” commented Dr. Warren Levy, President and CEO of Unigene. “The terms of the new notes are much more favorable to Unigene and they substantially improve our balance sheet. We appreciate Jay Levy’s continued support of Unigene, and his willingness to accommodate these new terms, that will further strengthen our ability to advance our product pipeline.”


Unigene Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Janet Vazquez, 212-825-3210

Source: Business Wire (May 11, 2007 - 7:01 AM EDT)

News by QuoteMedia
www.quotemedia.com

[mieckymaus]

Antwort auf Beitrag Nr.: 29.284.501 von MrSeriousInvestor am 12.05.07 18:35:23

Hi Mr. Serious, dann bist du ja schon ein "Langfristinvestor".
Ich glaub so lang halt ich´s net aus, wenn ich einigermassen im Plus bin ( was ja auch noch dauern kann ) dannn bin ich bei Unigene draussen. Die Aktie gehört zu meinen "unrecherchierten Dummheiten". Bin mittlerweile mehr in deutsche Nebenwerte invesiert.
schöne Grüße
mieckymaus

[Dorfmeister]

Hey Miecky

Dann gib ich dir mal ein Update!!

fundamental siehst so gut aus wie noch nie. Sie sind nun in der lage praktisch alle wirkstoffe (welche bis dato nur via nadel verabreicht werden konnten) oral zu verabreichen. ZB Insulin, welches dir wohl am bekanntesten sein sollte ... wobei insulin steht bei ihnen nicht auf der prio liste weil es nur ein sehr enges terrapeutic window gibt, was schwierig ist genau zu treffen (eine overdose kann tödlich sein)

der durchbruch gelang in den letzten monaten ... nun muss dies natürlich durch lizenzabkommen mit grossen pharma firmen bestätigt werden. Mit GSK haben sie schon seit jahren eins und dies soll nun (dank dem durchbruch) weitergehen. Anscheinend sind sie schon dabei die tableten für den nächsten menschenversuch zu kreieren. Weitere Wirkstoffe könnten dazukommen .. anscheinend sei das interesse an ihnen so gross wie noch nie und sie sind mit praktisch allen grossen firmen im gespräch. Die wahrscheinlichsten Medikamente sind:

PYY (gegen Fettleibigkeit, Potential über 1Mrd)
Calcitonin (gegen Osteoporose (Markt aktuell 6Mrd) und Osteoarthritis (Markt sicher über 2Mrd)
GLP-1 (gegen Diabetes, Markt sicher auch über 1Mrd)

Sagen wir sich machen mit allen wirkstoffen lächerliche 2 Mrd und verdienen 20% mit. Gibt 400 Mio Gewinn mal P/E von 30 gibt 12 Mrd Marktkapitalisierung was 60 mal dem aktuellen kurs entspricht und dies in den nächsten 10 Jahren ... dies heisst man macht im Schnitt pro Jahr immer mal 6. Wenn Du jetzt 5000 Euro investierst dann hast Du in 10 Jahren 300'000 Euro ... Cool hä!

[mieckymaus]

Antwort auf Beitrag Nr.: 29.343.055 von Dorfmeister am 16.05.07 14:01:00

Ja Meister, das wär cool
Aber ich bin mittlerweile bei den US Biotechfirmen "gebranntes Kind", wie ich schon geschrieben habe bin ich mit Neopharm 80 % im Minus weil ich sie leider nicht verkauft habe bei 10 EUR vor lauter Gier. Und ich möchte den gleichen Fehler nicht 2 x machen.
Aber ich wünsch mir natürlich das du Recht hast und halte die Aktie weiterhin. Schaun mer mal.
Danke für die Info
Grüße
mieckymaus

[MrSeriousInvestor]

Antwort auf Beitrag Nr.: 29.345.410 von mieckymaus am 16.05.07 16:20:39

Heyyy miecky,

was dorfmeister schreibt,erklärt schon viel, aber nicht alles.... UNIGENE wird eventuell in nächster Zukunft das Marktsegment wechseln (sie kommen aus dem NYSE, sind abgestuft worden in die OTCCB), sie wollen wieder an den NYSE, was dazu führt, dass viele Fonds sich wieder ernsthaft mit UNIGENE beschäftigen werden.

Darüber hinaus arbeitet das Management an der Zulassung von CALCITONIN am chinesichen Markt, welches Potential da dahinter steckt, brauche ich wohl nicht aufzuführen

Daher erlaube ich mir zu sagen, dass UNIGENE ein relativ 'sicheres' Risikoinvest (nur scheinbar ein Widerspruch) darstellt, nicht zu vergleichen mit anderen Werten die im gleichen Bereich tätig sind oder auch nur an der OTCCB gehandelt werden.....

In diesem Sinne... ein bisschen Geduld ist schon gefragt... aber - à bon entendeur salut-... (sinngemäss: dem guten Zuhörer winkt das Glück)

Freundlichst

MSI

[mieckymaus]

Antwort auf Beitrag Nr.: 29.358.501 von MrSeriousInvestor am 17.05.07 16:06:40

Danke für die ganzen Infos, ihr braucht mich ja aber nicht mehr zu überzeugen, bin ja schon investiert,
Aber jetzt kommt endlich mal ein bisschen mehr Info in diesen Thread..
Schönes Wochenende wünscht Euch
mieckymaus

[mieckymaus]

Antwort auf Beitrag Nr.: 29.358.501 von MrSeriousInvestor am 17.05.07 16:06:40

Danke für die ganzen Infos, ihr braucht mich ja aber nicht mehr zu überzeugen, bin ja schon investiert,
Aber jetzt kommt endlich mal ein bisschen mehr Info in diesen Thread..
Schönes Wochenende wünscht Euch
mieckymaus

[Dorfmeister]

Antwort auf Beitrag Nr.: 29.370.372 von mieckymaus am 18.05.07 12:26:32

alles ich weiss so ziemlich alles über die aktie sprich produkte, konkurrenz etc .. wenn du/ihr fragen habt, fragt einfach.

Vielleicht noch ein Input zu diesem side directed bone growth. Sie sind da mit den absoluten profis am werk. Der eine Doktor den sie engagiert haben ist praktisch der Erfinder von der Technik Vertebroplasty (cement als knochenstabilisator oder auf english hier: http://en.wikipedia.org/wiki/Vertebroplasty ) und hiervon werden in den USA eine ganze Menge durchgeführt (siehe unten). Keine Ahnung was das kostet aber wenn diese Firma nur auf 200'000 a 500 $ kommt, gibt das auch gleich wieder ein schönes Sümmchen ..

Das gute hierbei ist eben, dass es sich mehr um einen device(Gerät) als um ein Medikament handelt. Die Zulassung für Geräte geht etwas halb so schnell .. sprich so um die 4-5 Jahre.


Spine

Treatment and Prevention of Vertebral Compression Fractures (2004 worldwide device market for spine - $3.5 billion)
-- Treatment - (2006 U.S. incidence - 800,000). SDBG could
be performed as an alternative to the use of current
cements in certain spinal stabilization procedures,
such as vertebroplasty/kyphoplasty, which do not foster
bone integration or growth.

-- SDBG could be used in conjunction with standard
vertebroplasty to protect adjacent vertebrae from
subsequent compression fractures.

-- Prevention - in patients who are severely osteoporotic
(2006 U.S. incidence - 430,000), the physician could
target vertebrae deemed susceptible to future
fractures.

Treatment of Chronic Back Pain (2006 U.S. market for chronic back pain surgery - $5 billion, with 5 million surgical candidates)
-- SDBG could be used to replace more invasive surgical
procedures, including spinal fusion and diskectomy.

-- Vertebral instability has been identified by leading
clinicians as a possible contributing factor in chronic
back pain. Targeting specific vertebrae and stimulating
new bone synthesis may result in a more stable
vertebrae with a subsequent reduction in bone pain.

Hip

Treatment of hip fractures (2003 U.S. surgical admissions for hip fractures - 310,000). SDBG may be useful in improving the healing process and clinical outcome.
Prevention of hip fractures - in patients who are severely osteoporotic (2006 U.S. incidence - 430,000), SDBG may be useful in preventing future hip fractures by specifically increasing bone mineral density at a hip deemed susceptible to future fracture.
Long Bone

SDBG may be useful in improving the clinical outcome for non-union long bone fractures due to trauma and reducing patient recovery times (2006 U.S. incidence - 390,000). The technology may also reduce the occurrence of subsequent fractures.

[Dorfmeister]

Unigene Reports That Oral Calcitonin Phase III Clinical Study for Osteoarthritis Treatment is Initiated
Tuesday June 5, 7:00 am ET


FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE - News) reported that Novartis Pharma AG and its development partner Nordic Bioscience have initiated a multi-center Phase III clinical study to evaluate the use of their oral formulation of calcitonin to treat osteoarthritis. The calcitonin to be used in the study was produced by Novartis using Unigene's patented manufacturing process, and Unigene will receive royalty payments if the product is successfully commercialized using this calcitonin.
ADVERTISEMENT


This is the second pivotal study involving an oral calcitonin dosage form that Novartis and Nordic Bioscience have commenced this year. On February 27th, Unigene announced that the formulation was being evaluated in a Phase III trial for the treatment of osteoporosis.

Osteoarthritis is a progressively degenerative and often painful disease that affects approximately 20 million people in the U.S. It is the most common form of arthritis and results in the destruction of cartilage, primarily in the weight-bearing joints.

"Preliminary reports in the medical literature suggest that calcitonin treatment has beneficial effects on both cartilage tissue and subchondral bone, and hence has the potential to be the first therapeutic agent that can modify the course of the disease," stated Dr. Ronald S. Levy, Executive Vice President of Unigene. "Current osteoarthritis treatments primarily provide only symptomatic relief to patients."

[pepe05]

Unigene Laboratories Unigene to Present Initial Animal Data on Site-Directed Bone Growth
Datum : 18/06/2007 @ 12h30
Quelle : BusinessWire
Name : Unigene Laboratories, Inc. (UGNE)
Kurs : 2.12 0.02 (0.95%) @ 17h00
<< Zurück Kurs Chart Reports Trades Level2


Unigene Laboratories Unigene to Present Initial Animal Data on Site-Directed Bone Growth

Unigene Laboratories, Inc. (OTCBB: UGNE) will present initial animal data for its site-directed bone growth (SDBG) technology on Monday, June 25, 2007 at the 17th Scientific Meeting of the International Bone and Mineral Society in Montreal, Canada.

The poster presentation is entitled “Rapid Site-Specific Bone Growth by a Combination of Bone Marrow Ablation and Anabolic Therapy,” and will demonstrate the technology’s ability to create new bone within the femur of an animal and thereby improve the biomechanical properties of the bone.

“We believe that SDBG has the potential to decrease cost and improve the quality of life of patients with certain bone conditions,” commented Dr. Warren Levy, President and CEO of Unigene. “Our team of researchers at Unigene and Yale, in collaboration with leading clinicians in interventional radiology and orthopedic surgery at Johns Hopkins Medical School, is actively exploring the capabilities of the technology. We will seek to complement our activities with those of a development partner having experience with products that combine biological agents and devices.” About SDBG The SDBG technology was developed by scientists at Unigene and Yale University Medical School. It involves a minimally invasive surgical procedure in conjunction with a proprietary device and the administration of one or more biological agents, including a systemic anabolic agent. Additional animal studies are underway and human studies are planned in the near future.

The technology may find utility in the treatment and/or prevention of vertebral compression, hip and long bone fractures, and chronic back pain.

About Unigene Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.’s management’s current expectations, estimates, beliefs, assumptions, and projections about Unigene’s business and industry. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

[Dorfmeister]

neues interview

http://www.wallstreetreporter.com/profile.php?id=24674&a=1

er sagt die firma ist massiv unterbewertet. Die Zukunft sehe rosig aus etc ..
Erträge werden zunehmen.
Sie werden neue Phase 1 Studien machen ..
Fortical läuft sehr gut.

[MrSeriousInvestor]

Antwort auf Beitrag Nr.: 30.324.467 von Dorfmeister am 26.06.07 13:57:13

Hey dorfmeister,

dem Kurs scheint das Interview ziemlich egal zu sein

gruss

MSI

[pepe05]

Antwort auf Beitrag Nr.: 30.324.467 von Dorfmeister am 26.06.07 13:57:13

na,sieht doch schon mal ganz gut aus

[pepe05]

[hellblau]

schaut nicht schlecht aus, oder ?

http://biz.yahoo.com/bw/070810/20070810005073.html?.v=1

[pepe05]

Press Releases
Date : 10-Aug-2007
Unigene Announces Financial Results for the Second Quarter of 2007
Revenue for Six Months Exceeds $11 Million

FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 10, 2007--Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the three months and six months ended June 30, 2007.

Revenue for the three months ended June 30, 2007 increased to $4,718,000 compared with $556,000 for the three months ended June 30, 2006. Revenue for the six months ended June 30, 2007 increased to $11,046,000 compared with $943,000 for the six months ended June 30, 2006. Revenue from Fortical sales and royalties was $3,374,000 and $7,836,000, respectively, for the three months and six months ended June 30, 2007.

Fortical royalties were $1,075,000 and $348,000 for the three months ended June 30, 2007 and 2006, respectively, and $2,920,000 and $546,000 for the six months ended June 30, 2007 and 2006, respectively. Fortical sales were $2,300,000 and $4,915,000 for the three months and six months ended June 30, 2007, respectively. Sales of peptide to Novartis were $792,000 and $2,200,000 for the three months and six months ended June 30, 2007, respectively. There were no product sales during the first half of 2006.

Net loss for the three months ended June 30, 2007 was $1,294,000, or $0.01 per share, compared with a net loss of $3,002,000, or $0.03 per share, for the three months ended June 30, 2006.

Net loss for the six months ended June 30, 2007 was $1,538,000, or $0.02 per share, compared with a net loss of $6,244,000, or $0.07 per share, for the six months ended June 30, 2006.

Operating expenses were $5,758,000 for the three months ended June 30, 2007, compared with $3,300,000 for the three months ended June 30, 2006 and were $11,962,000 for the six months ended June 30, 2007, compared with $6,543,000 for the six months ended June 30, 2006. The increases were primarily due to cost of goods sold resulting from the increased product sales to Upsher-Smith and Novartis. The three months ended June 30, 2007 and 2006 includes $289,000 and $262,000, respectively, in expenses for non-cash stock option compensation. The six months ended June 30, 2007 and 2006 includes $682,000 and $427,000, respectively, in expenses for non-cash stock option compensation.

The Company's cash balance at June 30, 2007 was $6,765,000, an increase of approximately $3,407,000 from December 31, 2006. Accounts receivable at June 30, 2007 were $2,608,000, an increase of $1,368,000 from December 31, 2006.

Deferred licensing fees increased $4,955,000 from December 31, 2006, primarily due to the $5,500,000 Phase III milestone payment received from Novartis which was only partially recognized as revenue in the first half of 2007.

The Company believes that cash on hand, as well as cash generated from Fortical sales and royalties, will be sufficient to meet our obligations for the next twelve months. Therefore, disclosure relating to the uncertainty of the Company's ability to continue as a going concern is not included in our June 30, 2007 Form 10Q.

Following are highlights for the second quarter of 2007:

According to IMS, prescriptions for Fortical(R), the Company's first U.S. product that was launched in August 2005, totaled 263,000 for the quarter, reflecting a 15% increase from the first quarter and a nasal calcitonin market share of approximately 47%.
The Company restructured its loan obligations, recasting $15.7 million in debt as eight-year term loans. The interest rate associated with these new notes is 9%, and although no payments are required for the first three years of the notes, there is also no prepayment penalty. This reduces the Company's aggregate annual interest payments and eliminates all notes that had been in default. This restructuring strengthens the Company's financial position and, in conjunction with the elimination of the going concern disclosure in our 10Q, it is an important step in achieving compliance with the listing requirements of certain stock exchanges.
"Increasing revenue from Fortical in combination with the restructured loan obligation has materially strengthened Unigene's financial position," commented Dr. Warren Levy, President and CEO of Unigene. "We are implementing a three-pronged strategy utilizing these resources to strengthen our technology platforms, advance the development of certain internal programs and broaden the Company's pipeline."

Recently, the Company announced that it had improved its Enteripep(R) oral delivery technology, moved its internal oral calcitonin program into the clinic and announced the in-licensing of certain products for inflammation and cardiovascular treatment.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.

UNIGENE LABORATORIES, INC.
CONDENSED BALANCE SHEETS

June 30, December 31,
2007 2006
--------------- ---------------
ASSETS (Unaudited)
--------------------------------------
Current assets:
Cash and cash equivalents $ 6,764,506 $ 3,357,351
Accounts receivable 2,608,459 1,240,114
Inventory 3,712,889 5,283,000
Prepaid expenses and other current
assets 385,972 303,444
------------- --------------
Total current assets 13,471,826 10,183,909

Noncurrent inventory 348,075 --
Property, plant and equipment, net 2,436,513 2,364,141
Investment in joint venture 29,953 30,545
Patents and other intangibles, net 1,656,294 1,438,848
Other assets 129,305 33,879
------------- --------------
Total assets $ 18,071,966 $ 14,051,322
============= ==============
LIABILITIES AND STOCKHOLDERS' DEFICIT
--------------------------------------
Current liabilities:
Accounts payable $ 965,485 $ 884,958
Accrued expenses - other 1,906,132 1,806,707
Current portion - deferred
licensing fees 1,262,756 762,752
Notes payable - stockholders -- 8,105,000
Accrued interest - stockholders -- 8,081,180
Current portion - capital lease
obligations 57,324 70,780
------------- --------------
Total current
liabilities 4,191,697 19,711,377

Notes payable stockholders 15,737,517 --
Deferred licensing fees, excluding
current portion 12,611,212 8,156,262
Capital lease obligations, excluding
current portion 18,226 40,880
Deferred compensation 354,118 330,643
Accrued interest-stockholders 197,905 --
------------- --------------
Total liabilities 33,110,675 28,239,162
------------- --------------
Commitments and contingencies

Stockholders' deficit:
Stockholders' deficit:
Common Stock - par value $.01 per
share, authorized 135,000,000
shares, issued and outstanding:
87,738,515 shares in 2007 and
87,731,015 shares in 2006 877,385 877,310
Additional paid-in capital 105,427,441 104,740,178
Accumulated deficit (121,343,535) (119,805,328)
------------- --------------
Total stockholders'
deficit (15,038,709) (14,187,840)
------------- --------------
Total liabilities and
stockholders deficit $ 18,071,966 $ 14,051,322
============= ==============
UNIGENE LABORATORIES, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

Three months ended Six months ended
June 30, June 30
------------------------- -------------------------
2007 2006 2007 2006
------------ ------------ ------------ ------------
Revenue:
Product sales $ 3,091,677 $ -- $ 7,115,409 $ --
Royalties 1,074,657 347,944 2,920,099 545,646
Licensing
revenue 347,690 189,189 578,546 378,378
Development fees
and other 204,188 18,854 432,430 18,854
------------ ------------ ------------ ------------

4,718,212 555,987 11,046,484 942,878
------------ ------------ ------------ ------------
Operating
expenses:
Cost of goods
sold 1,659,753 -- 3,679,404 --
Research,
development and
facility
expenses 2,178,960 1,860,699 4,303,095 3,403,805
General and
administrative 1,919,088 1,439,708 3,979,323 3,139,585
------------ ------------ ------------ ------------

5,757,801 3,300,407 11,961,822 6,543,390
------------ ------------ ------------ ------------

Operating loss (1,039,589) (2,744,420) (915,338) (5,600,512)

Other income
(expense):
Interest and
other income 117,977 114,012 149,700 141,036
Interest
expense- (372,427) (371,373) (772,569) (784,977)
principally to
stockholders
------------ ------------ ------------ ------------

Loss before income
taxes (1,294,039) (3,001,781) (1,538,207) (6,244,453)

Income tax expense -- -- -- --
------------ ------------ ------------ ------------
Net loss $(1,294,039) $(3,001,781) $(1,538,207) $(6,244,453)
============ ============ ============ ============

Loss per share -
basic and
diluted:
Net loss per
share $ (0.01) $ (0.03) $ (0.02) $ (0.07)
------------ ------------ ------------ ------------

Weighted average
number of shares
outstanding -
basic and
diluted 87,735,922 87,663,388 87,733,661 85,884,031
============ ============ ============ ============
CONTACT: Unigene Investor
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media
Lynn Granito, 212-825-3210

SOURCE: Unigene Laboratories, Inc.


Other News
July, 2004 - BioPharm International - Oral Delivery and Recombinant Production of Peptide Hormones
April 28, 2004 - Agreement Between Unigene and Novartis Benefits Upsher Smith's Commercialization of Nasal Calcitonin

[Dorfmeister]

Antwort auf Beitrag Nr.: 30.335.275 von MrSeriousInvestor am 26.06.07 21:36:23

Du wenn die Leute blind sind kann ich auch nichts dafür ... kaufen wir halt weiter und die Frühpensionierung kommt dann halt schon in drei Jahren anstatt in vier .. who cares?!?

[MrSeriousInvestor]

Antwort auf Beitrag Nr.: 31.413.704 von Dorfmeister am 06.09.07 12:45:47

Hallo Dorfmeister,

habe meine UGNE abgestossen, brauchte ein neues Auto habe sie zu USD 2,25 verkauft, ist schon ein paar Wochen her

Kaufe vielleicht wieder welche, sollten sie nochmals in die Gegend von USD 2 kommen.

Greetz

MSI

[Dorfmeister]

ich weiss man wird gerne ungeduldig aber ich denke diese Zeit ist so ziemlich die Dümste um auszusteigen. Keep the faith. Der Mini Trial wird ein Erfolg. Und dann gehts dann langsam aber sicher los und dies nicht zu knapp. GSK, Oral CT Partner, ev. neue Peptide Partner nächstes Jahr, AMEX, Indexaufnahem, Coverage etc etc ...

GSK Phase II und Oral CT Partner sollten zusammen upfront so um die 20-30 Mio abwerfen, mindestens!

[pepe05]

Date : 20-Sep-2007
Unigene and Yale Present Longer-Term Animal Data for Novel Site-Directed Bone Growth Technology

FAIRFIELD, N.J.--(BUSINESS WIRE)--Sept. 20, 2007--Unigene Laboratories, Inc. (OTCBB: UGNE) and Yale University yesterday presented data at the 29th Annual Meeting of the American Society for Bone and Mineral Research in Honolulu, Hawaii that demonstrated the ability to preserve new bone created using their proprietary Site-Directed Bone Growth Technology.

The poster presentation was entitled "Rapid Site-Specific Bone Growth by a Combination of Bone Marrow Ablation, PTH and Bisphosphonate Therapy." The data illustrated that the technology promotes rapid, targeted new bone formation within the thigh bone of an animal that can be maintained for an extended period of time by treatment with a bone building agent, such as PTH, followed by a commonly used bone protective agent, such as a bisphosphonate. The presentation will be posted this week on Unigene's website, www.unigene.com.

"Although still in the early stages of development, we continue to believe that this technology could represent an important breakthrough in the prevention and treatment of certain commonplace but serious bone-related medical conditions," commented Dr. Warren Levy, President and CEO of Unigene. "There is an important unmet need for a rapid, minimally-invasive procedure to strengthen specific bones that are at risk of fracture, or to accelerate fracture repair. Our team of researchers at Unigene and Yale, along with leading clinicians in interventional radiology and orthopedic surgery at Johns Hopkins Medical School, continues its work with animal models to evaluate the ability of the technology for various applications. If future animal and human studies confirm the utility of this technology, it could represent a much more attractive alternative for patients considering hip replacement, spinal fusion, vertebroplasty, or other common bone-related surgeries."

About Site-Directed Bone Growth (SDBG)

The patent-pending SDBG technology involves the synergistic combination of a proprietary device to irrigate the marrow of a targeted bone and the systemic administration of a biological compound, such as PTH, that promotes bone growth. The appearance of new bone in animals after only three weeks of PTH therapy was documented previously by various techniques and resulted in improvement in the strength and biomechanical properties of the targeted bone. Earlier studies demonstrated that the use of calcitonin following PTH treatment protected the new bone that was created. The amount of new bone observed following the combined use of PTH and calcitonin far exceeded that achieved by treatment with PTH or calcitonin alone. The most recent results extend those findings to three months and confirm the extensive creation of bone preferentially at the desired location.

In clinical practice, the technology may find application in skeletal sites such as the spine, hip, or wrist for preventing fractures of bones weakened by osteoporosis, to accelerate fracture repair and bone healing, or to reinforce the implantation of prosthetic devices. The potential markets for these technologies include the prevention and/or treatment of vertebral compression fractures, hip fractures, and long bone fractures. The market for products and procedures for each of these indications currently exceeds $1 billion annually. This technology may also be useful in treating chronic back pain, an indication involving expenditures of more than $5 billion in 2006.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH, and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

CONTACT: Unigene Investor:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Lynn Granito, 212-825-3210

SOURCE: Unigene Laboratories, Inc.

Other News
July, 2004 - BioPharm International - Oral Delivery and Recombinant Production of Peptide Hormones

[Dorfmeister]

Antwort auf Beitrag Nr.: 31.764.745 von pepe05 am 27.09.07 16:31:40

Habt ihr die Präsentation gehört?

www.ibb.ubs.com und dann auf Conferneces anklicken.

Vielleicht eine kleine Zusammenfassung
- Endlich hat er mal auf die phasen III mit Novartis hingewiesen
- Hat sich stark mit der Frage beschäftigt ob Calcitonin ein Blockbuster (über 1mrd Umsatz) werden kann:

3 Bereiche weshalb dies geschehen sollte:
- Sicherheit (Fosamax wird bereits von mehreren 100 Leuten verklagt)
- Osteoarthritis; über 21 Millionen in den USA daran erkrankt. Calcition der einzige Wirkstoff mit heilender Wirkung!!!
- Bessere Verabreichungsform, nämlich als Tablette!

Wie weit sind sie? Er tönte so, und dies wurde mir auch bestätigt, als der trial ein voller Erfolg sein wird. In den nächsten Wochen werden wir deshalb etwas über einen neuen Partner und von Glaxo hören! .. wahrscheinlich die letzen Wochen um zu kaufen ..

[Dorfmeister]

Neues von unseren Amerikanischen Freunden:

Also wenn Ihr EIER habt dann kauft ihr bis Ende Oktober zu ...

http://ragingbull.quote.com/mboard/boards.cgi?board=UGNE&rea…
If one has large cojones and you believe WL statements that UGNE will have an oral sct partner well before year end, this is the time to get buying. That's that.

Weitere interessante Beiträge:

I understood that the short oral human trials were complete and excellent results. This supports a soon oral pth. They can show the data to GSK but GSK may want to do a short human trial for PTH,,,they are not the same but the reformulated tablets are good for sct. They sound very encouraged in all areas. Things go slowly out there on bio-pharma land.

[pepe05]

Unigene Reports Successful Completion of Oral Calcitonin Human Study
BusinessWire - October 25, 2007 8:00 AM ET




Unigene Laboratories, Inc. (OTCBB: UGNE) reports that the clinical study that was initiated in August with its proprietary formulation of oral calcitonin has now been successfully completed. All of the subjects achieved a biological response and the study met the desired goals for blood levels and variability.

The tablets used in the study utilized an improved solid dosage form of Unigene's Enteripep(R) oral delivery technology for which a patent application has been filed. The study measured the blood levels of an established marker of bone resorption in eighteen post-menopausal women.

"These results suggest that the solid dosage form development effort conducted by Unigene over the last year may result in a significant improvement in formulation performance," stated Dr. Warren Levy, President and CEO of Unigene. "The study confirms that the calcitonin measured in the blood of the subjects is intact and biologically active. This novel formulation will also simplify the tablet manufacturing process. Unigene intends to utilize this improved formulation for the development of its oral calcitonin product and for the development of other oral peptide products. We believe that these results have the potential to broaden the range of products that may be commercialized using our technology."

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

SOURCE: Unigene Laboratories, Inc.

Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210

[pepe05]

[pepe05]

November 1, 2007 - 8:09 AM EDT


Unigene to Present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference

Unigene Laboratories, Inc.’s (OTCBB: UGNE, http://www.unigene.com) President and CEO, Dr. Warren Levy, will speak at the Acumen Biofin Rodman & Renshaw 9th Annual Conference on Monday, November 5, 2007. Dr. Levy will present information on Unigene’s products and collaborations. The conference will be held at the New York Palace Hotel in New York City on November 5-7, 2007.


The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210

Source: Business Wire (November 1, 2007 - 8:09 AM EDT)

[pepe05]

Unigene to Release Third Quarter Results and Host Conference Call on November 12th

Unigene Laboratories, Inc. (OTCBB: UGNE, www.unigene.com) will release financial results for the third quarter ended September 30, 2007, before the market opens on Monday, November 12th. The Company will also host a conference call that morning, at 9:00 AM EST, to discuss its third quarter financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing 866-585-6398 for participants in the United States and 416-849-9626 for international participants. A replay will be available for seven days after the call and can be accessed by dialing 866-245-6755 for participants in the United States and 416-915-1035 for international participants. When prompted, enter passcode #596692. The conference call may also be accessed via the Web at www.unigene.com; a link will be provided for listeners to join the call.


The Investor Relations Group
Investors:
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
Media:
Lynn Granito, 212-825-3210

Source: Business Wire (November 7, 2007 - 8:04 AM EST)

[Dorfmeister]

Antwort auf Beitrag Nr.: 32.355.539 von pepe05 am 09.11.07 07:52:17

earnings werden flat rein kommen. und bald gehts weiter ... im aktionär kommt auch bald wieder was! its time to buy!

[Dorfmeister]

Antwort auf Beitrag Nr.: 32.357.618 von Dorfmeister am 09.11.07 10:23:25

6.3 Mio Revenues (Break Even!) ... Super Quartal!

Revenue

Revenue is summarized as follows for the three-month and nine-month periods
ended September 30, 2007 and 2006:



Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
Product Sales $ 4,142,635 $ 837,217 $ 11,258,044 $ 837,217
Royalties 1,628,476 672,771 4,548,575 1,218,417
Licensing Revenue 280,691 189,189 859,237 567,567
Development Fees - - 300,000 -
Grant and Other Revenue 291,668 1,693 424,098 20,547

$ 6,343,470 $ 1,700,870 $ 17,389,954 $ 2,643,748

[pepe05]

Unigene Announces Financial Results for the Third Quarter of 2007

Revenue for Nine Months Exceeds $17 Million; Sequential Quarterly Revenues up 34%

Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the three months and nine months ended September 30, 2007.

Revenue for the three months ended September 30, 2007 increased to $6,343,000 compared with $1,701,000 for the three months ended September 30, 2006. Revenue for the nine months ended September 30, 2007 increased to $17,390,000 compared with $2,644,000 for the nine months ended September 30, 2006. Revenue from Fortical sales and royalties was $5,771,000 and $13,607,000, respectively, for the three months and nine months ended September 30, 2007.

Fortical royalties were $1,628,000 and $673,000 for the three months ended September 30, 2007 and 2006, respectively, and $4,549,000 and $1,218,000 for the nine months ended September 30, 2007 and 2006, respectively. Fortical sales were $4,143,000 and $9,058,000 for the three months and nine months ended September 30, 2007, respectively. Fortical sales were $837,000 for the three months and nine months ended September 30, 2006. Sales of peptide to Novartis were $2,200,000 for the nine months ended September 30, 2007.

Net loss for the three months ended September 30, 2007 was $240,000, or $0.00 per share, compared with a net loss of $2,515,000, or $0.03 per share, for the three months ended September 30, 2006.

Net loss for the nine months ended September 30, 2007 was $1,778,000, or $0.02 per share, compared with a net loss of $8,759,000, or $0.10 per share, for the nine months ended September 30, 2006.

Operating expenses were $6,304,000 for the three months ended September 30, 2007, compared with $3,897,000 for the three months ended September 30, 2006 and were $18,266,000 for the nine months ended September 30, 2007, compared with $10,440,000 for the nine months ended September 30, 2006. The increases were primarily due to cost of goods sold resulting from the increased product sales to Upsher-Smith and Novartis. The three months ended September 30, 2007 and 2006 includes $84,000 and $134,000, respectively, in expenses for non-cash stock option compensation. The nine months ended September 30, 2007 and 2006 includes $766,000 and $561,000, respectively, in expenses for non-cash stock option compensation.

The Company’s cash balance at September 30, 2007 was $7,004,000, an increase of approximately $3,647,000 from December 31, 2006. Accounts receivable at September 30, 2007 were $3,416,000, an increase of $2,176,000 from December 31, 2006.

Deferred licensing fees increased $4,641,000 from December 31, 2006, primarily due to the $5,500,000 Phase III milestone payment received from Novartis which was only partially recognized as revenue in the first nine months of 2007.

The Company believes that cash on hand, as well as cash generated from Fortical sales and royalties, will be sufficient to meet its obligations for the next twelve months.

Following are financial highlights:

* Third quarter revenues increased 34% from second quarter
* Third quarter Fortical sales and royalties increased 71% from second quarter
* Fortical’s market share improved to 49%
* Positive operating income for third quarter
* Positive cash flow from operations for nine months

“We are encouraged by the significant improvements in our financial performance,” commented Dr. Warren Levy, President and CEO of Unigene. “With a stronger balance sheet and cash position, we intend to proceed with additional clinical studies for some of our peptides, as well as pre-clinical and clinical studies in our Site Directed Bone Growth Program.”

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.



The Investor Relations Group
Investors:
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (November 12, 2007 - 6:01 AM EST)

[pepe05]

[Dorfmeister]

Antwort auf Beitrag Nr.: 32.395.999 von pepe05 am 12.11.07 17:25:51

Nun scheint es definitiv zu sein. CEO diese Woche in der Schweiz und in Deutschland für eine Roadshow! Dies kann ja nur mehr Käufer bedeuten.... !!
In der Schweiz liegt ja genug Geld rum und BB Biotech als grösste Biotechgesellschaft wäre auch noch da ... screaming buy!

[Dorfmeister]

http://www.depotliga.de/xist4c/web/Unigene---Operativ-macht-…

Endlich mal was in Deutsch

Unigene - Operativ macht das Unternehmen schon Gewinn

Am 12. November hat Unigene die Ergebnisse für das dritte Quartal bekannt gegeben. Demnach stiegen die Produktumsätze im Jahresvergleich um 394,8 Prozent auf 4,14 Millionen US-Dollar, die Royalty-Zahlungen um 142,1 Prozent auf 1,63 Millionen Dollar und die Lizenzeinnahmen um 48,4 Prozent auf 280.691 Dollar. Die gesamten Erlöse erhöhten sich um 273 Prozent auf 6,34 Millionen Dollar. Die Ausgaben für Forschung, Entwicklung und Produktion verringerten sich um 0,6 Prozent auf 1,91 Millionen Dollar, die allgemeinen Aufwendungen erhöhten sich allerdings um 16,2 Prozent auf 1,71 Millionen Dollar. Das operative Ergebnis verbesserte sich von minus 2,2 Millionen auf plus 39.514 Dollar. Der Vorsteuerverlust verringerte sich um 93,8 Prozent auf 154.928 Dollar. Der Nettoverlust verringerte sich um 90,5 Prozent auf 239.928 Dollar beziehungsweise Null Cent je Aktie.


ANZEIGE

Vorstandsvorsitzender Dr. Warren Levy sagte: “Die deutliche Verbesserung unserer Finanzkraft ermutigt uns, zusätzliche klinische Studien für einige unserer Peptide zu beginnen. Zudem beabsichtigen wir vorklinische und klinische Studien für unser Programm für den Knochenwachstum anzufangen.“

ES GIBT NOCH ZWEI WEITERE ARTIKEL

[Dorfmeister]

ugne wurde am 28.11 ins biotech report depot reingenommen

http://www.depotliga.de/xist4c/web/realdepot-biotech-report_…

[Dorfmeister]

Habt ihr gesehen im "der Aktionär"

Seite 14 / Ausgabe #51/07

!!!

[Dorfmeister]

Für alle die sich ein wenig mit der Thematik befasst haben .. dies sind die absoluten hammer News!

Aussage 1

Alle Medikamente wirken gleich gut

Aussage 2 (eher impliziter Natur)

Alle Medikamente ausser Calcitonin haben schwerwiegende Nebenwirkungen: Fosamax, Boniva, Actonel:
- Jaw Death http://www.usatoday.com/news/health/2005-03-13-jawbone-death…
- Heart Rythm Problems http://www.msnbc.msn.com/id/18443859/
Evista / SERM
- "But estrogen and raloxifene can have serious side effects such as strokes, blood clots in the lungs or bleeding in the uterus." (sogar in diesem Artikel direkt erwähnt)

So nun liebe Leute .. zählt mal schön 1 plus 1 zusammen!

WASHINGTON, Dec 17 (Reuters) - There is no evidence to show that any one group of osteoporosis drugs works better than other drugs designed to fight the bone-thinning disease, U.S. government researchers reported on Monday.

But some choices can cause severe side-effects such as blood clots, the Agency for Healthcare Research and Quality, which paid for the study, reported.

The team at the Rand Corporation in California compared six drugs in the class known as bisphosphonates -- Merck & Co Inc's (MRK.N: Quote, Profile, Research) Fosamax, known generically as alendronate; Novartis AG's (NOVN.VX: Quote, Profile, Research) Zometa or zoledronic acid and its pamidronate or Aredia; Procter & Gamble's (PG.N: Quote, Profile, Research) etidronate, sold under the brand name Didronel, as well as P&G's Actonel or risedronate; and GlaxoSmithKline PLC's (GSK.L: Quote, Profile, Research) Boniva or ibandronate.

The report also looked at estrogen, a lab-engineered hormone called calcitonin, calcium, vitamin D, testosterone, parathyroid hormone and drugs in the selective estrogen receptor modulators or SERM class such as raloxifene.

Writing in the Annals of Internal Medicine, the researchers said they could not find enough evidence to show whether bisphosphonates prevent fractures better than estrogen, calcitonin or raloxifene.

But estrogen and raloxifene can have serious side effects such as strokes, blood clots in the lungs or bleeding in the uterus.

The report also found that many osteoporosis patients stop taking their drugs, some because of side-effects and others because they do not notice any osteoporosis symptoms. These patients have a higher risk of bone fractures, they noted.

Not enough evidence exists to determine how exercise or taking testosterone compares to medications in preventing osteoporosis-related fractures, the researchers said.



http://www.reuters.com/article/health-SP/idUSN17398701200712…

[pepe05]

na,läuft ja wieder prima

[Dorfmeister]

Antwort auf Beitrag Nr.: 32.882.284 von pepe05 am 27.12.07 20:22:05

easy ... nur noch wenige tag und dann sieht das bild schon wieder ganz anders aus ..

und diese korrektur wird in ein paar monaten gar nicht mehr zu sehen sein ?!?

[pepe05]

Antwort auf Beitrag Nr.: 32.885.534 von Dorfmeister am 28.12.07 10:17:21

[pepe05]

Unigene and Shijiazhuang Pharmaceutical Group to Expand Chinese Joint Venture

Unigene Laboratories, Inc. (OTCBB: UGNE) announced plans to broaden the activities of its joint venture with the Shijiazhuang Pharmaceutical Group Co., Ltd (“SPG”) and to expand the potential product line to be developed and marketed by the joint venture.

Unigene and SPG plan to establish the SPG-Unigene Biotechnology Research Institute in China. The Institute will continue ongoing registration activities for Unigene’s calcitonin products, develop biopharmaceutical manufacturing facilities compliant with U.S. current Good Manufacturing Practice guidelines, and establish and supervise the creation of a new pharmaceutical distribution network for joint venture products in China, all to take advantage of the world’s largest osteoporosis market. Unigene will maintain its 45% ownership position in the joint venture. The combined capital investment commitment for the joint venture will remain at $15 million. Unigene’s initial cash contribution to the joint venture will remain at $900,000, which will be paid by Unigene upon the satisfaction of certain conditions, while the majority, or possibly all, of its remaining contribution will be in the form of technology.

“The creation of the Institute should allow for the addition of potential new revenue-generating products and programs to our joint venture distinct from calcitonin, thereby expanding our commercial opportunities in China,” commented Dr. Warren Levy, President and CEO of Unigene. “The formation of the Institute will allow us to take advantage of the rapidly growing market potential for biotechnology products in China, to apply for government funds to support joint venture programs and to more fully utilize the additional resources available as a result of the acquisition of SPG by a private equity fund led by Legend Holdings and Goldman Sachs, which occurred in August of 2007.”

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.’s management’s current expectations, estimates, beliefs, assumptions, and projections about Unigene’s business and industry. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Unigene Investors:
The Investor Relations Group
Erika Moran / Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (January 8, 2008 - 8:26 AM EST)

News by QuoteMedia
www.quotemedia.com

[pepe05]

[pepe05]

FDA Approves Improvement to Unigene´s Calcitonin Manufacturing Process


Unigene Laboratories, Inc. (OTCBB:UGNE ) reported that the US Food and Drug Administration (FDA) approved a modification for a key enzyme, the first of two proposed improvements for its patented manufacturing process for calcitonin, the active ingredient in Fortical(R), Unigene´s nasal spray product for the treatment of osteoporosis. The FDA is still reviewing a second improvement to the production process that, if approved, is expected to improve batch yields of the product by a factor of three.

"We believe that these improvements to our production process will increase efficiency and productivity at our manufacturing facility," commented Dr. Warren Levy, President and CEO of Unigene. "In addition to reducing our manufacturing costs, these improvements should enable us to more easily increase our capacity if Fortical demand increases. We believe that the comparability in efficacy of many osteoporosis products, as reported last month in a study commissioned by the Department of Health and Human Services, along with the safety concerns reported for several of the leading osteoporosis products, may ultimately create a larger commercial opportunity for calcitonin-based therapies."

The leading osteoporosis products fall within a class of drugs called bisphosphonates. Although they are effective in reducing the incidence of fracture and in preventing bone loss, they have been associated with osteonecrosis, an infrequent but severe condition. The FDA has also announced that it is conducting a safety review of this class of drugs regarding a possible increased risk of atrial fibrillation, an established risk factor for stroke. Most recently, the FDA issued a new warning that bisphosphonates may be associated with severe joint pain.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene´s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene´s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene´s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.´s management´s current expectations, estimates, beliefs, assumptions, and projections about Unigene´s business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene´s cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene´s Securities and Exchange Commission filings.


© Business Wire
© Business Wire

[Dorfmeister]

Antwort auf Beitrag Nr.: 32.885.534 von Dorfmeister am 28.12.07 10:17:21

Quote from another board ...
The market does not care about any good news right now. Mr. Market (reminds me kind of good old Graham, hope at least some of you are familiar with that name) didn't appraise any of the really good things we got from various sources in the last couple of months and weeks, which you all have commented on this board. I'm happy we did not get news like yesterdays Nastech PR.
I understand that a lot of you guys are frustrated that we haven't got an oral partner yet, that we are still waiting for Glaxo, even though Unigene has improved the technology last autumn.
I was kind of involved in Warrens trip to Europe last November and I had the chance to attend a couple of the meetings in Zurich with really good potential investors. After these meetings I am more than convinced that we will be rewarded big time for our patience. Not going into any more details I can at least confirm, that there is quite some interest in the new oral technology and I learned in one of those meetings from a third party that Unigene is doing feasibility studies for one of the companies their invested in with another analog (funny enough one of the Merck Fosamax guys is also involved in this Company). I have to believe Warren, that they are doing a series of such studies with different peptides, and we might get deals even later this year. The delay in announcing an oral partner for Calcitonin in the US has already been perfectly explained by Mogel and I am not going to repeat the reasons. I am confident that we will soon hear about this. I also would expect some new info out of China; I believe that this week some guys from Unigene are again over there only one month after their last visit late in December.
I know it's sometimes very hard to really understand what Warren tries to deliver with his PR's, but just talking about the patents they got in London: I know that at least one big pharma was very much interested in this stuff and I am sure that the potential is just enormous (combinig already approved ingridients and lowering the side effects significantly! Sounds great, doesn't it?). I also believe that only few people got the PR about the biotech platform in China right. We are not only talking about peptides or delivery and manufacturing technologies from Unigene, but of all kinds of biotech products they could possibly license for this nice market (45% of the proceeds going to Unigene) I know we have not seen or heard of any of this yet but it would add nicely to all other things which are in the pipeline.
What we are witnessing right now has much to do with "normal" investor behaviour. When stocks or markets fly high everybody cheers and buys; once things turn sour and markets and stocks really turn cheap people run for the exit. To make big money, these are the times you have to cheer out loud and take the discounts as you do when shopping. Keep your faith.

[Dorfmeister]

The Long Case for Unigene Laboratories

http://seekingalpha.com/article/63234-the-long-case-for-unig…

[pepe05]

[pepe05]

Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin

Unigene Laboratories, Inc. (OTCBB: UGNE) has initiated a Phase I/II clinical study in the U.S. with its proprietary formulation of oral calcitonin for the treatment of osteoporosis. Twenty-four healthy postmenopausal women have been enrolled in the study, which will measure the effect of the drug on a well-established biochemical marker. The dosing is scheduled to be completed by the end of February.

The tablets being tested in the study utilize the same improved solid dosage form of Unigene’s Enteripep® oral delivery technology used in Unigene’s prior oral calcitonin study that was completed last fall. In that study, the new dosage form achieved a biological response in 100% of the study subjects.

“We are very pleased with the performance to date of these improved tablets,” reported Dr. Ronald S. Levy, Executive Vice President of Unigene. “They have performed well in both animal and human studies and have demonstrated all of the properties required for a pharmaceutically-acceptable dosage form, including stability, bioavailability and dosing consistency. We have already shown that they can effectively deliver other peptides in repeated animal testing. The refinements that we have incorporated have clearly enhanced our original formulation technology and at the same time have enabled us to establish an even stronger intellectual property portfolio.”

Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (February 11, 2008 - 8:26 AM EST)

[pepe05]

Unigene Announces Publication of Initial Results of Site-Directed Bone Growth Studies
Tuesday February 12, 8:01 am ET
Research Performed at Yale Demonstrates Ability of Technology to Create and Maintain Natural Bone

FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) reported that the results of animal studies confirming the ability of its novel technology to rapidly form and maintain natural bone growth at targeted locations has been published. The paper, entitled “Replacement of Bone Marrow by Bone in Rat Femurs: The Bone Bioreactor,” summarizes the early-stage collaborative work performed by researchers at Yale University School of Medicine and Unigene, and appears in the most recent edition of the journal Tissue Engineering.

ADVERTISEMENT
The paper evaluated the effect of bone marrow removal from targeted sites followed by different schedules of daily injections of anabolic agents such as parathyroid hormone (PTH). The procedure created new bone tissue that appears structurally and biologically normal and demonstrated improved biomechanical properties. The combination of bone marrow removal and anabolic therapy resulted in new bone formation at a rate and to an extent that could not be achieved with anabolic agents alone. Additional studies that extend the results of this work in different animal models are ongoing. These studies should provide further evidence that the newly formed bone can be preserved over a long period of time, and will be described in future publications.

“This technology could radically change the way patients are currently treated for weakened or fractured hips, vertebrae and acute traumatic long bone fractures,” stated Dr. Agnès Vignery, principal investigator at Yale University and senior author of the publication. “Physicians currently treat such conditions using invasive techniques that require operating room time, utilize artificial materials, and result in imperfect outcomes. The ideal approach would be to create new bone where it is needed and at a faster rate.”

“The goal of this program is to develop a simple, minimally invasive outpatient procedure in conjunction with the administration of one or more drugs that can lead to the growth of new, structurally normal bone in precisely targeted locations,” said Dr. Warren Levy, President and CEO of Unigene. “If we are successful in the human studies that are planned, patients will have an inexpensive alternative to spinal fusion, vertebroplasty, total joint replacement or the insertion of metal or plastic supports that will strengthen specific bones naturally. These are major commercial opportunities and we have been told by leading experts in the medical community that there is a great need for new approaches to treat these conditions.”

Tissue Engineering is an authoritative, peer-reviewed journal that explores the application of engineering to biological tissues, with the goal of developing biological approaches to treat pathological conditions.



Contact:

Unigene Investor Contact:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD
212-825-3210
Media Contact:
Lynn Granito, 212-825-3210

Source: Unigene Laboratories, Inc.

[pepe05]

Unigene to Present at the 20th Annual Roth Capital Partners Growth Stock Conference
Wednesday February 13, 8:01 am ET

FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc.’s (OTCBB: UGNE - News) President and CEO, Dr. Warren Levy, will speak at the ROTH Capital Partners Growth Stock Conference on Thursday, February 21, 2008. Dr. Levy will present information on Unigene’s products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Ritz Carlton, Laguna Niguel, CA, February 18-21, 2008.



Contact:

Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Lynn Granito, 212-825-3210

Source: Unigene Laboratories, Inc.

[Andrija]

Der Kurs entwickelt sich ja katastrophal. Gut, bei Bio geht derzeit nicht viel, aber eine bessere Performance wären bei dem Newsflow doch zu erwarten gewesen?

[geritg1]

Antwort auf Beitrag Nr.: 33.545.304 von Andrija am 04.03.08 15:12:43

unigene befindet sich in einem seit Januar 2006 intakten
Abwärtstrend
und bei der derzeitigen Marktsituation ist ein Ausbruch nach oben (trotz vielleicht guter Fundamentaldaten) in den nächsten Wochen eher nicht zu erwarten (zumindest deutet nichts darauf hin)
sondern wahrscheinlich ein weiteres Nachgeben der Kurse

[pepe05]

Boning up on New Osteoporosis Risk Guidelines

Osteoporosis — a skeletal disease that traditionally affects those age fifty and older — is a major public health problem. New guidelines released by the National Osteoporosis Foundation (NOF) call for bone mineral density (BMD) testing for all men ages seventy and older and for younger men with risk factors for bone loss. BMD testing is also urged for women sixty-five and older, and postmenopausal women that have risk factors for bone loss.

“These guidelines represent the newest advances healthcare professionals can use to identify and treat patients with low bone mass, risk of fracture, or osteoporosis,” says noted expert Dr. Warren Levy, President and CEO of Unigene Laboratories. “As life expectancy rates continue to rise, osteoporosis will only have a greater impact on national health. The NOF guidelines will help physicians to diagnose and treat the disease.”

Osteoporosis occurs when deteriorating tissue reduces bone density in the spine, hip, and other areas. Today, osteoporosis is a major health threat for forty-four million Americans, 80% of whom are women. In the United States, ten million individuals already have the disease while three times as many are believed to have osteopenia, a decrease in bone mineral density that can be a precursor condition to osteoporosis.

Fractures caused by either osteoporosis or low bone density can lead to chronic pain, disability, or worse. Fortunately, if osteoporosis does develop, various treatments are available.

The leading category of osteoporosis drugs is bisphosphonates, non-hormonal drugs that bind to bones to protect against tissue breakdown. However, recent reports have associated bisphosphonates with osteonecrosis (“bone death”) of the jaw, severe bone/joint pain and potentially severe gastrointestinal side effects.

Alternative drug treatments for reduction in fracture risk do exist such as: calcitonin, parathyroid hormone, estrogen, and testosterone. Calcitonin is the active ingredient in Fortical, a nasal treatment developed by Unigene and marketed by Upsher-Smith Laboratories. “Nasal calcitonin products have been shown to help maintain proper bone density,” says Dr. Levy.

While until now, the medical community had no clear guidelines for assessing fracture risk, Dr. Levy believes the new NOF guidelines will help to educate the public and medical community on the prevention and treatment of osteoporosis. “As in most things,” says Dr. Levy, “education is a strong first line of defense.”

For more information, log on to www.unigene.com.

IRG
Lynn Granito, 212-825-3210

Source: Business Wire (March 10, 2008 - 4:36 AM EDT)

News by QuoteMedia
www.quotemedia.com

[hellblau]

TRIAL SUCCESS

Unigene Successfully Completes Phase I/II Clinical Study for Oral Calcitonin
BusinessWire
8:03 AM ET
Unigene Laboratories, Inc. (OTCBB: UGNE) has successfully completed the Phase I/II oral calcitonin clinical study that it initiated last month. This study, which achieved all of its planned objectives, primarily measured the ability of Unigene's proprietary oral delivery technology to significantly reduce the levels of an established biochemical marker that correlates with bone loss. All of the twenty-two subjects who completed the study demonstrated a robust reduction in this marker. In addition, the study demonstrated a dose-dependent increase in calcitonin blood levels.

This is the second successful clinical study that the company has conducted using its improved oral calcitonin formulation. In October of last year, Unigene reported that all of the subje cts in its first study achieved a biological response and that the goals for blood levels and variability were met. Those results will be reported next month at the Eighth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.

"The extremely significant findings of this study should enable us to select the optimal oral calcitonin dose that will be carried forward in the program," commented Dr. Ronald S. Levy, Executive Vice President of Unigene. "This achievement strongly advances our calcitonin development efforts and should facilitate the partnering activities that we are pursuing in parallel. It also confirms the importance of the delivery technology modifications that we have developed and optimized over the past year, which improve performa nce while simplifying the tablet manufacturing process. Finally, these improvements should provide the basis for additional intellectual property that will strengthen our patent portfolio and should improve the performance of our delivery platform for virtually any peptide that would be a suitable candidate."

[pepe05]

[pepe05]

http://www.americanbulls.com/StockPage.asp?CompanyTicker=UGN…

[pepe05]

Unigene Reports Transfer of Beneficial Ownership of Shares by Management

FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) reported that the W & R Levy Family Limited Partnership, owner of 286,123 shares of Unigene common stock, has been dissolved under a statutory termination and the shares have been reacquired by Jay Levy, Chairman, and his family.



March 12, 2008 05:37 PM Eastern Daylight Time

[hellblau]

ZURICH, Switzerland and FAIRFIELD, New Jersey, March 13 /PRNewswire-FirstCall/ -- "The new Stonegate Report about Unigene confirms that we are uniquely positioned as the only biopharma company that manufactures peptides by recombinant techniques, while also having oral and nasal delivery systems to administer the peptides. Since the launch of "Fortical" in 2005 with partner Upsher-Smith Laboratories, "Fortical" has captured a near dominant 49% market share of the U.S. nasal calcitonin market that is estimated to be in the $200 million range."
Stonegate Securities, Inc. Unigene Laboratories Inc. (WKN 875852, ISIN US9047531002, UUL, OTCBB: UGNE)


Price $1.80
52-Week Range $1.50 - $2.70
Market Capitalization 157,952,000
Enterprise Value 166,734,000
Primary Shares Outstanding 87,751,000
Float 83,190,000
Insider Ownership 5%
Institutional Ownership 15%
Daily Volume (3-Month Avg.) 94,000
Industry Biopharmaceuticals
Website http://www.unigene.com
Corporate Headquarters Fairfield, NJ

[pepe05]

Unigene Restates Policy on Analyst Reports

FAIRFIELD, New Jersey, March 13 /PRNewswire-FirstCall/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it did not issue, authorize or approve the press release titled 'Stonegate Report About Unigene Laboratories Inc.', which was released yesterday. Pursuant to the Company's policies and procedures, Unigene does not endorse, confirm, validate or otherwise comment on reports issued by analysts and unrelated third parties. Any opinions, estimates or forecasts regarding Unigene's performance made by analysts or other third parties are theirs alone and do not represent the opinions, estimates, forecasts or predictions of Unigene or its management.

Contact:

Warren P. Levy
President and CEO
Unigene Laboratories, Inc.
110 Little Falls Road
Fairfield, NJ 07004
Tel.: [phone]
Fax: [phone]
E-Mail: [e-mail]



SOURCE Unigene Laboratories Inc.

Source: PR Newswire (March 13, 2008 - 5:09 PM EDT)

[pepe05]

Unigene Announces Financial Results for Fourth Quarter and Year-End 2007

Record Revenue for 2007 Increases 237% to $20,400,000

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) has reported its financial results for December 31, 2007.

http://www.unigene.com/investor_relations/news_detail.php?re…

[pepe05]

http://www.wallstreet-online.de/nachrichten/nachricht/235176…

[hellblau]

FDA Approves Second Improvement to Unigene's Calcitonin Manufacturing Process



Tuesday April 29, 7:02 AM EDT


FAIRFIELD, N.J., Apr 29, 2008 (BUSINESS WIRE) -- The U.S. Food and Drug Administration (FDA) has approved the use of a new clone for the manufacture of calcitonin, the active ingredient in Fortical(R), Unigene Laboratories, Inc.'s (UGNE, http://www.unigene.com) nasal spray product for the treatment of osteoporosis. This is the second improvement to the production process approved by the FDA this year. The combination of these improvements is expected to increase batch yields of the product by a factor of three.

"We believe that these improvements to our manufacturing process will reduce our future costs and allow us to increase capacity for Fortical," said Dr. Warren Levy, President and CEO of Unigene. "Given the safety concerns reported for certain other osteoporosis products, we believe that the availability of alternative products may become important for osteoporosis sufferers. The global history of calcitonin products has shown that these products are effective with no significant side effects. Also, FDA approval of our improved manufacturing process should provide additional capacity for other peptide products."

[pepe05]

[pepe05]

Unigene to Release First Quarter 2008 Results and Host Conference Call

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for its first quarter ended March 31, 2008, after the market closes on Monday, May 12, 2008. The Company will also host a conference call the next morning, Tuesday, May 13th at 9:00 AM EDT, to discuss its 2008 first quarter financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing 866-585-6398 for participants in the United States and 416-849-9626 for international participants. A replay will be available for seven days after the call and can be accessed by dialing 866-245-6755 for participants in the United States and 416-915-1035 for international participants. When prompted, enter passcode #343608. The conference call may also be accessed via the Web at www.unigene.com; a link will be provided for listeners to join the cal.


The Investor Relations Group
Investors:
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (May 8, 2008 - 8:49 AM EDT)

[pepe05]

http://www.unigene.com/investor_relations/news_detail.php?re…

http://www.unigene.com/investor_relations/news_detail.php?re…

[pepe05]

Unigene CEO Discusses Value of Peptides and Company's Technologies in Two Leading Pharmaceutical Trade Publications

Coverage Features Bylined Articles in Genetic Engineering & Biotechnology News and PFQ Magazine

Warren P. Levy, Ph.D., CEO and President of Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com), a biopharmaceutical company focusing on the manufacturing and oral delivery of large-market peptide drugs, recently contributed a by-lined story in two leading pharmaceutical publications. The article, which highlights the importance of peptides in pharmaceutical research as well as the potential value of the company’s proprietary technologies, appeared in Genetic Engineering & Biotechnology News (GEN), the most widely read biotechnology publication in the world, and Pharmaceutical Formulation & Quality Magazine (PFQ), a health care journal with national circulation .

In the July 2008 article, titled “Focusing on the Task of Reinventing Peptide Drugs; Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides,” Dr. Levy discussed the importance of peptides, and small proteins, which regulate many important metabolic processes through their roles as hormones, neurotransmitters, growth factors, enzymes, and structural components of cells. The articles note how in addition to the discovery, and testing of peptides in the clinic, developers will need to address the problems of achieving adequate scale in the manufacturing process and enabling the oral delivery of peptides.

According to Dr. Levy, Unigene’s proprietary technology can make the oral delivery of peptide drugs a viable commercial opportunity. In the article, he comments on the company’s development of a new enzyme-based assay for the discovery of amidated peptides, which he believes should help identify low-concentration peptide hormones and ultimately enable the discovery of novel, biologically active peptides suitable for pharmaceutical development.

“Unigene’s technologies may enable the introduction of several oral peptide hormone drugs for administration in chronic osteoporosis and diabetes,” says Dr. Levy. “While certain individual development projects are early stage, the trend is positive and the possibilities are plentiful. There has never been a more exciting time to be involved in peptide pharmaceutical development. Oral delivery methods have changed the paradigm for peptide drugs irrevocably—and for the better.”


The Investor Relations Group
Investors:
Erika Moran / Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (July 10, 2008 - 8:39 AM EDT)

News by QuoteMedia

[pepe05]

Unigene to Release Second Quarter Financial Results and Host Conference Call

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for the second quarter ended June 30, 2008, after the market closes on Monday, August 11, 2008. The Company will also host a conference call the next morning, Tuesday, August 12th at 9:00 AM EDT, to discuss its second quarter 2008 financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing 866-585-6398 for participants in the United States and 416-849-9626 for international participants. A replay will be available for seven days after the call and can be accessed by dialing 866-245-6755 for participants in the United States and 416-915-1035 for international participants. When prompted, enter passcode #848765. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.


Unigene Investors:
The Investor Relations Group
Erika Moran / Dian Griesel, PhD
212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (August 6, 2008 - 8:40 AM EDT)

News by QuoteMedia

[pepe05]

Unigene Announces Financial Results For Second Quarter 2008

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) has reported its financial results for the quarter ended June 30, 2008.

Revenue for the three months ended June 30, 2008 was $4,978,000, compared to $4,718,000 for the three months ended June 30, 2007. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $4,110,000 for the three months ended June 30, 2008, and $3,374,000 for the three months ended June 30, 2007. The three months ended June 30, 2007 included $900,000 in revenue from Novartis under a 2007 supply agreement, consisting of $792,000 in product sales and $108,000 in development service fees.

Revenue for the six months ended June 30, 2008 was $9,292,000, compared to $11,046,000 for the six months ended June 30, 2007. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $7,900,000 for the six months ended June 30, 2008, and $7,835,000 for the six months ended June 30, 2007. The six months ended June 30, 2007 included Fortical royalties for the seven-month period of December 2006 through June 2007 and also included $2,500,000 in revenue from Novartis under a 2007 supply agreement, consisting of $2,200,000 in product sales and $300,000 in development service fees.

Total operating expenses were $5,846,000 for the three months ended June 30, 2008, an increase of $88,000 from $5,758,000 for the three months ended June 30, 2007.

Total operating expenses were $11,707,000 for the six months ended June 30, 2008, a decrease of $255,000 from $11,962,000 for the six months ended June 30, 2007.

Net loss for the three months ended June 30, 2008 was $1,201,000, or $.01 per share, compared to a net loss of $1,294,000, or $.01 per share, for the three months ended June 30, 2007.

Net loss for the six months ended June 30, 2008 was $3,055,000, or $.03 per share, compared to a net loss of $1,538,000, or $.02 per share, for the six months ended June 30, 2007.

Cash at June 30, 2008 was $1,737,000, a decrease of approximately $1,941,000 from December 31, 2007. Accounts receivable at June 30, 2008 were $2,448,000.

Following are recent highlights of, and developments during, the second quarter ended June 30, 2008:

* Revenues for the three months ended June 30, 2008 increased 15% compared to revenues for the three month period ended March 31, 2008 due to an increase in Fortical sales and royalties. Fortical royalties for the second quarter increased 30% compared to the first quarter. Quarterly Fortical sales and royalties will continue to fluctuate due to the ordering patterns of Upsher-Smith and their supply contracts with third parties.
* In April 2008, Unigene and its partner expanded the scope of their Chinese joint venture and broke ground for a global biotechnology park. The joint venture, named Unigene Biotechnology Co. Ltd., will initially focus on producing and distributing calcitonin and parathyroid hormone (PTH) products for the Chinese market as well as global peptide manufacturing. The joint venture will also perform research, development, formulation and manufacturing. In May 2008, a subsidiary of our joint venture partner purchased $2 million of Unigene common stock.
* According to IMS, as of June 30, 2008, Fortical prescriptions have captured more than 57% of the U.S. nasal calcitonin market, making Fortical the most frequently prescribed nasal calcitonin product in the U.S.
* Novartis, Unigene’s manufacturing technology licensee, has completed patient recruitment for its multi-center Phase III oral calcitonin osteoporosis study.
* In Unigene’s internal Enteripep® oral calcitonin program, the Company has met with the FDA to discuss the design of the pivotal oral calcitonin Phase III clinical study that Unigene intends to take forward with a corporate partner. FDA discussions to finalize study parameters are continuing.
* Preparations are being finalized for a clinical study utilizing our improved oral formulation of PTH. Under a new amendment to our original licensing agreement, GlaxoSmithKline can acquire rights to the PTH data obtained during the optimization program for a fixed purchase price.

Unigene will host a conference call tomorrow morning, Tuesday, August 12th at 9:00 AM EDT, to discuss its second quarter 2008 financial results and to provide a Company update. The Company invites all those interested in hearing management’s discussion to join the call by dialing 866-585-6398 for participants in the United States and 416-849-9626 for international participants. A replay will be available for seven days after the call and can be accessed by dialing 866-245-6755 for participants in the United States and 416-915-1035 for international participants. When prompted, enter passcode #848765. The conference call may also be accessed via the Web at www.unigene.com; a link will be provided for listeners to join the call.

[pepe05]

Olympian Bone Health for China

An Olympian irony exists for the People’s Republic of China (PRC): as the eyes of the world turn to Beijing this August for the Summer Olympics, China continues to lead the world in poor bone health.

“China has the largest population of osteoporosis patients in the world,” says noted osteoporosis expert Warren Levy, PhD, president, and CEO of Unigene Laboratories (UGNE), a publicly traded biopharmaceutical company based in Boonton, New Jersey. “However, the Chinese are paying more and more attention to improving bone health.”

Indeed, the Chinese market for Western-style pharmaceuticals has reached over $13 billion in recent years, representing one of the fastest growth rates in the world. It has been projected that the PRC will become the world’s leading consumer of pharmaceutical products by the year 2020.

Many U.S. biotechnology companies have formed joint ventures in China to tap into this growing market for healthcare and pharmaceuticals. Unigene recently expanded its joint venture with in the PRC and with the Shijiazhuang Pharmaceutical Group Corporation (SPG) and its subsidiary, China Pharmaceutical Company Group Ltd. (CPGC), a publicly traded company based in Hong Kong. Together, they have recently broken ground on new facilities in Shijiazhuang, Hebei Province that will focus on manufacturing and research and development of biotechnological and other cutting-edge pharmaceutical products for the PRC and other global markets.

The joint venture, named Unigene Biotechnology Co. Ltd., is planning to bring new treatments and technologies to China including calcitonin and parathyroid hormone (PTH) products. The partnership will initially focus on the manufacturing and research and development of salmon calcitonin, a naturally occurring hormone that has helped many osteoporosis sufferers prevent further bone loss. Calcitonin is the active ingredient in Fortical®, a nasal calcitonin treatment developed by Unigene and marketed by Upsher-Smith Laboratories in the U.S. “We believe that this joint venture will help men and women in China struggling with the disease.”

The International Osteoporosis Foundation estimates that one-third of all women over fifty, and one-fifth of men over 70, will experience an osteoporosis-related fracture during their remaining life.

“As its population gets older, the Chinese government is beginning to realize that the longer we live, the more important bone health becomes,” says Dr. Levy. “Fortunately, China is looking to become world class when it comes to bone health.”

For more information please visit the company website at www.unigene.com.

IRG
Lynn Granito, 212-825 3210

Source: Business Wire (August 11, 2008 - 8:45 AM EDT)

[pepe05]

Unigene Reports on Design of Clinical Program for Oral Calcitonin

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that, following its end-of-Phase II meeting and subsequent discussions with the US Food and Drug Administration (FDA), it has reached an understanding relating to the key design parameters of a pivotal Phase III study for an oral calcitonin product formulated using its Enteripep® oral delivery technology. The following elements of the study have been established:

* The product will be evaluated in accordance with Section 505 (b)(2) of the Food, Drug and Cosmetic Act
* The study will involve 400-450 patients
* The study will evaluate the performance of the oral product compared to a marketed nasal calcitonin product and placebo
* The primary endpoint for the study will be the change in spinal bone mineral density over a twelve-month period
* US and European clinical sites will be used to facilitate recruiting and manage program cost
* The Company has entered into agreements with the service providers for the performance of the study

The Company has submitted a Special Protocol Assessment to the FDA to confirm the final study design and the data analysis to be performed and is awaiting their final response.

“We believe that the study design is reasonable and will give us the best chance for success in determining the efficacy of our oral calcitonin product,” commented Dr. Warren Levy, President and CEO. “It is our intention to secure an agreement with a partner prior to initiating the study in order to provide the necessary capital.”

The Company also reiterated that its current plans do not include any discounted equity sales. “Given that we have other alternatives, we do not believe that it is in our shareholders’ best interest to pursue an equity financing at this time,” stated Dr. Levy.


Investor:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210

Source: Business Wire (September 18, 2008 - 8:18 AM EDT)

[fischlie]

Antwort auf Beitrag Nr.: 35.171.002 von pepe05 am 18.09.08 16:49:08

Bitte auch in Deutsch. Danke

[pepe05]

Antwort auf Beitrag Nr.: 35.222.859 von fischlie am 22.09.08 20:35:00

Babelfish Übersetzung

Unigene Berichte über Entwurf des klinischen Programms für MundCalcitonin

BOONTON, NEW JERSEY--(GESCHÄFTS-DRAHT)--Sept. 18, 2008--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) verkündete, dass, nach seiner Ende-vonPhase II das Treffen und die folgenden Diskussionen mit dem US-Behörde zur Überwachung von Nahrungs- und Arzneimitteln (FDA), es ein Verständnis in Bezug auf die Schlüsselentwurfsparameter einer Angelstudie der phase III für ein Mundcalcitoninprodukt erreicht hat, das unter Verwendung seines Enteripep formuliert wird (R) Mundlieferverfahren. Die folgenden Elemente der Studie sind hergestellt worden:

-- Das Produkt wird in Übereinstimmung mit Abschnitt 505 ausgewertet
(b) (2) der Nahrung, der Droge und der kosmetischen Tat

-- Die Studie bezieht 400-450 Patienten mit ein

-- Die Studie wertet die Leistung des Mundproduktes aus
verglichen mit einem vermarkteten nasalen Calcitoninprodukt und -placebo

-- Der Primärendpunkt für die Studie ist die Änderung innen
Mineraldichte des spinalen Knochens über einen Jahrzeitraum

-- US und europäische klinische Aufstellungsorte werden benutzt, um zu erleichtern
einziehend und handhaben Sie Programmkosten

-- Die Firma hat Verträge mit dem Service schlossen
Versorger für die Leistung der Studie

Die Firma hat eine spezielle Protokoll-Einschätzung bei der FDA eingereicht, um den abschließenden durchgeführt zu werden Studienentwurf und die Datenanalyse zu bestätigen, und ihre abschließende Antwort erwartet.

„Wir glauben, dass der Studienentwurf angemessen ist und uns die beste Wahrscheinlichkeit für Erfolg geben wird, wenn man die Wirksamkeit unseres Mundcalcitoninproduktes feststellt,“ kommentiertem Dr. Waren Levy, Präsident und Vorstandsvorsitzende. „Es ist unsere Absicht, eine Vereinbarung mit einem Partner vor der Einführung der Studie zu sichern, um das notwendige Kapital zur Verfügung zu stellen.“

Die Firma reiterierte auch, dass seine gegenwärtigen Pläne keine verbilligten Billigkeitsverkäufe umfassen. „Angenommen, wir andere Alternativen haben, glauben wir nicht, dass sie im besten Interesse unserer Aktionäre, eine Billigkeitsfinanzierung diesmal auszuüben ist,“ angegebenem Dr. Levy.

[pepe05]

[pepe05]

Unigene Enters into Agreement for $20 Million Non-Convertible Debt Financing BOONTON, N.J., Sep 30, 2008 (BUSINESS WIRE) -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today announced that it has entered into a financing agreement for $20 million three-year non-convertible, senior secured term notes and up to 1,500,000 shares of Common Stock. Unigene will draw down $15 million at closing and have an option for an additional $5 million within two years of the closing. An entity managed by Victory Park Capital Advisors, LLC is the sole investor in the transaction. Details of the transaction can be found in the Company's 8-K which will be filed with the SEC.
"We are very pleased to be able to complete this debt financing with an existing stockholder that will provide us with the capital to execute our business plan," commented Dr. Warren P. Levy, President and CEO of Unigene. "Given the challenging current market conditions, we are pleased that Victory Park, who has a comprehensive understanding of our business, continues to support us through this transaction."

SOURCE: Unigene Laboratories, Inc.

Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210

[pepe05]

Unigene Initiates Phase I Clinical Study for Oral PTH

Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) has initiated a Phase I clinical study in the U.S. with its proprietary formulation of oral PTH for the treatment of osteoporosis. Twenty-four healthy postmenopausal women have been enrolled in the study, which is designed to assess product safety and measure PTH blood levels at varying doses. The dosing is scheduled to be completed this month and the data analysis is expected to be completed before year end.

The tablets being tested in the study utilize the improved Enteripep® oral delivery technology. This same solid dosage form was previously used in the Phase I/II oral calcitonin clinical study conducted by Unigene earlier this year. In that study, the improved version of the tablet demonstrated a more consistent biological response and reduced blood level variability when compared with earlier studies that utilized Unigene’s original oral delivery technology.

“We are looking forward to the evaluation of the tablet’s performance with our PTH molecule,” commented Dr. Ronald S. Levy, Executive Vice President of Unigene. “We have previously shown that it improved PTH delivery performance in animal models, so it is appropriate to now move the program into the clinic. We gain valuable information about our delivery technology from each study that we conduct, and we hope to leverage that knowledge into additional enhancements that can further strengthen our broad intellectual property portfolio.”


Unigene:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Lynn Granito, 212-825-3210


Source: Business Wire (October 6, 2008 - 8:33 AM EDT)

[pepe05]

Unigene to Release Third Quarter Financial Results and Host Conference Call

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for the third quarter ended September 30, 2008, after the market closes on Monday, November 10, 2008. The Company will also host a conference call the next morning, Tuesday, November 11th at 9:00 AM EDT, to discuss its third quarter 2008 financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing 877-407-0782 for participants in the United States and 201-689-8567 for international participants. A replay will be available for seven days after the call and can be accessed by dialing 877-660-6853 for participants in the United States and 201-612-7415 for international participants. When prompted, enter account #286 and conference ID #301594. The conference call may also be accessed via the Web at http://www.unigene.com and a link will be provided for listeners to join the call.


Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210

Source: Business Wire (November 5, 2008 - 8:41 AM EST)

[pepe05]

Unigene Laboratories, Inc. Joins Scrip World's Biotechnology Top Fifty

Company Ranked 33rd in Scrip World Pharmaceutical News Yearly Ranking of Top Biotechnology Companies by Sales

Unigene Laboratories, Inc. (OTCBB: UGNE, http:// www.unigene.com), a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs, has been included in the Scrip World Pharmaceutical News “Company League Tables” ranking of the top fifty biotechnology companies in the world ranked by 2007 sales of pharmaceutical products. In the October 31, 2008, edition of the publication, Unigene ranked number thirty-three in the listing, with $12.76 million in sales, representing an increase of over 350% from 2006. Unigene ranked 18th among US-based companies. The executive briefing also singled out Unigene as one of a handful of companies that “reported significantly increased sales for 2007 compared with the previous year.”

“We are delighted to be recognized in this fashion by so authoritative a publication as Scrip World Pharmaceutical News,” said Dr. Warren Levy, President and CEO of Unigene. “Fortical has now captured more than 59% of U.S. nasal calcitonin prescriptions, further solidifying its position as the most frequently prescribed nasal calcitonin product in the U.S. We continue to be optimistic about the future prospects for Fortical, as well as improved formulations of calcitonin.”

About Scrip World Pharmaceutical News

Established in 1976, Scrip World Pharmaceutical News is the leading source of global news in the pharmaceutical industry. Delivering an unrivalled range of pharma market intelligence, Scrip’s network of experienced, locally based journalists provide you with a truly international and independent perspective. Scrip World Pharmaceutical News keeps readers abreast of licensing activity, distribution and trade agreements, the actions of companies and associations, and of the policies and practices of governments and their agencies. From drug manufacturers to CROs, biotech companies to regulators, Scrip subscribers know the value of the unbiased, independent pharmaceutical business intelligence that only Scrip provides. For more information, please visit www.scripnews.com.


Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD
212-825-3210
or
Media:
Janet Vasquez, 212-825-3210


Source: Business Wire (November 14, 2008 - 8:33 AM EST)

News by QuoteMedia

[Andrija]

Antwort auf Beitrag Nr.: 33.155.286 von Dorfmeister am 24.01.08 13:15:36

Hallo Dorfmeister,
kein Interesse mehr an Unigene? Der Kurs ist inzwischen "unterirdisch" und Du hast doch immer so an Sie geglaubt. Nach meiner überschlägigen Durchsicht hat sich fundamental nichts verändert. Wie ist die Meinung aktuell zu Unigene.
Gruß Andrija

[pepe05]

Unigene Announces Preliminary Injunction Entered in Patent Infringement Lawsuit

Apotex Prohibited from Marketing Fortical® Generic Equivalent Prior to Court Ruling

Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) announced today that Judge Robert P. Patterson, Jr. of the United States District Court for the Southern District of New York entered a preliminary injunction, consented to by defendants Apotex, Inc. and Apotex Corp., preliminarily enjoining them from engaging in the commercial manufacture, use, marketing, distribution, selling, transportation or importation of any Fortical® generic equivalent product in the United States. The preliminary injunction will remain in effect until the court renders a final decision on the validity and infringement of Unigene’s U.S. Patent.

In June 2006 Unigene received a Paragraph IV Certification letter from Apotex alleging that Unigene’s U.S. Patent No. 6,440,392 is invalid. On July 24, 2006, Unigene and Upsher-Smith Laboratories jointly filed a lawsuit against Apotex for infringement of that patent.

“We are pleased that this action has been taken,” said Dr. Ronald S. Levy, Executive Vice President of Unigene. “We will continue to vigorously defend the intellectual property that we have worked so hard to develop.”



Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Janet Vazquez, 212-825-3210


Source: Business Wire (December 8, 2008 - 8:51 AM EST)

News by QuoteMedia

[pepe05]

Unigene Laboratories, Inc. Announces Addition of Independent Director to Company Board

Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) today announced that it has appointed Zvi Eiref to join the Company’s Board of Directors as an independent director effective January 5, 2009.

Mr. Eiref brings over 30 years of financial management and operating experience primarily in the consumer packaged goods business. During his 20-year tenure as Chief Financial Officer of Church & Dwight Co., Inc. Mr. Eiref worked with the executive team to help shape overall corporate strategy and transform Church & Dwight from a single product company to a broad-based household, personal care and OTC products company with sales of over $2 billion a year. Earlier in his career, Mr. Eiref worked for Chanel, Unilever and Arthur Andersen in the USA and Europe. He currently also serves on the boards of FGX International Holdings Ltd. and Physicians Formula Holdings, Inc. Mr. Eiref graduated from Oxford University, and is an English Chartered Accountant.

“I am very pleased to welcome Zvi to our Board,” said Dr. Warren Levy, President and CEO. “Zvi brings a vast amount of operational and financial experience to Unigene.”

“I am honored to serve on the Board of Unigene,” said Mr. Eiref. “The Company has developed a wealth of technology applicable to the treatment of two major diseases, osteoporosis and osteoarthritis, both of which are of personal interest to me. I look forward to working closely with the Company’s executive team and other board members on strategies for commercializing this technology and building a truly profitable business.”

Unigene Laboratories, Inc.
Investor:
The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Janet Vazquez, 212-825-3210


Source: Business Wire (January 7, 2009 - 5:24 PM EST)

[Dorfmeister]

Antwort auf Beitrag Nr.: 36.146.785 von Andrija am 04.12.08 13:28:07

Salut

Ja unterirdisch und trotzdem besser als nstk, aig, citi und whatever. Mehr als müssig die ganze Angelegenheit. Aber fundamental hat sich nichts geändert ..

Diverse News sind und bleiben pending.
- sct partner (ich weiss ich weiss .. aber man kann sich nur wiederholen!) Das FDA okey plus Partner sollte doch möglich sein im Q1 zu finalisieren! Diversen Pharma buden läuft sprichwörtlich die Zeit davon und wenn Du die Gelgenheit hast ein Produkt, das in 2 Jahren die Zulassung erhalten soll, zu liznzieren, dann machst Du das. So einfach ist die Welt!

- pth, GSK muss sich eintscheiden und da der Kurs eh schon am Arsch ist, kanns ja nur aufwärts gehen!

- Die elenden Chinesen ... die müssen doch auch was für Ihr Wirtschaftswachstum machen und ich behaupte immernoch, dass da irgendein versteckter Deal vorhanden ist: Ihr baut eine Fabrik hier und wir geben euch die Zulassung .. die Fabrik steht zu 90% und somit kanns hier auch nicht mehr allzulange gehen ... aber eben, wir warten schon ewigkeiten ... aber und das ist das gute! Bis jetzt ist alles eingetroffen wie angekündigt jedoch einfach mit x Monaten Verspätung! Und da die X Monate langsam durch sind, man für 5000 Dollar nun schon 10000 Stück kriegt, ist es wahrscheinlich langsam an der Zeit den Einstandskurs runterzubringen und kaufen ...

[pepe05]

Unigene Reports Positive Results on a Novel Peptide for Reducing Food Consumption

Animal Studies Show Significant Decreases in Food Intake and Body Weight

Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) will present data this week regarding a novel peptide that has been shown to reduce food consumption in animals. The poster, entitled “Reduction in Food Consumption and Weight in Dogs by Oral Delivery of a Novel Anorexigenic Peptide,” will be presented at the Keystone Symposium Conference on “Obesity: Novel Aspects of the Regulation of Body Weight” in Alberta, Canada.

The peptide, currently designated UGL269, is an analog of a natural peptide hormone, and was designed by Unigene scientists. It was tested against two other peptides in a placebo-controlled crossover study and demonstrated significant reductions in food intake and body weight when orally administered to dogs. The ability of UGL269 to reduce food intake was superior to that of other peptides reported to decrease food intake, including an analog of peptide PYY.

In the studies, oral administration of UGL269 resulted in a decrease in food intake by up to 50% and a significant decrease in body weight. Oral administration of an analog of peptide PYY resulted in a smaller reduction in food intake and minimal change in weight. Cessation of treatment with UGL269 resulted in a resumption of food intake to pre-dosing levels. Administration of placebo capsules had no effect on food intake.

“Therapies that modify feeding behavior and result in weight loss represent a significant unmet medical need,” commented Dr. Warren Levy, President and CEO of Unigene. “UGL269, which can be manufactured and orally delivered using our patented Secrapep® and Enteripep® technologies respectively, may offer a new, orally administered approach for weight loss through appetite reduction.”



The Investor Relations Group
Erika Moran/Dian Griesel, Ph.D., 212-825-3210
or
Media
Janet Vazquez, 212-825-3210

Source: Business Wire (January 20, 2009 - 8:39 AM EST)

News by QuoteMedia

[pepe05]

Unigene to Release Year-End Results and Host Conference Call

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for the year ended December 31, 2008, after the market closes on Monday, March 16, 2009. The Company will also host a conference call the next morning, Tuesday, March 17th at 9:00 AM EDT, to discuss its 2008 year-end financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing [phone] for participants in the United States and [phone] for international participants. A replay will be available for seven days after the call and can be accessed by dialing [phone] for participants in the United States and [phone] for international participants. When prompted, enter account number 286 and conference ID#314958. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.

For more news and information on Unigene Laboratories please visit www.IRGnews.com/coi/UGNE where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.

Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD, 212-825-3210
OR
Media:
Janet Vasquez, 212-825-3210

Source: Business Wire (March 9, 2009 - 8:44 AM EDT)

News by QuoteMedia

[pepe05]

Unigene to Release First Quarter 2009 Results and Host Conference Call

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for the quarter ended March 31, 2009, after the market closes on Monday, May 11, 2009. The Company will host a conference call the following morning, Tuesday, May 12, 2009, at 9:00 AM EDT, to discuss its 2009 first quarter financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing [phone] for participants in the United States and [phone] for international participants. A replay will be available for seven days after the call and can be accessed by dialing [phone] for participants in the United States and [phone] for international participants. When prompted, enter account number 286 and conference ID#322126. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.

For more news and information on Unigene Laboratories please visit www.IRGnews.com/coi/UGNE where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.


Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210


Source: Business Wire (May 5, 2009 - 9:26 AM EDT)

News by QuoteMedia

[pepe05]

[hellblau]

Antwort auf Beitrag Nr.: 37.109.913 von pepe05 am 06.05.09 16:22:14

das ist real-time


http://www.advfn.com/p.php?pid=staticchart&s=NB^ugne&p=0&t=1…

[pepe05]

Unigene to Release Second Quarter 2009 Results and Host Conference Call

Conference Call Tuesday, August 11th, 9:00 AM EDT

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for the quarter ended June 30, 2009, after the market closes on Monday, August 10, 2009. The Company will host a conference call the following morning, Tuesday, August 11, 2009, at 9:00 AM EDT, to discuss its 2009 second quarter financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing [phone] for participants in the United States and [phone] for international participants. A replay will be available for seven days after the call and can be accessed by dialing [phone] for participants in the United States and [phone] for international participants. When prompted, enter account number 286 and conference ID#329625. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.


Unigene Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210

Source: Business Wire (August 4, 2009 - 8:23 AM EDT)

News by QuoteMedia

[pepe05]

U.S. District Court Confirms Validity of Unigene's Fortical(R) Patent

Sep. 2, 2009 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) has reported that the U.S. District Court, Southern District of New York, has confirmed the validity of Unigene’s patent on Fortical® and issued an order permanently enjoining Apotex Inc. and Apotex Corp. from further infringement of the patent. The motion of the plaintiffs, Unigene and its licensee Upsher-Smith Laboratories, for summary judgment in the case was granted while the request for summary judgment by Apotex was denied.

“This decision is a very significant development for the plaintiffs,” commented Dr. Warren P. Levy, President and CEO of Unigene. “Although this decision may not close all of the legal proceedings, we are encouraged by the court’s decision in our favor.”



Source: Business Wire (September 2, 2009 - 8:01 AM EDT)

News by QuoteMedia

[hellblau]

Antwort auf Beitrag Nr.: 37.917.067 von pepe05 am 04.09.09 09:39:47

Sehr schön!

Wenn sie jetzt endlich mal ihren deal hinbekommen, könnte es aufwärts gehen.

[hellblau]

zur info:


http://finance.yahoo.com/news/Unigene-Licenses-Phase-III-bw-…

[pepe05]

Unigene to Release Third Quarter 2009 Results and Host Conference Call
Conference Call Tuesday, November 10th,9:00AM ET

Nov. 4, 2009 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release financial results for the quarter ended September 30, 2009, after the market closes on Monday, November 9, 2009. The Company will host a conference call the following morning, Tuesday, November 10, 2009, at 9:00 AM ET, to discuss its 2009 third quarter financial results and to provide a Company update.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing [phone] for participants in the United States and [phone] for international participants. A replay will be available for seven days after the call and can be accessed by dialing [phone] for participants in the United States and [phone] for international participants. When prompted, enter account number 286 and conference ID#336844. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.



Source: Business Wire (November 4, 2009 - 7:31 AM EST)

News by QuoteMedia

[pepe05]

Unigene Files Shelf Registration Statement

Dec. 23, 2009 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”). Under the shelf registration statement, when declared effective by the SEC, Unigene may offer and sell, from time to time in the future in one or more public offerings, up to $30 million of equity or debt securities or any combination thereof. The Company does not have any immediate plans or current commitments to sell securities. The specific terms of any future offering, including the prices, and use of proceeds will be determined at the time of any such offering and will be described in detail in a prospectus supplement which will be filed with the SEC at the time of the offering.

“The shelf registration gives Unigene the flexibility to access additional capital at some point in the future when market conditions are appropriate,” commented Dr. Warren Levy, President and CEO of Unigene Laboratories, Inc.

Unigene’s shelf registration statement has been filed with the SEC but has not yet become effective. The securities registered may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state of jurisdiction. Any offering of the securities covered by the registration statement will only be by means of a prospectus and an accompanying prospectus supplement.

Source: Business Wire (December 23, 2009 - 5:06 PM EST)

News by QuoteMedia

[pepe05]

Unigene to Release Fiscal 2009 Results and Host Conference Call
BOONTON, N.J., Mar 10, 2010 (BUSINESS WIRE) --

UnigeneLaboratories, Inc. (OTCBB:UGNE) (http://www.unigene.com) will release financial results for the full year ended December 31, 2009, after the market closes on Tuesday, March 16, 2010. The Company will host a conference call the following morning, Wednesday, March 17, 2010, at 9:00 AM EDT, to discuss its 2009 financial results and to provide a Company update.

Unigene invites all those interested in hearing management's discussion to join the call by dialing [phone] for participants in the United States and [phone] for international participants. A replay will be available for seven days after the call and can be accessed by dialing [phone] for participants in the United States and [phone] for international participants. When prompted, enter account number 286 and conference ID#346611. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.


SOURCE: Unigene Laboratories, Inc.

Unigene Investor Contact:
The Investor Relations Group
Erika Moran / Dian Griesel, PhD, 212-825-3210
or
Media Contact:
Janet Vasquez, 212-825-3210


Other News
July, 2004 - BioPharm International - Oral Delivery and Recombinant Production of Peptide Hormones

[pepe05]

Unigene to Release First Quarter 2010 Results and Host Conference Call
April 28, 2010 4:20 PM ET


UnigeneLaboratories, Inc. UGNE(http://www.unigene.com) will release financial results for the quarter ended March 31, 2010, after the market closes on Monday, May 10, 2010. The Company will host a conference call the following morning, Tuesday, May 11, 2010, at 9:00 AM EDT, to discuss its 2010 first quarter financial results and to provide a Company update from our Chairman Richard Levy.

Unigene invites all those interested in hearing management’s discussion to join the call by dialing 877-407-8035 for participants in the United States and 201-689-8035 for international participants. A replay will be available for seven days after the call and can be accessed by dialing 877-660-6853 for participants in the United States and 201-612-7415 for international participants. When prompted, enter account number 286 and conference ID#350056. The conference call may also be accessed via the Web at http://www.unigene.com; a link will be provided for listeners to join the call.

The Investor Relations Group
Investors:
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210

Copyright 2010 Business Wire

[pepe05]

Unigene Appoints New CEO, Ashleigh Palmer

Jun. 9, 2010 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced today the appointment of Ashleigh Palmer as President and Chief Executive Officer of the Company, replacing Dr. Warren Levy. Mr. Palmer also has been named a member of Unigene’s Board of Directors. He brings to Unigene extensive healthcare operational experience, as well as a successful track record in building out R&D and commercial capabilities. Mr. Palmer’s appointment is effective immediately.

“We are delighted to welcome Ashleigh to the Unigene team. His areas of expertise and understanding of Big Pharma, as well as his appreciation for our oral delivery platform and peptide manufacturing capabilities, will help ensure Unigene maximizes its core assets and existing partnerships,” commented Richard Levy, Chairman of Unigene’s Board and Managing Principal at Victory Park Capital. “We soon will complement Ashleigh’s leadership with the addition of a seasoned business development professional, further expanding the talented team at Unigene.”

Mr. Palmer commented, “I am thrilled to be joining Unigene, which has a well-established presence in the growing peptide therapeutics space. Compelling assets include a commercialized product, Fortical, as well as a broad product R&D pipeline and advanced clinical-stage partnerships. Importantly, Unigene has demonstrated it is the partner of choice for GMP recombinant peptide manufacturing, a distinctive competence that, when combined with its validated delivery platform, enables the Company to offer a competitive profile that is truly unique in this sector.”

Prior to joining Unigene, Mr. Palmer served as CEO of Critical Biologics Corporation, a critical care company where he remains a Director, and headed the strategic advisory firm, Creative BioVentures™ Corporation. Previously, Mr. Palmer was Vice President of Business Development at Ohmeda, Inc. During his tenure, Mr. Palmer played a key role in the $1.2 billion sale of Ohmeda to a consortium including Baxter and Becton, Dickinson by spinning out Ohmeda’s nitric oxide assets to found INO Therapeutics, Inc. Under his leadership as President and CEO, INO commercialized the world’s first selective pulmonary vasodilator, INOmax®, establishing a greater than $100 million revenue stream within the first 24 months of launch. Subsequently, INO was sold to critical care company Ikaria in 2007 for $670 million.

Earlier in his career, Mr. Palmer held positions of increasing responsibility at Seton Healthcare Group and, prior to this, Reckitt and Colman PLC. He received his MBA degree from the University of Bradford, England, and his BSc degree from the University of Manchester, England.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline, worldwide rights for its calcitonin manufacturing technology to Novartis and sold worldwide rights (except for China) for its oral calcitonin program to Tarsa Therapeutics, Inc.

Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin and PTH analogs. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.


Source: Business Wire (June 9, 2010 - 7:30 AM EDT)

News by QuoteMedia

[pepe05]

July 23, 2010, 9:05 a.m. EDT · Recommend · Post:
Unigene Notes Progress of Tarsa's Phase III ORACAL Trial of its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis

BOONTON, N.J., Jul 23, 2010 (BUSINESS WIRE) -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.

The ORACAL study is a multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. Tarsa also announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories.

Further, in addition to its license agreement with Tarsa, Unigene licensed to Novartis worldwide rights to its SecraPep(R) E. coli peptide manufacturing technology, and licensed to GlaxoSmithKline worldwide rights to its patented EnteriPep(R) oral delivery technology for parathyroid hormone.

Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin and PTH analogs. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call [phone] or visit www.unigene.com. For information about Fortical, visit www.fortical.com.



SOURCE: Unigene Laboratories, Inc.

Unigene Laboratories, Inc.
William Steinhauer, 973-265-1100
VP of Finance
or
GendeLLindheim BioCom Partners
Tarsa Therapeutics
Barbara Lindheim, 212-918-4650
or
Burns McClellan
Justin Jackson (media)
212-213-0006
[e-mail]
or
Michelle Szwarcberg (media)
212-213-0006
[e-mail]




Copyright Business Wire 2010

[pepe05]

Unigene CEO Presents New Strategy and Corporate Realignment at Rodman & Renshaw 12th Annual Healthcare Conference

Sep. 14, 2010 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced a strategic realignment and the creation of two new highly focused Strategic Business Units – “Unigene Biotechnologies” and “Unigene Therapeutics”. Unigene Biotechnologies will focus on opportunities where the Company can apply its industry-leading Peptelligence™ platform of peptide drug delivery and manufacturing assets, expertise and capabilities to partners’ proprietary development programs. Unigene Therapeutics constitutes Unigene’s own pipeline of novel, proprietary peptide development programs focused on metabolic disease and inflammation.

According to President and Chief Executive Officer, Ashleigh Palmer, Unigene is pursuing this new strategy and restructuring into two separate business units in order to increase the visibility of its Peptelligence™ technologies and capabilities; focus the Company’s business development initiatives, and enhance its lead position in the peptide market, as well as accelerate the progress of lead compounds and advance earlier-stage candidates.

“Peptides are a rapidly growing therapeutic class with more than 130 programs currently in active development throughout the industry. To date, more than fifty peptide-based therapeutics have reached the market,” said Mr. Palmer. “It is critical Unigene be at the forefront of creating tailored solutions for current and future partners. Our goal is to see our Peptelligence™ platform, which represents a distinctive set of capabilities and assets, incorporated into as many peptide programs as possible that are advancing through development towards commercialization.”

Unigene’s Peptelligence™ encompasses extensive intellectual property covering superior drug delivery and manufacturing technologies, unsurpassed peptide research and development expertise, and proprietary know-how representing a genuine distinctive competence and dominant competitive advantage. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible recombinant manufacturing technologies.

“Unigene has a strong base from which we intend to launch our expanded business-to-business marketing initiatives,” Mr. Palmer continued. “Based on an extensive situational analysis and competitive benchmarking we have aligned our strengths with the substantial opportunities available to us. These include focusing our high-risk, high-return Unigene Therapeutics pipeline on metabolic and inflammatory diseases with significant unmet medical and socioeconomic needs. Further, it is our intention that programs which don’t fit our core focus, including our Chinese joint venture and site-directed bone growth program, will be monetized, out-licensed or terminated. We know our greatest strengths are in customizing delivery and manufacturing solutions for novel therapeutic peptides, and we will focus the Unigene Biotechnologies business unit on doing just that, generating near-term fee-for-service revenues and longer-term milestone payments and royalties.”

Unigene’s technologies have earned extensive clinical and partner validation. The Company’s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of osteoporosis. Other validating partnerships include oral parathyroid hormone (PTH), licensed to GlaxoSmithKline and entering Phase 2 planning and development. In addition, Unigene has a manufacturing license agreement with Novartis, which is currently completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

Mr. Palmer concluded, “In the next months, our investors and current or potential partners will see a continuity of strong business development and business-to-business marketing communications initiatives. We anticipate filling key management positions, including a VP of Business Development, as well as adding other members to the leadership team and board of directors. As the recently appointed CEO of Unigene, I view my mission as nothing less than to transform Unigene into a peptide powerhouse, providing a sense of excitement, focused direction and enduring momentum among our key audiences. Welcome to the New Unigene!”

Unigene is presenting today its new strategy and organizational realignment at the Rodman & Renshaw 12th Annual Healthcare Conference in New York, NY. To access the audio broadcast of the presentation, log onto http://www.wsw.com/webcast/rrshq18/ugne.


Unigene Laboratories, Inc.

William Steinhauer, 973-265-1100

VP of Finance

or

Burns McClellan

Justin Jackson (media)

212-213-0006

[e-mail]

or

Michelle Szwarcberg (media)

212-213-0006

[e-mail]

[pepe05]

Unigene to Advance Phase 2 Development of Oral PTH Program by Entering into an Amended and Restated Exclusive Worldwide License Agreement with GSK
Phase 2 study for treatment of osteoporosis in postmenopausal women
expected to commence in Q1 2011; Unigene to receive $4M upfront for
development costs and $4M upon completion of Phase 2 patient enrollment

Dec. 13, 2010 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that the Company entered into an amended and restated exclusive worldwide license agreement with GlaxoSmithKline (GSK) to develop and commercialize an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women and plans to initiate a Phase 2 study in the first quarter of 2011.

Under the terms of the amended and restated agreement, Unigene will conduct the Phase 2 study and will be eligible to receive the remaining milestone payments of up to $142M including an upfront payment of $4M, an additional $4M payment upon completion of Phase 2 patient enrollment and further payments based on the achievement of regulatory and commercialization milestones. In addition, Unigene is eligible to receive tiered low double-digit royalties on global sales. Once the Phase 2 study has been completed and based on a review of the data, GSK may elect to assume responsibility for all future development and commercialization of the product.

In April 2002, GSK and Unigene signed the original exclusive worldwide license agreement to develop and commercialize the oral PTH program for osteoporosis with potential payments totaling approximately $150M upon the successful achievement of development and commercialization milestones. Prior to the revised agreement, an aggregate of $8M in up-front and milestone payments were made to Unigene. In addition, Unigene was entitled to reimbursement for development expenses, as well as tiered low double-digit royalties on global sales.

Ashleigh Palmer, Chief Executive Officer of Unigene Laboratories, Inc., said, “Over the past several months we have been focused on multiple strategic imperatives, including working closely with GSK on prioritizing the advancement of our oral PTH Phase 2 program for osteoporosis.” Palmer continued, “The completion of our amended agreement with GSK provides a clear path forward for the PTH program and is a significant milestone for Unigene. This is a strong validation of our new management team’s commitment to our strategy and our ability to deliver results. Importantly, we now have the financial resources needed to continue to advance our oral PTH program. We are thrilled to be continuing our collaboration with GSK to advance our oral PTH program while leveraging their impressive global clinical, regulatory and commercial expertise.”

About the Oral PTH Phase 2 Study

Unigene plans to initiate the Phase 2 oral PTH study in the first quarter of 2011. This multicenter, double blind, randomized, repeat dose placebo controlled study will include an open label comparator arm and will evaluate approximately 90 postmenopausal osteoporotic women for a period of 24 weeks. The primary endpoint will be an increase in bone mineral density in subjects at 24 weeks compared to baseline. Patient enrollment for this study is expected to be completed in the first half of 2011.

About Osteoporosis

Osteoporosis is a disease in which bones become brittle and so are more likely to break. In osteoporotic women and men, the density and quality of bone are reduced, leading to deterioration of the skeleton and increased risk of fracture. It's often diagnosed only after an osteoporosis-related fracture happens because prior to such an event, the patient has no outward signs or symptoms. The disease has a significant impact on patients' quality of life and it is estimated that one in three women and one in five men over the age of 50 will develop osteoporosis during their lifetimes.

The prevalence of osteoporosis is growing as the number of post-menopausal women rises, along with the general increase in life expectancy. Osteoporosis affects an estimated 75 million people in Europe, the US and Japan. In women over 45, osteoporosis accounts for more days spent in hospital than many other diseases, including diabetes, heart attack and breast cancer. There is currently no cure for osteoporosis, but available treatments can strengthen bones and help reduce the risk of fractures.

Source: International Osteoporosis Foundation


Unigene Laboratories, Inc.

Jenene Thomas, 973-265-1107

VP, Investor Relations and Corporate Communications

[e-mail]



Source: Business Wire (December 13, 2010 - 8:00 AM EST)

News by QuoteMedia

[pepe05]

Unigene Provides 2011 Business Outlook

-Company committed to executing on its new strategic plan and expects
2011 to be a transformational year-

Jan. 10, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2011, highlighting multiple opportunities within its highly focused business units, Unigene Biotechnologies and Unigene Therapeutics, and reiterated its commitment to executing upon its strategic intent:

* Increase cash runway in the near-term by prudent cash conservancy and incremental revenue generation;
* As resources permit, retire debt and selectively invest in advancement of existing core development programs and technologies; and
* Maximize shareholder value by exploiting the full potential of the Company’s Peptelligence™ platform.

Ashleigh Palmer, CEO, Unigene Laboratories, Inc., stated “2010 was a year of transition for Unigene. We have entered 2011 with a compelling new strategy that will enable multiple shots on goal, and we now have a world class management team prepared to deliver results.” Palmer continued, “We believe 2011 will be a transformational year for the new Unigene. Our mission remains nothing less than for Unigene to be recognized as a peptide powerhouse and the partner of choice for the co-development of therapeutic peptides. We are poised to realize multiple near-term initiatives to extend our cash runway, establish a viable portfolio of longer-term opportunities and strengthen our strategic and financial position to ensure corporate success.”

Unigene Biotechnologies Outlook

The Company is expanding and exploiting its industry-leading Peptelligence(TM) platform of peptide oral drug delivery and manufacturing assets, expertise and capabilities to establish a robust high-value portfolio of partnered opportunities. A solid execution of the Company’s planned awareness campaign and focused business development activity should generate near-term revenue from feasibility studies and service fees and establish a solid foundation for potential high-value milestone payments and royalties to ensure long-term success and maximize shareholder value.

Unigene has already received strong validation of its recombinant manufacturing technology by way of the Company’s out-licensing of a process to manufacture the active pharmaceutical ingredient in Novartis’ development-stage oral calcitonin product currently in Phase 3 clinical trials for osteoarthritis and osteoporosis.

Palmer, commented, “I am convinced that Unigene has the potential to be at the forefront of creating tailored solutions for current and future partners. Our goal is to become a “technology venture capitalist.” We will invest our Peptelligence platform, which represents a distinctive set of capabilities, know-how and proprietary technologies, into as many therapeutic peptide programs as possible and help our partners co-develop those peptides through advanced clinical testing and commercialization.”

Unigene Therapeutics Outlook

Unigene will continue to advance its own pipeline of novel, proprietary peptide development programs focused on metabolic disease and inflammation. The Company also expects to report several important milestones with its late-stage development programs throughout 2011.

As previously reported, in 2009, Unigene licensed its late-stage oral calcitonin formulation to Tarsa Therapeutics, a venture financed company founded exclusively to conduct Phase 3 clinical testing and prepare Unigene’s proprietary oral calcitonin formulation for commercialization. Unigene owns a 25% stake in Tarsa. During the third quarter of 2010, Tarsa announced it had completed patient enrollment for its multinational, randomized, double-blind, placebo-controlled Phase 3 ORACAL trial in postmenopausal women with osteoporosis and that an independent Data Monitoring Committee had conducted two separate safety reviews of patient data and recommended the trial proceed as planned.

The Company along with Tarsa expects to announce the completion of the Phase 3 study top-line results in the second quarter of 2011 and registration filings with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in the second half of 2011.

In December 2010, the Company entered into an amended and restated exclusive worldwide license agreement with GSK to develop and commercialize an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

Under the terms of the amended and restated agreement, Unigene will conduct the Phase 2 study and will be eligible to receive the remaining milestone payments of up to $142M including an upfront payment of $4M, an additional $4M milestone payment upon completion of Phase 2 patient enrollment and further payments based upon the achievement of regulatory and commercialization milestones. In addition, Unigene is eligible to receive tiered low double-digit royalties on global sales. Once the Phase 2 study has been completed, and based on a review of the data, GSK may elect to assume responsibility for all future development and commercialization of the product.

The GSK agreement provides a clear path forward for the PTH program. Unigene is on track to initiate the Phase 2 oral PTH study and commence patient enrollment in the first quarter of 2011. This multicenter, double blind, randomized, repeat dose placebo controlled study will include an open label comparator arm and will evaluate approximately 90 postmenopausal osteoporotic women for a period of 24 weeks. The primary endpoint will be an increase in bone mineral density in subjects at 24 weeks compared to baseline. Patient enrollment for this study is expected to be completed in the first half of 2011 with top-line results expected by year end.

Unigene's satiety program remains a priority and continues in advanced pre-clinical development. The Company is exploring multiple partnering opportunities for its satiety analogs both for companion animal obesity and human clinical development along with its preclinical anti-inflammatory peptides.

Palmer continued, “Unigene's platform technologies have earned, and are now beginning to enjoy the benefits and rewards of, extensive clinical and partner validation. The Company’s Peptelligence platform encapsulates medically important and commercially relevant competitive advantages including our superior oral drug delivery technology, our commercial scale recombinant peptide manufacturing technology, our FDA approved API production facility, our proprietary formulation know-how, and our clinical development and regulatory expertise and proven track record. We anticipate meaningful news flow relating to our established partners’ late-stage programs during the course of 2011, which should not only further validate our Peptelligence platform but contribute potential additional milestone payments to the bottom line. With our 2011 goals accomplished, we should be in a position to begin retiring debt and strengthen our financial position.” Palmer concluded, “Today, we reiterate our commitment to our strategy and believe we are well positioned to deliver results over the course of the year to ensure that 2011 is truly transformational for Unigene.”


Unigene Laboratories, Inc.

Jenene Thomas, 973-265-1107

VP, Investor Relations and Corporate Communications

[e-mail]


Source: Business Wire (January 10, 2011 - 8:03 AM EST)

News by QuoteMedia

[pepe05]

February 7, 2011 - 8:00 AM EST

Unigene to Present at the 13th Annual BIO CEO and Investor Conference on February 14, 2011


Feb. 7, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that Ashleigh Palmer, President and CEO will be presenting a corporate overview at the 13th Annual BIO CEO & Investor Conference. Mr. Palmer’s presentation is scheduled to begin at 9:30 a.m. Eastern time on Monday, February 14, 2011.

Individuals can listen to a live webcast of the presentation by logging on to the Investors and Media section of the Unigene web site, http://www.unigene.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.


For more information about Unigene, please visit http://www.unigene.com. For information about Fortical, please visit http://www.fortical.com.

Unigene Laboratories, Inc.

Jenene Thomas, 973-265-1107

VP, Investor Relations and Corporate Communications

[e-mail]



Source: Business Wire (February 7, 2011 - 8:00 AM EST)

News by QuoteMedia

[geritg1]

Antwort auf Beitrag Nr.: 40.833.510 von pepe05 am 10.01.11 16:37:45

Ich hoffe nach einem "Jahr des Übergangs" kommt endlich auch mal irgendwann ein Jahr mit ordentlichen Gewinnen und Kurssteigerungen.

[pepe05]

Unigene to Present at the 9th Annual BioPartnering North America(TM) Conference on March 1, 2011

Feb. 23, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that Alex Martin, Vice President, Business Development and Head of Commercial Operations and Greg Mayes, Vice President, Corporate Development and General Counsel will be presenting at the 9th Annual BioPartnering North America™ Conference at 1:30 p.m. Eastern time on Tuesday, March 1, 2011. The conference is being held at the Vancouver Convention Centre, Vancouver, BC, Canada.

Annually attracting 800+ decision-makers and industry leaders in the life sciences from over 30 countries, the BioPartnering North America Conference offers access to a global network of potential partners and provides the opportunity to introduce Unigene and showcase the Company’s distinctive core competence and proprietary technology platforms.

Alex Martin commented, “Regular attendance at prestigious partnering meetings and conferences complements our robust and targeted business development initiatives and further establishes Unigene as the peptide development partner of choice.”

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Unigene’s technologies have extensive clinical and partner validation. The Company’s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, with Phase 3 testing for the treatment of osteoporosis completed and results expected in the second quarter of 2011. Other validating relationships include an oral parathyroid hormone entering Phase 2 in the first quarter of 2011 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

For more information about Unigene, please visit http://www.unigene.com. For information about Fortical, please visit http://www.fortical.com.

Unigene Laboratories, Inc.

Jenene Thomas, 973-265-1107

VP, Investor Relations and Corporate Communications

[e-mail]



Source: Business Wire (February 23, 2011 - 8:00 AM EST)

News by QuoteMedia

[pepe05]

Unigene to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011

Mar. 3, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that management will host a conference call and live audio webcast on Thursday, March 10, 2011 at 5 p.m. EST to discuss fourth quarter and full year 2010 financial results.

Interested participants and investors may access the conference call at 5 p.m. EST by dialing 800-659-1966 (U.S./Canada) or 617-614-2711 (international); participant code 42647062. An audio webcast can be accessed by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com.

A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 30308774. The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Unigene’s technologies have extensive clinical and partner validation. The Company’s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, with Phase 3 testing for the treatment of osteoporosis completed and results expected in the second quarter of 2011. Other validating relationships include an oral parathyroid hormone entering Phase 2 in the first quarter of 2011 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

For more information about Unigene, please visit http://www.unigene.com. For information about Fortical, please visit http://www.fortical.com.

Unigene Laboratories, Inc.

Jenene Thomas

VP, Investor Relations and Corporate Communications

Direct: 973-265-1107

[e-mail]



Source: Business Wire (March 3, 2011 - 8:00 AM EST)

News by QuoteMedia

[Fruehrentner]

gute news:


Unigene’s Oral Peptide Drug Delivery Technology Validated with Positive Top-Line Phase 3 Results from Tarsa’s ORACAL Trial of Oral Calcitonin

24 Mar 2011

-Primary Endpoint Achieved for Phase 3 Trial for Treatment of Postmenopausal Osteoporosis-
-Results Support Decision to Proceed with Submission of NDA Before Year End-

BOONTON, NJ, USA | March 23, 2011 |

Unigene Laboratories, Inc. (OTCBB:UGNE.ob - News) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology. The ORACAL study achieved its primary endpoint and the results support Tarsa’s plans for a New Drug Application (NDA) submission to the Food and Drug Administration (FDA) targeted before the end of 2011. The study design and endpoints were agreed with the FDA through a formalized Special Protocol Assessment (SPA) process. Tarsa also plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the first half of 2012.

Ashleigh Palmer, Unigene’s President and Chief Executive Officer, commented, “The positive results from the Phase 3 oral calcitonin trial represent the second game-changing event for the New Unigene since launching our turn-around strategy last quarter! The successful outcome of this study not only validates our propriety oral peptide delivery technology and state-of-the-art recombinant manufacturing capabilities, but highlights our overall competence in the peptide sector. Our mission is to become nothing less than the pre-eminent peptide powerhouse.”

The ORACAL study is a Phase 3 multinational, randomized, double-blind, double-dummy placebo-controlled trial of oral recombinant salmon calcitonin compared to commercially available synthetic salmon calcitonin administered by nasal spray. The ORACAL study’s primary endpoint was the percent change in lumbar spine bone mineral density (BMD) after one year of treatment. The results of the study demonstrated that oral salmon calcitonin was significantly superior to placebo and non-inferior to nasal salmon calcitonin spray in increasing BMD at the lumbar spine after one year of treatment. The trial enrolled 565 postmenopausal women with established osteoporosis in six countries. The trial also assessed the tolerability of oral calcitonin, which was similar to that of calcitonin administered by nasal spray and to placebo. Tarsa expects that the full data from the study will be presented in a prestigious, peer-reviewed forum in the second half of 2011.

Dr. Nozer Mehta, Vice President, Biological Research and Development stated, “The positive Phase 3 results confirm our belief that Unigene’s oral drug delivery technology leads the industry. Our internally-developed calcitonin tablet formulation now has the potential to be the first oral calcitonin to reach the market and will provide patients with a once-a-day easy to use osteoporosis therapy.” Dr. Mehta continued, “Furthermore, these results give added confidence for our ongoing development programs and feasibility studies using our propriety oral drug delivery technology.”

Calcitonin is approved for the treatment of postmenopausal osteoporosis, but its use has been limited by the fact that it is currently available only in intranasal and injectable forms. The efficacy of this oral calcitonin tablet formulation in delivering the desired blood levels of calcitonin and reducing levels of biomarkers of bone resorption has been demonstrated by Unigene in prior clinical studies.

About Osteoporosis

Osteoporosis is a disease in which bones become brittle and so are more likely to break. In osteoporotic women and men, the density and quality of bone are reduced, leading to deterioration of the skeleton and increased risk of fracture. It's often diagnosed only after an osteoporosis-related fracture happens because prior to such an event, the patient has no outward signs or symptoms. The disease has a significant impact on patients' quality of life and it is estimated that one in three women and one in five men over the age of 50 will develop osteoporosis during their lifetimes.

The prevalence of osteoporosis is growing as the number of post-menopausal women rises, along with the general increase in life expectancy. Osteoporosis affects an estimated 75 million people in Europe, the US and Japan. In women over 45, osteoporosis accounts for more days spent in hospital than many other diseases, including diabetes, heart attack and breast cancer. There is currently no cure for osteoporosis, but available treatments can strengthen bones and help reduce the risk of fractures.

About Unigene-Tarsa Agreement

In 2009, Unigene licensed its proprietary late-stage oral calcitonin program to Tarsa Therapeutics, a venture-financed company founded to conduct Phase 3 clinical testing and oversee commercialization arrangements for the oral calcitonin product. Tarsa owns exclusive development and worldwide commercialization rights to Unigene’s oral calcitonin product, with the exception of China. Unigene currently owns a 26% stake in Tarsa, subject to the potential for further dilution, and is eligible to receive sales-related milestone payments and royalties on worldwide sales.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Unigene’s technologies have extensive clinical and partner validation. The Company’s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Unigene licensed its oral calcitonin program to Tarsa Therapeutics and expects an NDA filing with the FDA before year end. The Company has a worldwide licensing agreement with GlaxoSmithKline for its parathyroid hormone product candidate currently in Phase 2. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

SOURCE: Unigene Laboratories, Inc.

[pepe05]

Unigene Completes Patient Enrollment of Oral PTH Phase 2 Study for the Treatment of Osteoporosis in Postmenopausal Women
- Completion of enrollment triggers $4M milestone payment from GSK-
-Phase 2 Top-line results expected before year end-

Apr. 27, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women. Unigene is developing its oral PTH in collaboration with GlaxoSmithKline (GSK) as part of an exclusive worldwide licensing agreement. According to the agreement with GSK, Unigene will receive a $4M milestone payment for completion of Phase 2 patient enrollment.

Ashleigh Palmer, President and Chief Executive Officer of Unigene Laboratories, Inc., said, “The completion of enrollment in this Phase 2 study with our proprietary oral formulation of the recombinantly produced PTH analog is a significant development milestone for Unigene. We are thrilled to have achieved this goal and remain focused on advancing this program that we believe has the potential to address an important medical need.” Palmer continued, “I am extremely impressed with the Unigene team’s execution of this study in just four months since the signing of our collaboration with GSK, and believe this not only showcases our clinical trial expertise, but represents an important competitive advantage.”

Phase 2 Study Design

This multicenter, double blind with respect to placebo, randomized, repeat dose placebo controlled study will include an open label comparator arm of the Forsteo® injectable formulation. The primary endpoint will be an increase in bone mineral density (BMD) at the lumbar spine in subjects at 24 weeks in 93 postmenopausal osteoporotic women following once daily treatment with the orally delivered PTH analog compared to baseline. Secondary endpoints will evaluate biochemical markers of bone formation and resorption, as well as the safety, tolerability and pharmacokinetics of the oral formulation.

The Company expects to report top-line results before year end.

About Osteoporosis

Osteoporosis is a disease in which bones become brittle and so are more likely to break. In osteoporotic women and men, the density and quality of bone are reduced, leading to deterioration of the skeleton and increased risk of fracture. It's often diagnosed only after an osteoporosis-related fracture happens because prior to such an event, the patient has no outward signs or symptoms. The disease has a significant impact on patients' quality of life and it is estimated that one in three women and one in five men over the age of 50 will develop osteoporosis during their lifetimes.

The prevalence of osteoporosis is growing as the number of post-menopausal women rises, along with the general increase in life expectancy. Osteoporosis affects an estimated 75 million people in Europe, the US and Japan. In women over 45, osteoporosis accounts for more days spent in hospital than many other diseases, including diabetes, heart attack and breast cancer. There is currently no cure for osteoporosis, but available treatments can strengthen bones and help reduce the risk of fractures.

Source: International Osteoporosis Foundation

About Unigene-GSK Agreement

On December 10, 2010, Unigene entered into an amended and restated exclusive worldwide license agreement with GSK to develop and commercialize an oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women. Under the terms of the amended and restated agreement, Unigene is responsible for the manufacture of the PTH and the conduct of the Phase 2 study. The Company received an upfront payment of $4M to cover costs associated with the Phase 2 study, and will also receive an additional $4M payment upon completion of Phase 2 patient enrollment, as well as further payments of up to $142M based on the achievement of regulatory and commercialization milestones. In addition, Unigene is eligible to receive tiered double-digit royalties in the low-to-mid teens on global sales. Once the Phase 2 study has been completed and based on a review of the data, GSK may elect to assume responsibility for all future development and commercialization of the product.


Investor/Media:

Unigene Laboratories, Inc.

Jenene Thomas

VP, Investor Relations and Corporate Communications

Direct: 973-265-1107

[e-mail]



Source: Business Wire (April 27, 2011 - 9:10 AM EDT)

News by QuoteMedia

[pepe05]

Unigene Announces Presentations on Proprietary Recombinant Production and Oral Peptide Drug Delivery Technology at Upcoming 2011 TIDES Summit


Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide® Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 – 25, 2011.

For more information about Unigene, please visit http://www.unigene.com. For information about Fortical, please visit http://www.fortical.com.

[pepe05]

Unigene Announces Manufacturing and Clinical Supply Agreement with Cara Therapeutics for Phase 1 Study of Novel Kappa Receptor Agonist
Unigene's proprietary oral peptide delivery technology receives
additional validation

May 19, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc. Unigene will use its validated, proprietary peptide manufacturing technology to provide clinical supply material for Cara’s Phase 1 study of investigational drug, CR845, a peripherally acting kappa opioid agonist being developed for the treatment of both acute and chronic pain. Cara’s Phase 1 study is expected to begin in the second half of 2011.

No financial terms were disclosed.

Ashleigh Palmer, Unigene’s President and CEO, stated, “Unigene Biotechnologies was created specifically to exploit the potential of our 'Peptelligence™' core competence and related technology platforms by providing proprietary solutions to the oral drug delivery and commercial scale manufacturing challenges of other companies’ therapeutic peptides. We are pleased to have had early success with Cara via the results of a feasibility study, then to be selected as their partner of choice to manufacture its Phase 1 study clinical trial material, and believe this transaction represents further validation of our oral delivery technology. The goal of our Biotechnologies strategic business unit is to deploy Peptelligence™ so that it becomes the 'Intel® Inside' equivalent for therapeutic peptides.” Palmer continued, “We remain focused on and committed to building a diverse portfolio of highly targeted project proposals, and we have had several enter feasibility studies, with others still expected to do so. We anticipate additional feasibility studies will be commissioned throughout the remainder of this year. While not all of the feasibility studies we initiate will materialize into formal partnerships or license agreements, we are confident that we will establish a viable portfolio of new opportunities to ensure long-term success for this compelling and vibrant strategic business unit.”

Unigene Laboratories, Inc.

Jenene Thomas, 973-265-1107

VP, Investor Relations and Corporate Communications

[e-mail]



Source: Business Wire (May 19, 2011 - 8:09 AM EDT)

News by QuoteMedia

[pepe05]

Unigene Continues Solid Execution of Focused Turnaround Strategy and Monetizes Non-Core Asset with the Termination of China Joint Venture
-Unigene to receive approximately $1MM from China Pharmaceutical Group
Limited-
-All licenses and rights to technologies returned to Unigene-

Jun. 13, 2011 (Business Wire) -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company entered into a Termination Agreement and an Equity Sale and Purchase Agreement under which Unigene will sell its 45% equity interest in Unigene Biotechnology Co., Ltd. (the “China Joint Venture”) to China Pharmaceutical Group Limited (“CPG”) or one of its affiliates for an aggregate purchase price of $1,050,000, payable to Unigene in two installments, subject to the receipt of government approvals and other conditions. CPG and its affiliates are subsidiaries of Shijiazhuang Pharmaceutical Group Corporation ("CSPC"), which holds a leading position in China’s pharmaceutical industry. In connection with the Termination Agreement, all technology licenses, sublicenses and other rights granted to the China Joint Venture and CPG have been returned to Unigene. The China Joint Venture was originally formed pursuant to a Joint Venture Contract dated June 15, 2000 between CSPC and Unigene.

Unigene has no further obligations to the China Joint Venture and all disputes previously reported in the Company’s Securities and Exchange Commission (SEC) filings in connection with the China Joint Venture have been resolved to both parties’ full satisfaction.

Ashleigh Palmer, Unigene’s President and CEO, stated, “When we launched our new turnaround strategy in the fourth quarter of 2010, we were determined to find ways in which we could monetize our non-core assets and focus our attention on the Company’s critical priorities. Our termination agreement with CPG represents yet another major step forward for Unigene, and we are now able to further focus our available resources on our core business strategy as we transform into the peptide development powerhouse and partner of choice.” Palmer continued, “We are extremely grateful for CPG’s and its affiliate’s willingness to buyout our interest in the joint venture and return our technologies. To be clear, this transaction does not reflect Unigene’s lack of interest in the rapidly growing and globally important Chinese biopharmaceutical market. We fully expect to explore Unigene’s potential to access opportunities in China in the future through traditional licensing agreements and partnerships rather than high-risk, high-cost joint ventures.”




For more information about Unigene, please visit http://www.unigene.com. For information about Fortical, please visit http://www.fortical.com.


Investors/Media:

Unigene Laboratories, Inc.

Jenene Thomas, 973-265-1107

VP, Investor Relations and Business Administration

[e-mail]


Source: Business Wire (June 13, 2011 - 9:14 AM EDT)

[mieckymaus]

Hallo ich hab mal eine Frage, ich habe schon 2 x eine Kauforder an der Börse Frankfurt die nicht bedient wurde. Da ist immer 0 Umsatz, wo sollte ich Unigene Aktien kaufen? Direkt in USA?
Danke schon mal für die Antwort

[Andrija]

Kapitalsplit, Insolvenz, Marsinvasion...? Konnte keine News finden!

[Andrija]

Antwort auf Beitrag Nr.: 43.421.856 von Andrija am 25.07.12 13:12:00

Unigene Announces Second Quarter 2012 Financial Results

-Company provides corporate review and status of key strategic initiatives-
-Management to host webcast and conference call today, August 9, 2012 at 11 a.m. ET-

AUGUST 9, 2012 – BOONTON, N.J. – Unigene Laboratories, Inc. (OTCBB: UGNE) today announced financial results for the second quarter ended June 30, 2012 and provided a corporate review on key development programs and strategic initiatives.

SECOND QUARTER 2012 FINANCIAL SUMMARY

Unigene announced that its net loss for the three months ended June 30, 2012 decreased to $5.5 million or $(0.06) per share from $8.4 million or $(0.09) per share for the corresponding period in 2011.
Revenue for the three months ended June 30, 2012 increased to $2.7 million from $2.5 million in the comparable period in 2011.
Cash and cash equivalents at June 30, 2012 totaled $1.7 million, a decrease of $2 million from March 31, 2012. Based on Management’s current cash flow projections, the Company will need to obtain significant additional financing to fund operations, address its debt and restructure its balance sheet. Without additional financing, Management believes the Company’s current cash flow will fund operations into the fourth quarter of 2012.

The Company is currently exploring various alternatives, including financing, debt restructuring and partnering options. If the Company is unable to obtain financing, it may not be able to continue as a going concern in the near future.

Ashleigh Palmer, Unigene’s President and CEO, commented, “The EMA’s unexpected recommendation regarding calcitonin-containing products is proving to be an untimely and crucial setback for the Company and our 2012 goal of addressing our substantial inherited debt. Prior to the EMA announcement, Management had been working exhaustively to restructure the balance sheet and recapitalize the Company. Indeed, we were making excellent progress in that regard, having reached a second quarter settlement agreement with the Founders and had entered into negotiations with Victory Park Capital with the intent to restructure their debt. Regrettably, the EMA recommendation has impacted our calcitonin-related business opportunities, and as a result, our discussions with Victory Park Capital. Under these circumstances, the prospect of our being able to complete the settlement of the Founders’ debt in September has become extremely unlikely.”

Palmer concluded, “While the coming months will be extraordinarily challenging for all of us; shareholders, creditors, management and employees alike, we remain deeply committed to weathering this storm and working with Victory Park Capital to identify the best pathway forward to capitalize on the multiple opportunities we believe exist for Unigene and its pipeline of novel therapeutic peptides and steadily growing portfolio of oral peptide drug delivery partnerships.”



CORPORATE REVIEW

EMA Recommendation Expected to Financially Impact Future Business Operations Significantly
On July 26, 2012, Unigene provided an update following the report issued on July 19, 2012 by the European Medicine’s Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), concluding that there was evidence of a small increased risk of cancer with long-term use of current calcitonin medications approved and commercially available in Europe since 1973 and calling for curtailment of calcitonin usage.

Unigene has licensed to Upsher-Smith Laboratories its patented nasal formulation of calcitonin for commercialization in the United States and has licensed the development and worldwide commercialization rights (except China) for its Phase 3 oral calcitonin to Tarsa Therapeutics. However, since neither the Company nor its licensees are Market Authorization Holders in Europe, they do not have the right to appeal the EMA’s recommendation. Management is currently evaluating the potential regulatory and commercial impact of this announcement on calcitonin related products marketed or under development by our licensees and partners in Europe and other markets, as well as the expected resulting financial impact on the Company’s future business operations.

There is a possibility that additional regulatory authorities, including the United States Food and Drug Administration (FDA), could take actions as a result of the recommendation, including withdrawing calcitonin-containing products from the market or limiting their use. This could materially adversely affect the Company by reducing or eliminating Fortical® sales and royalties, limiting the value of current calcitonin development projects and the potential value of our investment in Tarsa.

Unigene understands that Tarsa Therapeutics has requested that the CHMP opinion be reexamined, is evaluating possible opportunities to appeal the CHMP recommendation and also plans to discuss the situation with the FDA.

Victory Park Capital Debt Negotiation Discussions Ongoing
As previously disclosed, the Company is in discussions with Victory Park Management, LLC regarding the restructuring of its debt. As a result of the recent EMA recommendation and the potential impact on Unigene’s business operations, the discussions have changed significantly. At this time, there can be no assurance that the Company will be able to reach an agreement with Victory Park regarding its debt obligations or on any other matter.

Debt Settlement with the Founding Levy Family is Unlikely
On June 4, 2012, the Company entered into a settlement and release agreement with the founding Levy family (the “Founders”) that allows the Company to eliminate, on or before September 30, 2012, its entire outstanding indebtedness to the Founders $23.2 million as of June 30, 2012 upon paying $8 million in cash and issuing 5,000,000 shares of Unigene’s common stock. The 5,000,000 shares of common stock will be subject to a lock-up period through December 31, 2013. The Company made two interim payments of $150,000 each to the Founders, the first of which was paid in May 2012, and the second of which was paid in June 2012. Both interim payments will be applied against the $8 million cash payment. The remaining $7.7 million cash payment and the issuance of 5,000,000 shares of Unigene’s common stock to the Founders must occur by September 30, 2012 to avoid termination of the settlement and release agreement.

In addition, on May 29, 2012, the Company and Victory Park Management, LLC agreed that if on or before September 21, 2012, the Company has not secured sufficient funds to pay the remaining balance of $7.7 million to the Founders, then Victory Park shall have the right, but not the obligation, to finance the remaining $7.7 million payment to the Founders.

In light of the recent EMA recommendation and the expected financial impact on business operations, Management believes it is unlikely the Company will be in a position to fund the $7.7 million debt settlement to the Founders, nor does Unigene believe is it likely that Victory Park Capital will exercise its right to finance the remaining payment to the Founders.

Annual Shareholder Meeting Date Change
The Company previously announced that the Annual Shareholder Meeting will be held on September 5, 2012. Management announced today that the Company will be rescheduling that meeting to a future date given its ongoing discussions with Victory Park Capital and expects to announce the new date prior to year end.

THERAPEUTICS REVIEW
Oral Calcitonin Program – Tarsa Therapeutics Reviewing CHMP’s Recommendation and Next Steps
In 2009, Unigene licensed its late-stage oral calcitonin formulation to Tarsa Therapeutics, a venture financed company founded exclusively to conduct Phase 3 clinical testing and prepare Unigene’s proprietary oral salmon calcitonin formulation for commercialization.

On September 19, 2011, Unigene announced that Tarsa presented positive Phase 3 data from its ORACAL trial of its oral recombinant salmon calcitonin product during the American Society for Bone and Mineral Research (ASBMR) 2011 Annual Meeting. The data demonstrated that Tarsa’s oral recombinant salmon calcitonin achieved all of the efficacy endpoints in the trial and was also superior to nasal calcitonin spray in increasing bone mass at the lumbar spine, indicated that the safety profile of oral recombinant salmon calcitonin did not substantially differ from nasal calcitonin or placebo, and that oral recombinant salmon calcitonin appeared to be significantly less immunogenic than nasal calcitonin spray. Tarsa’s oral recombinant salmon calcitonin is in development for the treatment and prevention of postmenopausal osteoporosis.

Following the recommended restrictions on calcitonin use issued on July 19, 2012 by the CHMP of the EMA, Unigene understands that Tarsa is seeking additional data to better understand the rationale behind the CHMP’s recommendation and to determine the impact on its plans to file for marketing approval of its oral recombinant salmon calcitonin product in the U.S. and Europe. In the interim, Unigene believes that Tarsa is continuing the development of its oral calcitonin.
Unigene expects Tarsa to comment further regarding the situation and its potential impact on the Company as their analysis proceeds. Importantly, Tarsa has not noted any serious safety issues in two separate year-long studies of its oral calcitonin. While the combination of Tarsa’s two clinical studies provides limited power to detect differences in unusual adverse events, no signal of increased malignancy was observed. Tarsa also noted that in its recommendation, the CHMP cited a very small increased cancer risk for an unlicensed oral calcitonin product. This product differs in formulation, excipients and dosing from Tarsa’s oral calcitonin tablet, and Tarsa researchers accordingly question whether it is appropriate to extrapolate the safety experience with that product to Tarsa’s oral calcitonin.

Tarsa believes its oral calcitonin product may have the potential to be effective for the treatment and possibly the prevention of post-menopausal osteoporosis. Furthermore, Tarsa believes that the benefit versus risk profile of its unique oral formulation of calcitonin is favorable for the treatment of osteoporosis.

Unigene owns a 16% equity position in Tarsa on a fully diluted basis, subject to liquidating preferences. The Company is also eligible to receive sales-related milestone payments and royalties on worldwide sales excluding China of which Unigene owns the full rights.

Phase 2 Oral Parathyroid Hormone (PTH) Data Accepted in Prestigious Peer-reviewed Journal
On November 9, 2011, Unigene announced positive top-line results of its Phase 2 clinical study evaluating an experimental oral PTH analog for the treatment of osteoporosis in 93 postmenopausal women. The study achieved its primary endpoint with statistical significance and demonstrated an acceptable safety profile. The Phase 2 study was conducted by Unigene as part of a now terminated exclusive worldwide option and licensing agreement with GlaxoSmithKline (GSK).

The Company announced today that the full data set from the Phase 2 study has been accepted in the peer-reviewed journal, BONE, the Official Journal of the International Bone and Mineral Society, for publication expected in the coming weeks.

Unigene is actively seeking a licensing partner for the advanced development and commercialization of the oral PTH program.

UGP281 Development Program on Hold – Further Funding Required to Advance into Clinic
In light of the recent FDA approvals of obesity therapeutics, UGP281 remains a priority development program, but given the Company’s current cash position, the IND filing and commencement of the Phase 1 study, previously scheduled for the first half of 2013, has been placed on hold. Management expects to have discussions with Victory Park as to funding the continuation of the development program to file an IND and the commencement of a Phase 1 study for this high-value potential product candidate. However, the Company cannot guarantee a successful outcome from those discussions.

On May 22, 2012, Unigene reported positive data from recently completed preclinical studies in rats and dogs for UGP281, a potent proprietary anorexigenic peptide selectively targeting the amylin receptor. UGP281 is under development by Unigene for the treatment of morbid obesity. In multiple-dose pharmacology studies in rats and beagle dogs, UGP281, administered subcutaneously, produced a dose-related decrease in body weight of 10-15% over a 7-day treatment period. The reduction in food intake was acute and dramatic, falling close to zero at relatively low doses, and was consistent with the targeted pharmacology. Changes in body weight throughout the studies were tightly aligned with decreases in food consumption. UGP281 was well tolerated with no overt adverse findings in the studies conducted to date, and its therapeutic window appeared to be substantial.

These data compare favorably to what has been described preclinically with other weight loss compounds currently, or previously, under development. Additionally, since UGP281 does not bind to serotonin receptors, the risk of unwanted cardiovascular effects is expected to be significantly less as compared to other obesity product candidates.

Furthermore, as successfully demonstrated in previous preclinical studies, UGP281 has the potential to be dosed orally and manufactured recombinantly by way of Unigene’s Peptelligence™ technology platform.

Preliminary Lead Compound for T2D Indication under JDV to be Announced before Month-End
Under the established Joint Development Vehicle (JDV) formed in the fourth quarter of 2011, Unigene and Nordic Bioscience have been extensively evaluating the three (3) proprietary analogs developed by Unigene and licensed to the JDV. Unigene expects to announce the preliminary selection of the lead molecule for the Type 2 diabetes indication before the end of August 2012 and announce relevant preclinical study results before year end.

BIOTECHNOLOGIES REVIEW
Robust Portfolio of Feasibility Studies Continues to Expand
Unigene continues to aggressively target and exploit its industry-leading Peptelligence™ platform of peptide oral drug delivery and manufacturing assets, expertise and capabilities and is building a robust portfolio of strategically partnered opportunities. The Company’s business-to-business marketing initiatives and validated business development capabilities continue to generate near-term revenue feasibility studies evaluating Unigene’s ability to orally deliver both synthetic and natural peptides.

Unigene announced that it now has 13 feasibility studies ongoing or completed in exciting, high-potential therapeutic areas such as metabolic disease, cardiovascular disease, oncology, genitourinary disorders, central nervous system, genetic disorders and pain management. The 13 feasibility partnerships consist of development stage companies, as well as large, reputable pharmaceutical manufacturers. Importantly, the Company noted that one large pharmaceutical manufacturer has added a second peptide to the feasibility pipeline after testing delivery of the first one using Unigene’s Peptelligence™ platform.

The Company previously announced the completion of Cara Therapeutics, Inc.’s successful, first-in-man Phase 1 clinical trial using Unigene’s oral formulation of Cara’s peptide-based, peripherally-restricted kappa opioid receptor agonist, CR845, achieving 16% bioavailability. The trial was a single-center, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and pharmacodynamics of CR845 in healthy volunteers. CR845 oral capsules were formulated using Unigene’s validated, proprietary oral peptide delivery technology under a Manufacturing and Clinical Supply Agreement established in May 2011.

Additionally, in March 2012, Unigene announced it will use its validated, proprietary Peptelligence™ platform as part of the agreement to support Phase 1 clinical plans for one of Stealth Peptides’ investigational drug candidates. Unigene expects Stealth’s Phase 1 clinical study to begin before year end.
Stealth commenced an oral feasibility study for its pipeline candidate in August 2011. After analyzing the data produced using Unigene’s oral delivery technology relative to competitive technologies, Stealth chose to move forward into a clinical evaluation with the Peptelligence™ platform.

Unigene anticipates that at least one feasibility study from its expanded portfolio of 13 will have the potential to convert into a significant milestone and royalty licensing agreement before year end.

ADDITIONAL FINANCIAL RESULTS & NOTES

Revenue for the three months ended June 30, 2012 increased $268,000, or 11%, to $2.7 million from $2.5 million in the comparable period in 2011. This was primarily due to the timing of Fortical® shipments, partially offset by the continuing decline in royalties from Fortical® due to increased competition in the nasal calcitonin market and negative gross to net sales adjustments recorded by Upsher-Smith Laboratories, as well as to a decrease in licensing revenue.

Unigene had an operating loss of $1.9 million for the three months ended June 30, 2012, a decrease of $1.1 million when compared to the operating loss of $3 million for the three months ended June 30, 2011.

Net loss for the three months ended June 30, 2012 decreased approximately $3 million, or 35%, to $5.5 million from $8.4 million for the corresponding period in 2011. This was primarily due to a decrease in operating expenses of $865,000 and an increase in revenue of $268,000. In addition, in the three months ended June 30, 2011, Unigene recognized a loss of $1.1 million on the sale of its former joint venture in China and wrote off the Company’s investment in Tarsa of $1.5 million. In the three months ended June 30, 2012, the Company recognized a loss of $600,000 on the sale of its former joint venture in China.

CONFERENCE CALL AND WEBCAST

Unigene’s senior management team will host a conference call and webcast today, August 9, 2012 at 11:00 a.m. ET.

Interested participants and investors may access the conference call at 11 a.m. ET by dialing [phone] (U.S./Canada) or [phone] (international); participant code 33025219. An audio webcast can be accessed by logging on to the Investors & Media section under the Events tab of the Unigene web site, http://www.unigene.com.

A telephonic replay of the call will be available for two weeks beginning at 1:30 p.m. ET on August 9. Access numbers for this replay are [phone] (U.S./Canada) and [phone] (international); participant code 33025219. The webcast replay will remain available in the Investors & Media section of the Unigene Laboratories web site for 30 days.

ABOUT UNIGENE LABORATORIES, INC.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to whether the Company will be able to: obtain significant additional financing to fund operations, address its debt and restructure its balance sheet; fund operations into the fourth quarter of 2012 based on its current cash; continue as a going concern in the near future; restructure its debt with Victory Park; complete the settlement of the Founders’ debt in September; capitalize on the multiple opportunities it believes exist for the company and its pipeline of peptides; grow a portfolio of oral peptide drug delivery partnerships; successfully evaluate the potential regulatory and commercial impact of the EMA announcement on calcitonin related products marketed or under development by our licensees and partners in Europe and other markets, as well as the expected resulting financial impact on its future business operations; fund the $7.7 million debt settlement to the Founders or the likelihood that Victory Park Capital will fund such settlement; reach an agreement with Victory Park regarding its debt obligations or on any other matter; to receive sales-related milestone payments and royalties on worldwide sales excluding China on sales of a product by Tarsa; find a licensing partner for the advanced development and commercialization of the oral PTH program; fund the continuation of the PTH development program, file an IND and commence a Phase 1 study and achieve successful outcome from its discussions with Victory Park; orally dose UGP28 and manufacture it recombinantly by way of its Peptelligence™ technology platform; announce the preliminary selection of the lead molecule for the Type 2 diabetes indication before the end of August 2012 and announce relevant preclinical study results before year end; aggressively target and exploit its industry-leading Peptelligence™ platform of peptide oral drug delivery and manufacturing assets, expertise and capabilities and is building a robust portfolio of strategically partnered opportunities; generate near-term revenue generating feasibility studies and orally deliver both synthetic and natural peptides; convert at least one feasibility study from its portfolio of 13 into a significant milestone and royalty licensing agreement before year end; and use its proprietary Peptelligence™ platform to support Phase 1 clinical plans for one of Stealth Peptides’ investigational drug candidates. This press release also contains forward-looking statements relating to whether the United States Food and Drug Administration (FDA), could take actions as a result of the EMA recommendation, including withdrawing calcitonin-containing products from the market or limiting their use; the reduction or elimination of Fortical® sales and royalties, the value of current calcitonin development projects and the value of the company’s investment in Tarsa; potential discussions between Tarsa and FDA relating to the EMA situation; the rescheduling of the company’s annual stockholder meeting; Tarsa’s search for additional data to better understand the rationale behind the CHMP’s recommendation; Tarsa’s plans to file for marketing approval of its oral recombinant salmon calcitonin product in the U.S. and Europe; Tarsa’s continuing development of its oral calcitonin; any further comment by Tarsa regarding the EMA situation and its potential impact on the company; the risk of unwanted PTH cardiovascular effects is significantly less as compared to other obesity product candidates; Stealth’s Phase 1 clinical study begins before year end. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain efficiencies, our ability to enter into new financing arrangements, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission (“SEC”) filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[e-mail]

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
[e-mail] / [e-mail]

SOURCE: Unigene Laboratories, Inc.

[Andrija]

Hört sich nicht gut an, erneut drohende Insolvenz:

Unigene Announces Third Quarter 2012 Corporate Update
BOONTON, N.J., Nov. 20, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a corporate review on key development programs and strategic initiatives, including the Company's ongoing progress following the debt financing and forbearance agreement with Victory Park Capital (VPC).

Third Quarter Form 10-Q Filing

The Company previously announced in a Current Report on Form 8-K filed with the SEC on November 9, 2012 that it would delay the filing of its Form 10-Q for the three and nine months ended September 30, 2012 due to the Company's temporary inability to access its corporate headquarters and electronic data as a result of the impact of Hurricane Sandy. In the process of reviewing the Company's draft Form 10-Q, the Company's external auditors, Grant Thornton LLP, identified a potential issue in the Company's historic methodology of accounting for a non-cash embedded derivative liability related to the Senior Secured Convertible Notes issued on March 16, 2010 which included periods they had previously audited. The Company and Grant Thornton are in the process of assessing the potential issue and its related impact on the Company's financial statements and until such review is completed, the Company will be unable to finalize and file its Form 10-Q within the extended filing deadline of November 21, 2012.

THIRD QUARTER 2012 CORPORATE UPDATE

On September 21, 2012, Unigene entered into a Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement with affiliates of Victory Park Capital Advisors, LLC, whereby VPC loaned the Company $4.0 million (of which $0.5 million was deposited with VPC for the payment of its fees and expenses) and agreed to forbear from exercising certain rights due to existing events of default through September 21, 2013, subject to the terms and conditions of such agreement. As a result of this transaction, cash and cash equivalents at September 30, 2012 totaled $4.0 million, an increase of $2.3 million from the previous quarter.

Management's cash flow projections at the time of the issuance of the $4.0 million note estimated that cash on hand would be sufficient to fund operations through at least Q2 2013. This projection was based on the assumption that the Company's Biotechnologies Strategic Business Unit would be able to convert at least one of its ongoing oral peptide drug delivery feasibility partnerships into a definitive license agreement bearing a significant up-front cash payment, on or before December 31st, 2012. Based on the latest feedback from Unigene's lead feasibility partnerships, as well as delays to our ongoing feasibility and partner sponsored Peptelligence' research programs, Management believes it is no longer likely that such a licensing agreement and up-front cash payment will occur this year. The Company now projects that current cash on hand will be insufficient to fund operations through Q2 2013. The Company will therefore need to secure alternative sources of revenue to fund operations through this period and beyond, as well as obtain significant additional financing to address its debt and restructure its balance sheet. Management is actively pursuing various alternatives to extend the Company's cash runway. However, in the event that the Company is unable to generate additional revenue, it will not be able to fund operations through the end of Q1 2013 without defaulting on its minimum cash requirement under the VPC debt financing and forbearance agreement. In addition to our need to secure additional sources of revenue to fund operations in the near term, having failed in quarter three to complete the funding of the Founders debt settlement and release agreement, payments amounting to $362,000 become due this quarter under a prior agreement with the Company's founders. The payment of such amount this year would exceed the 10% deviation default threshold for the Q4 2012 forbearance budget previously submitted to Victory Park Capital.

Ashleigh Palmer, Unigene's President and CEO, commented, "Our $4.0 million debt financing and forbearance agreement with VPC was a vital achievement for Unigene in the third quarter. This initiative almost certainly averted imminent insolvency stemming primarily from the unexpected recommendation made by the European Medicines Agency ("EMA") at the beginning of the quarter calling for the curtailment of calcitonin usage for the treatment of osteoporosis. Prior to the EMA's announcement, we had been making excellent progress towards restructuring our balance sheet and recapitalizing the Company. The impact of the EMA's recommendation represents a devastating setback and has prevented any possibility of us accomplishing our 2012 goal of fundamentally addressing the Company's debt. In particular, we were unable to meet the September 30, 2012 deadline to fund a settlement and release agreement with the Company's founders, which would otherwise have eliminated $23.2 million of outstanding indebtedness upon paying the remaining $7.7 million of an $8.0 million cash payment and issuing 5 million shares of Unigene's common stock."

Palmer concluded, "I must again thank Victory Park Capital for its timely rescue and ongoing support. Nevertheless, the coming months will be extraordinarily challenging. Despite the catastrophic impact the EMA's recommendation has had on Unigene, we remain resolute and deeply committed to the multiple opportunities we believe exist for Unigene and its pipeline of novel therapeutic peptides and expanding portfolio of Peptelligence' oral peptide drug delivery partnerships."

THIRD QUARTER HIGHLIGHTS

■Entered into Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement with affiliates of Victory Park Capital Advisors, LLC whereby VPC loaned the Company $4.0 million (of which $0.5 million was deposited with VPC for the payment of its fees and expenses) and agreed to forbear from exercising certain rights due to existing events of default through September 21, 2013, subject to the terms and conditions of such agreement.
■With Tarix Pharmaceuticals, announced the successful completion of a feasibility study of an oral formulation of Tarix's lead peptide drug candidate, TXA127. Data from the feasibility study demonstrated that Unigene's proprietary oral formulation of TXA127 produced extremely high exposure in the blood that resulted in a several-fold increase in bioavailability as compared to unformulated oral delivery of the drug, and was equal to or greater than that achieved by a current subcutaneous formulation.
■With joint development partner, Nordic Bioscience, provided initial funding of our Joint Development Vehicle and announced preliminary selection of UGP302 as our lead compound for the treatment of Type 2 diabetes.
UPDATES SUBSEQUENT TO QUARTER END

■Announced that the Company's successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone ("PTH") analog for the treatment of osteoporosis in postmenopausal women was the subject of an oral presentation by Dr. Morten Karsdal, Chief Executive Officer of Nordic Bioscience, at the 2012 Annual Meeting of the American Society of Bone and Mineral Research (ASBMR).
■Our licensee, Tarsa Therapeutics, reported positive results from a Phase 2 trial at the recent ASBMR annual meeting of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis. Tarsa is developing its oral calcitonin under a licensing agreement with Unigene that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.
■Tarsa also announced an agreement with Therapicon® Slr to provide consulting assistance to the Italian firm in its appeal of the recommendation by the EMA to limit the use of calcitonin-containing medicines. The EMA has subsequently reported on its website that, following re-examination, its Committee for Medicinal Products for Human Use has reconfirmed its original conclusion that the benefits of the current calcitonin-containing medicines do not outweigh their risks in the treatment of osteoporosis and that they should no longer be used for this condition.
■Tarsa also presented a poster at the 2012 ASBMR meeting assessing whether there was any sign of increased cancer risk in either of its year-long trials of its oral calcitonin. Tarsa researchers integrated the safety databases from the two trials, which together included 694 women. The researchers reviewed all newly diagnosed adverse events in the trials consistent with malignancy and concluded that the combined safety data demonstrated no signal of carcinogenicity. They also concluded that there is little biological evidence to support the hypothesis that salmon calcitonin is carcinogenic in humans.
Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement

On September 21, 2012, Unigene entered into a Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement with affiliates of Victory Park Capital Advisors, LLC whereby VPC loaned the Company $4.0 million (of which $0.5 million was deposited with VPC for the payment of its fees and expenses) and agreed to forbear from exercising certain rights due to existing events of default through September 21, 2013, subject to the terms and conditions of such agreement.

Under the terms of the Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement, Unigene issued to an affiliate of Victory Park Capital Advisors, LLC a one-year senior secured convertible note in the aggregate principal amount of $4.0 million, which bears interest at a rate per annum equal to the greater of the prime rate plus 5% or 15%. Of the $4.0 million, $500,000 was deposited with VPC to cover certain of VPC's fees and expenses, including those fees related to the transaction. The remaining $3.5 million is being used by Unigene to finance operations.

The agreement allows for the $4.0 million of new debt to convert into shares of the Company's common stock based on a conversion rate of $0.05 per share, while the existing debt that was previously convertible at a rate of $0.70 per share has been re-issued and now converts into shares of the Company's common stock based on a conversion rate of $0.15 per share. As the Company lacks sufficient shares of common stock to deliver all of the conversion shares, the Company is required to obtain stockholder approval to increase the number of authorized shares to allow for the conversion of the debt in full. The agreement amended certain default provisions under the Amended and Restated Financing Agreement to include new events of default, including a default in the event that a required quarterly reconciliation shows a negative variance of 10% or more of actual cash revenue minus actual cash expenses for an applicable quarter versus the applicable quarterly cash flow forecast required to be delivered by the Company (as described more fully in the agreement); failure to maintain a cash balance of at least $250,000; and a breach of any agreement or covenant contained in the agreement.

Pursuant to the terms of the Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement, the Company approved and authorized key employee retention grants and executive team restructuring grants, as well as employee and director retention grants. The Company also entered into various ancillary agreements in relation to the transaction. Further details related to the Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement and ancillary agreements, along with full copies of such agreements, can be found in the Current Report on Form 8-K filed by the Company with the United States Securities and Exchange Commission ("SEC") on September 26, 2012.

Annual Shareholder Meeting

The Company announced today that a Special Meeting of Shareholders in Lieu of 2012 Annual Shareholder meeting has been rescheduled to January 15, 2013 and that the meeting will be held at 1:00pm CT, at the offices of Victory Park Capital in Chicago.

Quelle: Unigene

[dottore]

mit der heutigen Meldung zur Auslizensierung an Tarix und Kursaufschlag über 40 % ist eine Insolvenz wohl vom Tisch

[Andrija]

- Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -

BOONTON, N.J., April 8, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the Company has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors, LLC (VPC), whereby VPC has agreed to purchase an additional $750,000 senior secured note, providing Unigene with additional working capital. Under the terms of this financing, proceeds from the sale of the note, which is convertible into shares of UGNE common stock at a conversion price of $0.09 per share, will be used for working capital purposes.

In an effort to conserve capital and further extend its cash runway, Unigene also announced a strategic reorganization and downsizing, which involved a reduction of approximately 40% of its workforce. The majority of employees impacted by the reduction in workforce supported Unigene's Fortical® manufacturing and recombinant calcitonin production operations, which have been negatively impacted by regulatory recommendations in Europe and by an advisory committee to the U.S. Food and Drug Administration (FDA). The company also disclosed that certain of its assets, primarily related to its Fortical® business, are impaired as a result of this regulatory activity and its related impact upon Fortical manufacturing revenues and royalties. The asset impairment charges will be further discussed within the Company's reported financial results for the first quarter 2013.

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We value VPC's ongoing support and willingness to continue financing the company. Unigene remains focused on our efforts to conserve capital during these adverse conditions and challenging times. We view the reduction in workforce as an unfortunate, but necessary part of our path forward in continuing to explore and develop strategic options to protect and enhance shareholder value. On behalf of Unigene's Management and our Board of Directors, we thank our many dedicated colleagues and employees whose efforts have been instrumental to the success of our Fortical® business throughout the years."

Unigene also announced today that it has been notified by VPC that VPC has declared an event of default under certain loan documents, including approximately $55.8 million in notes issued to VPC by Unigene. VPC has further declared these notes (including principal and interest) due and payable. The declaration of default is based on, among other things, VPC's determination that a material default has occurred under various provisions of the loan documents. In connection with the existence and continuation of the default, VPC has notified Unigene that, pursuant to Article 9 of the Uniform Commercial Code (UCC), VPC has initiated a public disposition of certain of Unigene's assets that constitute VPC's collateral, including the Company's Peptelligence'Drug Delivery Platform and all other assets that are used or intended for use in connection with, or that are necessary or advisable to the continued conduct of, Unigene's biotechnology business (but excluding assets of the Company unrelated to such business). Such assets will be sold pursuant to public auction to be held at the offices of Katten Muchin Rosenman LLP, 525 West Monroe Street, Chicago, Illinois 60611 on April 15, 2013 at 11:00 a.m. Central time.

[stephan101010]

Istr hier irgend jemand, außer mir, noch investiert?

Andrija, ist ja sehr honorig von Dir die SEC-Fillings reinzustellen,

schöner wäre wie Du die Lage siehst.

Ich werde hier schon lange nicht mehr schlau raus...

[Andrija]

Antwort auf Beitrag Nr.: 44.525.397 von stephan101010 am 27.04.13 18:15:01

Was soll ich da noch sagen. Ausverkauf. Haben es nie geschafft ihre Ergebnisse zu refinanzieren und nun werden die verwertbaren Assets "zwangsversteigert".

[stephan101010]

Durch die News vom 09.05.2013 séhe ich wieder Licht am Ende des Tunnels!

[stephan101010]

Der Boden koennte gefunden sein.

[stephan101010]

Werde bald nachlegen.

[Andrija]

Antwort auf Beitrag Nr.: 44.883.879 von stephan101010 am 20.06.13 09:19:43

Warum? A

[stephan101010]

Das Geld sollte doch nur bis Mitte Juni reichen.


Bisher keine Meldung von Insolvenz.


Für mich steckt viel Substanz in der Firma.

[Andrija]

Antwort auf Beitrag Nr.: 44.896.439 von stephan101010 am 21.06.13 16:09:55

Na, da hattest Du wohl Recht, es hat bis Mitte Juni noch gereicht:

UGNE - BK From 8k filed 7/2/13:

"Bankruptcy or Receivership.
On July 2, 2013, Unigene Laboratories, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 7 of the United States Bankruptcy Code (the “Code”) in the United States Bankruptcy Court of the District of New Jersey (the “Bankruptcy Filing”). The Chapter 7 case is being administered under case No. 13-24696.

As a result of the Bankruptcy Filing, a Chapter 7 trustee will be appointed by the Court and will assume control of the Company. The remaining assets of the Company will be liquidated in accordance with the Code."

Ab Juli reicht es nicht mal mehr für Chapter 11!